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ABSTRACT 
lsoflurane interacts with cytochrome P-450 in rat and human hepatic 
microsomes and the ti6- and t.5-desaturases in rat hepatic microsomes. The 
interaction of isoflurane with cytochrome P-450 results in its metabolism to 
fluoride ion and organofluorine metabolites. The cytochrome P-450 isozymes 
catalysing the defluorination of isoflurane were assessed in hepatic microsomes 
from phenobarbital-, iS-naphthoflavone- and pregnenolone-16a-carbonitrile-
pretreated and untreated rats. One or more of the cytochrome P-450 isozymes 
induced by phenobarbital and pregnenolone-16a-carbonitrile appear to 
defluorinate isoflurane, but those induced by iS-naphthoflavone do not. From a 
comparison of the extent of defluorination of isoflurane in hepatic microsomes 
from phenobarbital- and pregnenolone-16a-carbonitrile-pretreated rats, and 
their Km and V max values, it appears that isoflurane is defluorinated by one or 
more isozymes induced by both phenobarbital and 
pregnenolone-16a-carbonitrile. The major isozyme is probably cytochrome 
P-450PCN1. 
The metabolites of isoflurane were identified in human and 
phenobarbital-induced rat hepatic microsomes. In microsomes from 
phenobarbital-pretreated rats, isoflurane is metabolised to fluoride ion and 
trifluoroacetaldehyde; trifluoroacetic acid is not produced in measureable 
amounts. The trifluoroacetaldehyde produced binds to microsomal 
constituents. In human hepatic microsomes, the organofluorine metabolite is 
identified as trifluoroacetic acid. It is proposed that isoflurane is metabolised by 
different pathways in human and phenobarbital-induced rat hepatic microsomes. 
V 
The interaction of isoflurane with the cyanide-sensitive factors was assessed by 
several criteria. Firstly, using the reoxidation of cytochrome b5 as an index of 
fatty acid desaturase activity, isoflurane appears to interact with the A6- and/or 
A5-desaturases, but not the A9-desaturase. Secondly, these results were 
confirmed and clarified by the use of direct assays to measure the fatty acid 
desaturase activity. Using the direct assay, we confirmed that isoflurane did not 
inhibit the A9-desaturase and inhibited AS-desaturation of linoleic acid, but not 
the AS-desaturation of a-linolenic acid. The inhibition of the AS-desaturation of 
linoleic acid occurred at low millimolar concentrations of isoflurane. lsoflurane 
inhibits the A5-desaturation of eicosa-8, 11, 14-trienoic acid to a small extent 
which is only apparent at much higher concentrations of isoflurane than that 
which inhibits the AS-desaturase. 
Further studies focussed on measurement of the activity of A6-desaturase in 
order to attempt to study the kinetics of the inhibition of the AS-desaturase by 
isoflurane: A6-desaturase activity was assessed using hepatic microsomes as 
the source of the enzyme and linoleic acid as substrate precursor. In the 
course of these studies, we identified a number of factors that affected the 
apparent activity of the AS-desaturase in hepatic microsomes. These included 
significant levels of endogenous substrate and competing reactions in the 
hepatic microsomes. Endogenous substrate levels were quantified and 
corrected for. We then resorted to computer modelling to extract the kinetics of 
the AS-desaturase free of contributions from acyl-CoA synthetase and 
lysophospholipid acyltransferase, as well as enzyme decay. The kinetics of 
isoflurane inhibition of the AS-desaturase were then superimposed and studied 
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from Figure 30. 
FIGURE 53 Overlay plots of the effect of time on the M-desaturation of 238 
linoleic acid (4.7 µM) using data from models 16, 19, 20, 21, 22 
the experimental and data from Figure 20. 
FIGURE 54 Overlay plots of the effect of time on the acylation of 239 
phospholipid measured during the metabolism of 
linoleic acid (4.7 µM) using data from models 16, 19, 
20, 21, 22 and the experimental data from Figure 30. 
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FIGURE 55 Overlay plots of the effect of time on the disappearance of 241 
linoleic acid measured during the metabolism of 
linoleic acid (4. 7 µM) using data from models 21, 23, 24, 25, 26 
and the experimental data from Figure 30. 
FIGURE 56 Overlay plots of the effect of time on the formation of acyl-CoA 242 
measured during the metabolism of linoleic acid (4.7 µM) using 
data from models 21, 23, 24, 25, 26 and the experimental data from 
Figure 30. 
FIGURE 57 Overlay plots of the effect of time on the M-desaturation of 243 
linoleic acid (4.7 µM) using data from models 21, 23, 24, 25, 26 
and the experimental data from Figure 20. 
FIGURE 58 Overlay plots of the effect of time on the acylation of 244 
phospholipids measured during the metabolism of 
linoleic acid (4.7 µM) using data from models 21, 23, 24, 25, 26 
and the experimental data from Figure 30. 
FIGURE 59 Overlay plots of the effect of time on the disappearance of 246 
linoleic acid measured during the metabolism of 
linoleic acid (4.7 µM) using data from models 23, 27, 28, 29, 
and the experimental data from Figure 30. 
FIGURE 60 Overlay plots of the effect of time on the formation of acyl-CoA 247 
measured during the metabolism of linoleic acid (4. 7 µM) using 
data from models 23, 27, 28, 29, and the experimental data from 
Figure 30. 
FIGURE 61 Overlay plots of the effect of time on the M-desaturation of 248 
linoleic acid (4.7 µM) using data from models 23, 27, 28, 29, 
and the experimental data from Figure 20. 
FIGURE 62 Overlay plots of the effect of time on the acylation of 249 
phospholipids measured during the metabolism of 
linoleic acid (4.7 µM) using data from models 23, 27. 28, 29, 









Overlay plots of the effect of time on the disappearance of 
linoleic acid measured during the metabolism of 
linoleic acid (4.7 µM) using data from model 27 run at 
concentrations of 11 µM and 2.2 µM lysophospholipid, and 
the experimental data from Figure 30. 
Overlay plots of the effect of time on the formation of 
acyl-CoA measured during the metabolism of linoleic acid (4.7 µM) 
using data from model 27 run at concentrations of 11 µM and 
2.2 µM lysophospholipid, and the experimental data from Figure 30. 
Overlay plots of the effect of time on the M-desaturation of 
linoleic acid (4.7 µM) using data from model 27 run at 
concentrations of 11 µM and 2.2 µM lysophospholipid, and 
the experimental data from Figures 19 and 20. 
Overlay plots of the effect of time on the acylation of 
phospholipids measured during the metabolism of 
linoleic acid (4.7 µM) using data from model 27 run at 
concentrations of 11 µM and 2.2 µM lysophospholipid, and 
the experimental data from Figure 30. 
Overlay plots of the effect of time on the disappearance of 
linoleic acid measured during the metabolism of 
linoleic acid (4.7 µM) using data from models 27, 30, 
31, 32, 33 and the experimental data from Figure 30. 
Overlay plots of the effect of time on the formation of 
acyl-CoA measured during the metabolism of linoleic acid (4.7 µM) 
using data from models 27, 30, 31, 32, 33 and the experimental 
data from Figure 30. 
Overlay plots of the effect of time on the fi6-desaturation of 
linoleic acid (4. 7 µM) using data from models 27, 30, 

















Overlay plots of the effect of time on the acylation of 
phospholipids measured during the metabolism of 
linoleic acid (4.7 µM) using data from models 27, 30, 
31, 32. 33 and the experimental data from Figure 30. 
Overlay plots of the effect of linoleic acid concentration on 
the formation of acyl-CoA measured during the metabolism of 
linoleic acid using data from model 33 and the experimental 
data from Figure 32 B. 
Overlay plots of the effect of linoleic acid concentration on 
the M-desaturation of linoleic acid using data from 
model 33 and the experimental data from Figure 33 B. 
Overlay plots of the effect of linoleic acid concentration on 
the acylation of phospholipids measured during the metabolism of 
linoleic acid using data from model 33 and the experimental 
data from Figure 34 B. 
Overlay plots of the effect of time on the disappearance of 
linoleic acid measured during the metabolism of linoleic acid (4. 7 µM) 
using data from models 33, 34, 35, 36 and the experimental data from 
Figure 30. 
Overlay plots of the effect of time on the formation of 
acyl-CoA measured during the metabolism of linoleic acid (4.7 µM) 
using data from models 33, 34, 35, 36 and the experimental data from 
Figure 30. 
Overlay plots of the effect of time on the M-desaturation of 
linoleic acid (4.7 µM) using data from models 33, 34, 
35, 36 and the experimental data from Figures 19 and 20. 
Overlay plots of the effect of time on the acylation of 
phospholipids measured during the metabolism of linoleic 
acid (4.7 µM) using data from models 33, 34, 35, 36, 










FIGURE 78 Overlay plots of the effect of linoleic acid concentration on 269 
the formation of acyl-CoA measured during the metabolism of 
linoleic acid using data from models 33, 34, 35, 36 
and the experimental data from Figure 32 B. 
FIGURE 79 Overlay plots of the effect of linoleic acid concentration on 270 
the ti6-desaturation of linoleic acid using data from 
models 33, 34, 35, 36 and the experimental data from 
Figure 33 B. 
FIGURE 80 Overlay plots of the effect of linoleic acid concentration on 271 
the acylation of phospholipids measured during the metabolism 
of linoleic acid using data from models 33, 34, 35, 36 
and the experimental data from Figure 34 B. 
FIGURE 81 The effect of time on the disappearance of fatty acid (substrate) 273 
measured during the metabolism of linoleic acid (4.7 µM) using 
experimentally obtained data and data obtained from model 35 
of the simulated reaction scheme. 
FIGURE 82 The effect of time on the formation of acyl-CoA measured 274 
during the metabolism of linoleic acid (4.7 µM) 
using experimentally obtained data and data obtained 
from model 35 of the simulated reaction scheme. 
FIGURE 83 The effect time on the M-desaturation of linoleic acid (4. 7 µM) 275 
using experimentally obtained data and data obtained from 
model 35 of the simulated reaction scheme. 
FIGURE 84 The effect of time on the acylation of phospholipids during the 276 
metabolism of linoleic acid (4.7 µM) using experimentally 
determined data and data obtained from model 35 of the 









Plot of rate of formation of acyl-CoA versus linoleic acid 
concentration by acyl-CoA synthetase using experimentally 
obtained data from Figure 30 and data from model 35 of 
the simulated reaction scheme. 
Plot of rate of formation of -y-linolenic acid versus linoleic 
acid concentration by '16-desaturase using experimentally 
obtained data and data obtained from model 35 of the 
simulated reaction scheme. 
Plot of rate of acylation of phospholipids versus linoleic acid 
concentration by the lysophospholipid acytransferases using 
experimentally obtained data and data obtained from 
model 35 of the simulated reaction scheme. 
Formation of all the species of linoleoyl-CoA and 
-y-linolenoyl-CoA from linoleic acid {4.7 µM) with time 
using data from model 35 of the simulated reaction scheme. 
Lineweaver-Burk (A) and Eadie-Hofstee (B) plots for the 
M-desaturation of linoleoyl-CoA using data from 
model 35 the simulated reaction scheme. 
Plot of rate of formation of -y-linolenic acid by 
'16-desaturase versus linoleic acid concentration in 
the presence of isoflurane {2mM) using experimentally 
obtained data and data obtained from model 35A of the 
simulated reaction scheme. 
Lineweaver-Burk plot for the M-desaturation of 
linoleoyl-CoA in the absence and presence of isoflurane 











.Since the discovery of the anaesthetic properties of nitrous oxide and diethyl 
ether during the last century, the quest for a safer, better anaesthetic agent has 
continued, with two goals in mind: anaesthetic non-flammability and the 
absence of anaesthetic toxicity (1,2). The non-flammable properties appeared 
to be achieved by halogenation, but chlorine proved to be unsuitable resulting 
in enhanced anaesthetic toxicity, as was observed with chloroform (1,2). The 
development of the atomic bomb provided the necessary chemical technology 
for the inclusion of fluoride into anaesthetic ethers and led to the synthesis of 
fluroxene, halothane, methoxyflurane, enflurane and isoflurane (1,2). 
Fluroxene was the first halogenated anaesthetic to be synthesised in 1951; it 
was non-flammable but unstable, and was soon replaced by the highly 
successful anaesthetic, halothane (3). The structures of the halogenated 
anaesthetics, halothane, methoxyflurane, enflurane, and isoflurane together 
with some of their physical properties, are shown in Table 1. Halothane is a 
non-flammable anaesthetic agent, first introduced into clinical practice in 
1956 (5). Halothane has enjoyed great popularity as an anaesthetic agent, but 
is associated with occasional cases of potentially fatal hepatitis and more 
frequent cases of abnormal liver function (6,7). 
Methoxyflurane was the first of the non-flammable fluorinated ethers to be used 
as an anaesthetic agent (8). However, it is now seldom used because 
methoxyflurane anaesthesia is associated with polyuric renal failure (9). The 












































































































































































































































































































































































































































































































































































































































































metabolism to fluoride ion; fluoride ion is thought to be the metabolite causing 
renal dysfunction (10-13). 
Enflurane is a non-flammable, stable anaesthetic agent which was first 
introduced into clinical practice in the mid-1970's (9). Although enflurane, like 
methoxyflurane, is metabolised to the potentially nephrotoxic fluoride ion, the 
rate of metabolism of enflurane is so low that toxic fluoride levels (ca. 50 µM 
urinary fluoride) are seldom, if ever, reached (9, 14, 15). lsoflurane, a structural 
analogue of enflurane (Table 1), appears to be virtually devoid of nephrotoxicity 
also due to the low extent of metabolism to fluoride ion (1, 16). Although 
isoflurane is more costly to manufacture, it appears to be potentially the safest 
of all the fluorinated anaesthetic agents presently marketed (16). 
lsoflurane was first manufactured in 1965, two years after enflurane (1 ). 
Following extensive testing in both animal and human subjects, isoflurane 
showed no signs of organ toxicity and was scheduled for release by the 
pharmaceutical industry in 1975 (1 ). Shortly before its release, Corbett 
implicated isoflurane as the cause of hepatic neoplasia observed in mice (17). 
Further studies showed that the neoplasia was caused by polybrominated 
biphenyls contaminating the animals' foodstuff, and isoflurane was finally 
released in 1981 (1, 18, 19). From its release until 1987, there were 45 cases of 
hepatic dysfunction reported following isoflurane anaesthesia (20). These 
cases have been examined for a possible association between anaesthetic 
administration and subsequent hepatic dysfunction. The conclusion reached 
was that, based on current evidence, there does not seem to be any 
association between isoflurane anaesthesia and post-operative hepatic 
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dysfunction (20). Therefore, it would appear that isoflurane may represent a 
major advance in the search for a perfect anaesthetic. 
The toxicity resulting from anaesthesia has normally been (i) renal, as in the 
case of methoxyflurane, which is the result of its conversion to fluoride ion, or (ii) 
hepatic, as in the case of halothane. Although isoflurane anaesthesia is thought 
not to result in nephrotoxicity or hepatotoxicity, it is still essential to elucidate the 
interaction of isoflurane and its metabolites with hepatic enzymes. This thesis 
has focussed on an investigation of the interaction of isoflurane (and in certain 
cases, other halogenated anaesthetic agents) with two hepatic microsomal 
enzyme systems, viz: 
i) the cytochrome P-450-dependent drug-metabolising system, which 
catalyses the defluorination of volatile anaesthetic agents, including 
possibly isoflurane. 
ii) the fatty acid desaturases, which play a role in the biosynthesis of 
polyunsaturated fatty acids and consequently in the maintenance of 
membrane structure and function, as well as the biosynthesis of 
eicosanoids. 
The background to both of these hepatic enzyme systems, together with their 
role in anaesthetic metabolism and, in the case of the fatty acid desaturases, 
fatty acid metabolism will be discussed. 
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1.1 DRUG METABOLISM 
Organisms are increasingly exposed to foreign chemicals such as drugs, 
insecticides, environmental pollutants and food additives, which usually have no 
biological value (21 ). These chemicals are called xenobiotics (21-23). The 
body metabolises and then excretes these compounds via urine, faeces or 
exhaled air. The enzyme systems involved in the metabolism of xenobiotics 
have been extensively studied over the last 3 to 4 decades. 
Xenobiotics are usually of a hydrophobic nature and can undergo several types 
of reactions in the liver and other tissues to render them more hydrophilic in 
order that they can be more easily excreted. Such reactions include 
conjugation, hydrolysis, reduction or oxidation, of which oxidation and 
conjugation are considered to be qualitatively the most important. 
Xenobiotic metabolism often occurs in two phases (Figure 1) (21,24) : 
i) Phase 1: 
ii) Phase 2: 
The oxidation, reduction or hydrolysis of a non-polar 
xenobiotic to yield a more hydrophilic or polar metabolite. 
Subsequent conjugation of the polar metabolite to a 
small endogenous, usually highly polar, compound e.g. 
glutathione, glucuronic acid, sulfate, glycine or water. 
The general function of drug metabolism is the conversion of a relatively toxic 
hydrophobic xenobiotic to a relatively non-toxic hydrophilic compound which 


















Phase 1 and Phase 2 of drug metabolism 
X, xenobiotic. 





biotransformation of a non-toxic compound by Phase 1 and/or Phase 2 of drug 
metabolism results in a more toxic reactive compound (25,26). 
Ongoing research into chemical carcinogenesis has shown that a large number 
of chemicals believed to be carcinogens, require metabolic activation by the 
enzymes of Phase 1 and/or Phase 2 of drug metabolism (25-27). Enzymatic 
activation of chemical pre-carcinogens usually results in a relatively unstable, 
electrophilic intermediate which can bind covalently to the nucleophilic centres 
of membranes and/or macromolecules (25,28); for example, benzo(a)pyrene is 
metabolised by cytochrome P-450 and epoxide hydrase to the 
7,8-diol-9, 10-oxide, which is thought to be the ultimate carcinogen (28,29). 
Similarly, benz(a)anthracene is metabolically activated to the 1,2-3,4-oxide, and 
aflatoxin 8 1 , to the 2,3-oxide by cytochrome P-450 (25,28,29). Other types of 
compounds which are activated by the enzymes of Phase 1 or Phase 2 of drug 
metabolism include: 
i) the nitroso compounds, e.g. dimethylnitrosamine which is activated by 
cytochrome P-450 resulting in the electrophilic alkyldiazonium ion (27); 
ii) the haloalkanes, e.g. carbon tetrachloride which is activated to the 
trichloromethyl radical and associated oxy radical which cause liver 
necrosis and lipid peroxidation (30); 
iii) the haloethylenes, e.g. vinylchloride which is activated to chloroethylene 
oxide and chloroacetaldehyde by cytochrome P-450 (31 ). 
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Drug metabolism occurs in all organisms except anaerobic bacteria (32,33). In 
mammals, the liver contains the highest concentration of the drug metabolising 
enzymes; lower activities are found in most organs and tissues of the body i.e. 
in the kidneys, lungs, intestine, blood and skin (32,33). Some of the reactions 
catalysed by the enzymes of Phase 1 of drug metabolism are shown in Table 2. 
The oxidative reactions are the most common and these are primarily catalysed 
by a group of enzymes known as cytochrome P-450 (21,25,34). 
The conjugation reactions of Phase 2 of drug metabolism are catalysed by a 
number of different enzymes, which include glucuronyl transferase, glutathione 
transferase, methyl transferase, sulphotransferase and epoxide hydrase. More 
details of the reactions of Phase 2 of drug metabolism can be found 
elsewhere (21 ). 
Sometimes only a single transformation of a xenobiotic occurs, e.g. the 
oxidative reaction of Phase 1 of drug metabolism, but more frequently two 
processes are involved, e.g. oxidation followed by conjugation (21). The aspect 
of drug metabolism investigated herein, viz: the Phase 1 reactions catalysed by 
cytochrome P-450, will be considered in more detail. 
1.1.1 Cytochrome P-450 
Cytochrome P-450 is a haem protein found deeply embedded in the lipid bilayer 
of the endoplasmic reticulum* in association with the other components of an 
electron transport chain of which cytochrome P-450 is the terminal oxidase 
(Figure 2) (35-41 ). Cytochrome P-450 consists of a group of isozymes having a 
characteristic absorption peak at 450 nm of the ferrous-carbon monoxide 
* On homogenisation of the liver, the endoplasmic reticulum becomes 
fragmented, and the fragments form vesicles, known as microsomes (24). 
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TABLE 2 
PHASE I OF HEPATIC METABOLISM OF XENOBIOTICS * 
Reaction Enzyme Example 
Oxidative metabolism 
Oxidation of a variety of Cytochrome P-450 (Table 3) 
compounds (Table 3) 
Oxidation and/or reduction of Alcohol dehydrogenase, Ethanol 
aldehydes and carboxylic acids aldehyde dehydrogenase 
Reductive metabolism 
Reduction of azo- and nitre- Flavin enzymes, azo- and Sulfanilamide 
compounds nitre-red uctases, 
cytochrome P-450 
Reduction of carbonyl compounds, Cytochrome P-450 Chloral, halothane 
haloalkanes 
Hydrolysis 
Hydrolysis of esters Est erases Aspirin 




NADPH _. NADPH-Cytochrorie P-450 ___. Cytochrorie P-450 --t> 
Reduc-to.se 
/ 
NADH --. NADH-Cytochrorie b, -. Cytochrorie b, -. Fo. tty a.cid _. 02 
Reduc-to.se 
Indica. :es !':lectron Flow 
Indico. tes ~e-.;o.bolisr, 
Deso.turo.ses 
FIGURE 2 Interaction of two microsomal electron transport pathways 
RH, substrate; ROH, hydroxylated product. 
Compiled from references 34 and 92 
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complex, after which it was named in 1962 by Omura and Sato (35). The 
molecular weight of the cytochrome P-450 isozymes range from 48,000 to 
56,000 daltons (42-44,46-49). 
Cytochrome P-450 is a b-type cytochrome with an active centre containing an 
iron protoporphyrin IX in a large relatively open hydrophobic crevice of the 
protein (36,50-52). The haem is bound to the apoprotein by non-covalent 
forces, primarily hydrophobic in nature (50,52). The fifth ligand to the haem iron 
is provided by the thiolate group of a cysteine residue in the protein, and the 
sixth ligand is thought to be a relatively weak field ligand, such as water or the 
hydroxyl group of a neighbouring amino acid residue in the protein, such as 
serine or threonine (51-58). 
The most remarkable features of cytochrome P-450 are its broad substrate 
specificity, and the wide variety of reactions it catalyses (Table 3). The broad 
substrate specificity is due, in part, to the existence of isozymes, but even the 
purified isozymes interact with a number of different substrates (23). 
Cytochrome P-450 probably first evolved to take on the function of the 
biosynthesis and degradation of endogenous substrates critical to the 
organism's life function (58). However, during the course of evolution, the 
substrate specificity broadened so that cytochrome P-450 now metabolises 
both endogenous substrates and foreign chemicals (23,58,59). 
Substrates for cytochrome P-450 can be considered to be of 3 classes (23), viz: 




SOME HYDROXYLATION REACTIONS CATALYSED BY CYTOCHROME P-450 * 
Aromatic hydroxylation 
NHCOCH3 NHCOCH3 




R-CH3 ... R-CHz-OH + H + 
N-Dealkytation 
[OH] 
R-NH-CH3 ... [R-NH-CH20H) ... RNH2 + CH20 (Formaldehyde) 
0-Dealkytation 
[OH] 
R-0-CH3 ... [R-O-CH20H] ... ROH + CH20 (Formaldehyde) 
Deamination 
[OH) 
R-CH(NH2)-CH3 ... [R-C(OH) (NH2)-CH3] R-CO-CH3 + NH3 
Sulphoxidation 
[OH) 
R-S-R' ... [R-SOH-R') + ... R-SO-R' + H+ 
N-Oxidation 
[OH] 
(CHJ)3N ... [(CHJ)3NOHJ + ... (CHJ)3NO + H+ 
* Reproduced from reference 34. 
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ii) natural products that are found in foodstuffs, or formed on ingestion, e.g. 
vitamins, steroids, fatty acids, mycotoxins and alkaloids. 
iii) xenobiotics, e.g. industrial chemicals, pesticides, drugs and 
environmental pollutants. 
1.1.1.1 Binding of Compounds to Cytochrome P-450 
The first step in the oxidative and reductive metabolism of compounds, 
including xenobiotics and endogenous substances, by cytochrome P-450, is 
the binding of the substrate to the oxidised form of the enzyme (32,45,61 ). The 
binding of a compound to cytochrome P-450 results in a characteristic 
spectrum which is most often identified by formation of a difference spectrum in 
microsomes (or with purified cytochrome P-450). The difference spectrum can 
be measured from the difference in absorbance between hepatic microsomes in 
which the compound is bound to cytochrome P-450 versus hepatic 
microsomes in the absence of a compound (61-63). The difference spectrum is 
thought to arise from a change in spin state of the haem iron (51,64-68). In 
hepatic microsomes, the cytochrome P-450 isozymes exist in an equilibrium of 
spin states which are regulated, in part, by the environment of the haem iron, 
and in part by the binding of endogenous substrates, such as fatty acids 
(32,51,52). In the high spin form of cytochrome P-450, all 5 d electrons are 
unpaired and the iron is penta-coordinate; four ligands are provided from the 
haem pyrrole nitrogens and the fifth ligand is a thiolate anion from a cysteine 
residue in the protein (32,50-52). In the low spin form, there are 2 electrons in 
each of the lowest d orbitals, and one unpaired electron in the next highest 
orbital and the haem is hexacoordinate; the sixth ligand position is either vacant 
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(pentacoordinate) or occupied by an easily exchangeable ligand, such as water 
or a hydroxyl group (hexacoordinate) (32,50-52). 
The difference spectrum resulting from the binding of a compound to 
microsomal cytochrome P-450 fall into one of three categories: Type I, Type II 
or Type IR difference spectra (63,64,69). A Type I difference spectrum arises 
from the formation of an enzyme-substrate complex, while Type II arises from 
the binding of a compound (ligand), usually a good electron donor, directly to 
the haem iron. The spectral and spin state changes associated with these 
types of difference spectra are illustrated in Figure 3. 
1.1.1.2 Oxidative Reactions Catalysed by Cytochrome P-450 
The oxidative reactions catalysed by cytochrome P-450 are thought to involve 
an initial hydroxylation of the compound, which may re-arrange to form a 
product of different structure (34) (Table 3). The overall reaction for the 
oxidative metabolism of compounds by cytochrome P-450 is thought to be: 
NADPH + H + + 02 + RH -+ ROH + NADP+ + H20 .............. (1) 
where RH represents lypophilic substrate and ROH represents hydroxylated 
product (32,34,69). As shown here, cytochrome P-450 exhibits 
'monooxygenase' activity, i.e. catalyses the incorporation of one atom of 
dioxygen into the substrate (32,34,69). The other atom of dioxygen is usually 
reduced to water (32,69)*. 
* Cytochrome P-450 is also known as a mixed function oxidase since the 
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wo.velength (nr,) 
The binding of a substrate (A) and ligand (B) to cytochrome P-450, showing the 
apoprotein (cloudy) and plane of the porphyrin ring 
The spin state changes and resulting difference spectra which accompany the binding 
of a substrate (A) and ligand (8) to cytochrome P-450 are also illustrated (83). 
Reproduced from reference 78 
1.1.1.3 
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Mechanism of Cytochrome P-450 Catalysed Oxidative 
Reactions 
Although cytochrome P-450 consists of a number of isozymes which catalyse 
the oxidative metabolism a wide variety of substrates, the mechanism of 
oxidation of all compounds has been assumed to be uniform for all forms of 
cytochrome P-450 (70). A mechanism for the oxidative metabolism of 
compounds by cytochrome P-450 which was initially proposed by 





The binding of the substrate to the substrate-binding site results in 
a Type I difference spectrum. The binding of the substrate 
changes the spin state of ferricytochrome P-450 from low to high 
spin, which facilitates the next step in the pathway 
(51,64,67,68,75). 
Reduction of the ferricytochrome P-450-substrate complex to 
ferrocytochrome P-450-substrate complex by reducing 
equivalents usually donated from NADPH via NADPH-cytochrome 
P-450 reductase (See Section 1.1.1.6); this step sets the stage for 
binding and activation of molecular dioxygen (75). 
The binding of molecular dioxygen with the ferrous cytochrome 
P-450-substrate complex yields a ferrous dioxygen complex 
(32,34). The dioxygen binds to the haem iron trans to the thiolate 
sulfur atom (fifth axial ligand) (32). 
FIGURE 4 
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Proposed scheme for the mechanism of action of cytochrome P-450 in xenobiotic 
hydroxylation 
RH, substrate; ROH, hydroxylated product; Fe2 + and Fe3 +, haem iron of 
cytochrome P-450. 




A second electron from NADH or NADPH via NADH-cytochrome 
b5 reductase and cytochrome b5 or via NADPH-cytochrome 
P-450 reductase, reduces the oxyferrocytochrome P-450-
substrate complex. 
The dioxygen bridge is broken resulting in the formation of an 
activated oxygen. 
Steps 6& 7: Once the dioxygen bridge has been broken, oxygen insertion into 
the substrate is thought to occur via hydrogen abstraction by the 
activated oxygen followed by recombination of the resultant 
c~rbon and hydroxyl radicals to give hydroxylated product (32). 
Step 8: The last step of the reaction involves dissociation of the 
hydroxylated product from cytochrome P-450 yielding the 
hydroxylated product and low spin ferric cytochrome P-450. 
Steps 1, 3 and 6 are probably rapid and not rate-limiting (32,74). The rates of 
the other steps are influenced by a variety of circumstances, such as the 
association of cytochrome P-450 with cytochrome b5 and NADPH-cytochrome 
P-450 reductase, the nature of the substrate, the cytochrome P-450 isozyme, 
availability of NADPH and type of membrane phospholipid used to reconstitute 
the cytochrome P-450 complex (32,50,74). It has been postulated that the 
rate-limiting step varies depending on specific conditions and more than one 
rate-limiting step may in fact exist (32,50,74). 
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1.1.1.4 Autooxidation of Cytochrome P-450 
The reductive metabolism of dioxygen by cytochrome P-450 gives rise to the 
formation of active oxygen species, viz: superoxide anion, from a one electron 
transfer to oxygen and/or peroxide anion from a two electron transfer to oxygen 
(32,68,75-77) (Figure 4). 
During the generation of active oxygen species, cytochrome P-450 exhibits 
oxidase activity, viz: 
-+ """. (2) 
In the absence of substrate, this process is termed "autooxidation" (75,77). The 
oxidase activity of cytochrome P-450 is thought to arise from the decay of 
oxyferrocytochrome P-450 to either superoxide anion or hydrogen peroxide 
(75-77). Superoxide is usually dismutated viz: 
superoxide 
-+ ....... (3) 
dismutase 
The oxidase activity of cytochrome P-450 gives rise to the formation of active 
oxygen species with the futile consumption of reducing equivalents. It has been 
suggested that the spin state of substrate free-cytochrome P-450 regulates the 
production of active oxygen species by minimising electron flow to the 
haemoprotein-bound molecular dioxygen; cytochrome P-450 in high spin form 
does not require substrate binding for rapid reduction (32,68). 
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The exact mechanism of hydrogen peroxide and superoxide formation in 
microsomal systems has, as yet, not been resolved (75, 78). Cytochrome P-450 
appears to play a role in the generation of hydrogen peroxide and superoxide 
anion in the microsomal system, rather than the other components of the 
electron transport pathway (79). The involvement of cytochrome P-450 in this 
process is demonstrated by the inhibition of hydrogen peroxide generation by 
ligands such as carbon monoxide and cimetidine which bind to the dioxygen 
binding site (75,78). However, the purified reconstituted system differs in its 
source of hydrogen peroxide; NADPH-cytochrome P-450 reductase is 
predominantly responsible for hydrogen peroxide production suggesting that a 
more intact system such as microsomes or cellular suspensions might be 
preferable for this type of investigation (82). 
1.1.1.5 Stoichiometry of Oxidative Reactions 
The stoichiometry of the monooxygenase activity of cytochrome P-450-
catalysed reactions ( equation 1, page 14) is expected to be: 1 molecule of 
NADPH consumed : 1 molecule oxygen utilised : 1 molecule product generated. 
In determining the stoichiometry of cytochrome P-450 monooxygenase 
reactions, it is necessary to make a correction for the oxidase activity (equation 
2, page 19) in which 1 molecule of NADPH and oxygen are consumed for every 
1 molecule of hydrogen peroxide generated. Such oxidase activity is found in 
hepatic microsomes on the addition of reducing equivalents in the absence of 
substrate. Therefore, by accounting for the oxidase activity in the stoichiometry 
of the monooxygenase activity of cytochrome P-450, the hydrogen peroxide 
plus product generated should be in a 1 : 1: 1 ratio with oxygen consumed and 
NADPH oxidised. The measurement of the stoichiometry of cytochrome P-450 
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dependent oxidations is further complicated by the proposal that the 
cytochrome P-450 monooxygenase and oxidase activities may not involve a two 
electron transfer: a one electron transfer may be involved in the production of 
superoxide and a four electron transfer has been reported for the oxidation of 
ethanol to acetaldehyde using a purified cytochrome P-450 isozyme in the 
reconstituted system (32,75,81,82). Furthermore, a four electron transfer to 
oxygen has been postulated as a source of water in microsomes, rather than 
the monooxygenase reaction (equation 1, page 14) (83). 
Besides the production of active oxygen species from autooxidation of 
cytochrome P-450, it has been well documented that some substrates of 
cytochrome P-450 channel electrons from NADPH into the formation of 
hydrogen peroxide as well as into making product i.e., these substrates 
increase the oxidase activity of cytochrome P-450 (32, 75,80). The production of 
active oxygen species by cytochrome P-450 in the presence of a substrate is 
termed uncoupling. The extent of uncoupling depends on the nature of the 
substrate, the cytochrome P-450 isozyme and the spin state of cytochrome 
P-450 (32,84). For example, perfluoro-n-hexane completely uncouples 
cytochrome P-450, i.e. there is increased hydrogen peroxide generation and 
NADPH consumption with no measurable product formation (75). Since many 
substrates partially uncouple cytochrome P-450, the stoichiometry of 1 : 1: 1, for 
NADPH consumption:oxygen utilisation:product formation expected from the 
monooxygenase reaction, may seldom be achieved. 
In addition to oxidative reactions, cytochrome P-450 also catalyses the 
reductive metabolism of a number of compounds, including halothane, carbon 
tetrachloride and hexachlorobenzene (85-88). 
1.1.1.6 
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The Role of the Other Components of the Electron Transport 
Pathway in Cytochrome P-450-dependent Oxidations 
Cytochrome P-450-catalysed oxidative metabolism can be reconstituted with 
NADPH-cytochrome P-450 reductase, cytochrome P-450, lipid, oxygen and 
reducing equivalents supplied preferentially by NADPH (Figure 2). The lipid, 
which is either that of the microsomal membrane or exogenous lipid, such as 
dilauroylphosphatydyl micelles, influences substrate binding and is required for 
optimal interaction of the proteins for electron transfer (32,89,90). 
Although NADPH is the preferential electron donor, reducing equivalents can be 
supplied directly to cytochrome P-450 from artificial electron donors such as 
dithionite and ascorbate, or via cytochrome b5 and NADH-cytochrome b5 
reductase from NADH (32,45,52,62,91 ). Although NADH only supports 
cytochrome P-450-dependent drug oxidations to a limited extent, it has a 
synergistic effect on drug oxidations when NADPH is also present (34,62,92). 
The mechanism of this observed synergism is not understood, but it is 
postulated that NADH can more effectively supply the second electron for 
oxygen activation via cytochrome b5 (62,93,94). 
A similar stimulatory effect on the cytochrome P-450-dependent oxidations of 
some substrates is observed in a reconstituted system in the presence of 
cytochrome b5. In the purified reconstituted system, the various isozymes of 
cytochrome P-450 have an absolute, a partial, or no requirement for 
cytochrome b5 (95-99). The requirement for cytochrome b5 depends also on 
the nature of the substrate. For example, for the oxidation of methoxyflurane 
(rabbit hepatic cytochrome P-450LM2) (95) and the 0-deethylation of 
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p-nitrophenetole (rat hepatic cytochrome P-450PB), the phenobarbital-
inducible isozymes show an absolute requirement for cytochrome b5 (96). In 
contrast, both the phenobarbital- and 3-methylcholanthrene-inducible forms 
show no requirement for cytochrome b5 for the oxidation of both aniline and 
ethylmorphine (rat hepatic cytochrome P-450MC) (96). 
Cytochrome b5 has been shown to bind tightly in a 1: 1 stoichiometry to 
cytochrome P-450 through electrostatic attractions mediated, in part, by 
cytochrome b5 haem proprionate groups (100-102). This association between 
cytochrome P-450 and cytochrome b5 is thought to be specific for the 
phenobarbital-induced forms of cytochrome P-450; it has been suggested that 
only certain cytochrome P-450 isozymes have a cytochrome b5 binding site 
(101). The interaction of cytochrome P-450 and cytochrome b5 is accompanied 
by a change in the cytochrome P-450 spin state to a relatively higher spin form 
which increases the rate of the first electron reduction of cytochrome P-450 
(100,103). 
NADPH-cytochrome P-450 reductase has recently been shown to bind to 
cytochrome P-450 at a different binding site from that of cytochrome b5 
(104,105); carboxyl groups of NADPH-cytochrome P-450 reductase are 
involved in charge-pair interactions with two cytochrome P-450LM2 amino 
groups (106). It has been suggested that both electrostatic interactions and 
steric constraints play a role in the binding and electron transfer step(s) (107). 
Cytochrome P-450 reduction by NADPH-cytochrome P-450 reductase is 
biphasic; the mechanism is complex and currently under investigation 
(108-110). 
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1.1.1.7 Inhibitors of Hepatic Microsomal Cytochrome P-450 
There are three steps in the cytochrome P-450 catalytic cycle (Figure 4) at 
which a compound can inhibit cytochrome P-450-dependent reactions (111). A 
compound can inhibit (i) substrate binding, (ii) the binding of molecular 
dioxygen subsequent to the first electron transfer, and (iii) the catalytic step at 
which the substrate is oxidised. 
1.1.1.7a Competitive Inhibitors 
Compounds which compete with the substrate for the substrate-binding site 
usually inhibit cytochrome P-450-dependent oxidations in a reversible 
manner (112). Any compound which is a substrate for cytochrome P-450 will 
inhibit cytochrome P-450 catalysed reactions in this way, e.g. hexobarbital, 
ethylmorphine and benzamphetamine (112,113). 
1.1.1.7b Non-competitive Inhibitors 
Compounds which bind directly to the haem iron inhibit cytochrome 
P-450-dependent oxidations by preventing dioxygen binding (111). Carbon 
monoxide and cyanide are examples of this type of inhibitor (111 ). Because of 
specificity of carbon monoxide for cytochrome P-450 among microsomal 
proteins, this inhibitor is commonly used to identify cytochrome 
P-450-dependent drug oxidations (111 ). Metyrapone is an inhibitor of 
cytochrome P-450 oxidations which is shown to bind to both the substrate 
(Type I) and ligand (Type II) binding sites (111,113). The binding of metyrapone 
to both ligand and substrate binding sites makes it a more effective inhibitor of 
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cytochrome P-450 oxidations than those that bind only to a single site (111 ). 
The binding of metyrapone to both sites is thought to arise from an allosteric 
mechanism in which metyrapone has contact with both binding sites (113). 
1.1.1.7c Metabolic Intermediate Inhibitors 
These inhibitors of cytochrome P-450 oxidations require metabolic activation by 
cytochrome P-450 giving rise to an intermediate which binds directly to the 
haem iron, e.g. isosafrole and piperonyl alcohol (114). These inhibitors, unlike 
metyrapone and carbon monoxide, require the presence of oxygen and NADPH 
for inhibition to occur, i.e. they inhibit the catalytic step of cytochrome P-450 
oxidations. Since the metabolite binds to the haem of cytochrome P-450, the 
resulting complex has spectral properties similar to those of carbon monoxide, 
viz: an absorbance maximum of the reduced cytochrome P-450 complex 
between 448 and 456 nm. The complex, once formed, appears to inhibit 
cytochrome P-450 catalysed oxidations in a non-competitive manner (114). 
1.1.1.7d Suicide Inhibitors 
Suicide inhibitors of cytochrome P-450-catalysed oxidations are compounds 
which usually modify the haem moiety of cytochrome P-450 into an N-alkyl 
porphyrin; this process requires oxygen and NADPH. This type of compound 
inhibits the catalytic step of cytochrome P-450 oxidations. Examples include 
2-allyl-2-isopropylacetamide, secobarbital and other olefinic compounds 
(115,116). For 2-allyl-2-isopropylacetamide, inhibition of cytochrome P-450 is 
as follows: formation of the enzyme-substrate complex is followed by reduction 
of the haem iron, binding of molecular oxygen and metabolism of the allyl group 
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of the substrate to a reactive intermediate (111,115,117). The reactive 
intermediate alkylates the haem moiety to yield a N-alkylated porphyrin 
derivative which may be released by the apoprotein and can be detected as 
one or more "green pigments". The cytochrome P-450 apoprotein can take up 
haem from the hepatic haem pool to reconstitute the cytochrome P-450 (115). 
1.1.1.8 Multiple Forms of Cytochrome P-450 
The multiplicity of cytochrome P-450 in animal species was first suggested by 
Conney in 1957 when benzo(a)pyrene was shown to increase the microsomal 
metabolism of substrates such as benzo(a)pyrene, zoxazolamine, but not 
meperidine (118). Subsequently, it was reported that liver microsomes isolated 
from phenobarbital-pretreated rats contained elevated levels of a form of 
cytochrome P-450 which differed in the carbon monoxide spectral 
characteristics and substrate specificity from that induced by 
3-methylcholathrene. Over the last decade, cytochrome P-450 isozymes from 
different species have been isolated, sequenced, cloned and assigned to 
specific chromosomal regions. This remains an area of active research. 
The similarity of function of the cytochrome P-450 isozymes plus the great 
degree of structural divergency has resulted in the proteins being divided into 
different gene families and subfamilies (119). The cytochrome P-450 gene 
superfamily presently consists of fourteen gene families, of which nine are from 
mammals (128). Cytochrome P-450 proteins within a gene family have a certain 
amount of structural similarity (ca. > 50%) (121 ). The cytochrome P-450 
isozymes, which are members of the gene families I to IV, are the primary 
drug-metabolising enzymes and are found to the greatest extent in the 
liver (119). 
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The properties of eight rat liver isozymes* from gene families I to IV are 
summarised in Table 4. Of particular interest here are the rat liver cytochrome 
P-450 isozymes induced by the polycyclic aromatic hydrocarbons, 
phenobarbital and pregnenolone-16a-carbonitrile. These isozymes are 
members of the gene families I, II and Ill and will be considered in more detail; 
tr:a other cytochrome P-450 isozymes are reviewed elsewhere (119,122 and 
references cited therein). 
1.1.1.Sa Phenobarbital-Inducible Cytochrome P-450 lsozymes 
Pretreatment of animals with phenobarbital raises the levels of hepatic 
microsomal cytochrome P-450 isozymes which are members of the P45011B 
subfamily, together with the levels of NADPH-cytochrome P-450 reductase 
(34,60, 119,134). This is parallelled by an increase in the oxygenation of a large 
number of lipophilic substrates, both exogenous (e.g. drugs such as 
methoxyflurane) and endogenous (e.g. steroids) (f0,60, 134). Initially, 
phenobarbital was thought to induce only one cytochrome P-450 isozyme, 
cytochrome P-450b (Table 4) which is the major phenobarbital-inducible form of 
the enzyme. Subsequently, the phenobarbital inducible gene family has been 
found to be the largest and most complex (121, 124,129); microheterogeneity 
has been observed in the purified enzyme and the cDNA encoding for the 
*The nomenclature of the cytochrome P-450 isozymes is very confusing as 
every laboratory involved in cytochrome P-450 purification has adopted its own 
system. Recently, a nomenclature system has been developed based on 
primary amino acid sequence alignment data, where the cytochrome P-450 
proteins are grouped into gene families and subfamilies (122). The 
nomenclature adopted herein follows that of Levin (132,133) and the 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































phenobarbital-inducible forms in rabbits (135). Cytochrome P-450b has been 
separated by HPLC into at least three different isozymes which have the same 
molecular weight and electrophoretic mobility; these isozymes are 
immunochemically indistinguishable (43,44, 124,130,131,136). 
In addition to cytochrome P-450b, phenobarbital induces another closely 
related isozyme, cytochrome P-450e (60,119,132,137). Cytochrome P-450b 
and e exhibit 97% similarity in content of amino acids (119). They are 
immunochemically related and show only minor differences in substrate 
specificities, but are encoded by distinct RNAs, which are transcribed by two 
closely linked genetic loci (60,127,130,133,136). Although cytochrome P-450b 
and e are co-induced, the levels of cytochrome P-450b has a 5-fold higher 
catalytic activity for certain substrates (e.g, benzamphetamine) than 
cytochrome P-450e (119,138,139). The higher activity of cytochrome P-450b 
compared to cytochrome P-450e is thought to be related to differences in their 
haem environments (125). 
Phenobarbital regulates cytochrome P-450 induction by increasing the 
transcriptional rate of the mRNAs for the phenobarbital isozymes. The increase 
in the transcriptional rate results in an accumulation of a mRNA which is 
undetectable in control animals (60,119,140). 
1.1.1.Sb Polycyclic Aromatic Hydrogen-Inducible Cytochrome P-450 
isozymes 
Compounds which induce the isozymes which are members of P4501A gene 
family include 3-methylcholanthrene, .B-naphthoflavone, benzo(a)pyrene and 
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isosafrole, all of which induce specific isozymes without increasing proliferation 
of the endoplasmic reticulum (34,118). The isozymes of this cytochrome P-450 
gene family catalyse the hydroxylation of a limited number of exogenous 
compounds, usually arylhydrocarbons, many of which are carcinogens such as 
benz(a)athracene, benzo(a)pyrene (34,60, 119). Consequently, the isozymes of 
this gene family play a major role in chemically induced neoplasia and toxicity 
(141-143). The isozymes induced by the polycyclic aromatic hydrocarbons are 
cytochrome P-450c and cytochrome P-450d (Table 4) (60,132). They are 
commonly known as "cytochrome P-448" because of the shift in absorbance 
maximum of the reduced carbon monoxide complex from 450 nm to 448 nm. 
3-Methylcholanthrene, ,8-naphthoflavone and benzo(a)pyrene preferentially 
induce cytochrome P450c, whereas isosafrole preferentially induces 
cytochrome P-450d (60,144,145). These two isozymes show a sequence 
homology of approximately 70%, and are weakly immunochemically related 
(146-148). Cytochrome P-450c does not exhibit microheterogeneity (43). 
Regulation of the cytochrome P-450c and d genes appears to be complex, and 
is still being investigated (119). There is, however, evidence that the polycyclic 
aromatic hydrocarbons induce cytochrome P-450 isozymes by a 
inducer-receptor complex mechanism (60,120,140). 
1.1.1.Sc Pregnenolone-16a-carbonitrile-lnducible Cytochrome P-450 
lsozymes 
Pregnenolone-16a-carbonitrile is a synthetic steroid derivative lacking in 
hormonal activity which induces cytochrome P-450 isozymes which are 
members of the P450111 gene family, as well as enhancing NADPH-cytochrome 
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P-450 reductase activity (60,149,119). It has been suggested that these 
isozymes play a role in the metabolism of endogenous compounds, although 
the physiological substrate is not known (60,150). Multiplicity of the isozymes of 
the P450111 gene family has been reported (126): cytochrome P-450PCN1 is 
induced by steroids and phenobarbital, whereas cytochrome P-450PCN2 is 
induced by only phenobarbital (119,126). 
The mechanism of pregnenolone-16cr-carbonitrile induction is unknown (60). 
Since pregnenolone-16cr-carbonitrile pretreatment results in an accumulation of 
mRNA for the pregnenolone-16cr-carbonitrile-inducible cytochrome P-450 
isozyme, pregnenolone-16cr-carbonitrile induction may operate at the 
transcriptional level (60). 
1.1.1.Sd Cytochrome P-450 lsozymes in the Liver of Untreated Animals 
In addition to the small amounts of phenobarbital-inducible cytochrome P-450b 
and polycyclic aromatic hydrocarbon inducible-cytochrome P-450c, there is a 
another isozyme, cytochrome P-450a, jn the hepatic microsomes from 
untreated rats (139). Cytochrome P-450a, a member of the P45011A gene 
subfamily, is slighlty inducible by phenobarbital and 3-methylcholanthrene, and 
is not very active in catalysing the metabolism of exogenous substrates 
(42,119,120). 
1.1.1.Se Cytochrome P-450 lsozymes in Human Liver 
The recent availability of fresh material from transplant donors has facilitated the 
isolation and characterisation of human cytochrome P-450 isozymes (156). At 
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least 16 microsomal cytochrome P-450 genes have been identified, 11 of which 
are hepatic (151,158). Some of these have been sequenced, cloned and 
localised to a chromosome and are reviewed elsewhere (151). 
There is evidence that human cytochrome P-450 exhibits polymorphism 
amongst different individuals, since the cytochrome P-450 isozymes have been 
linked to the observed polymorphism of drug metabolism in humans (159,160). 
Genetic polymorphism of drug metabolism has been demonstrated for a variety 
of drugs (Table 5), but the drug which has been most extensively studied is 
debrisoquine (162-164). The major metabolite of debrisoquine is the 
4-hydroxylated product and there are two phenotypes for debrisoquine 
metabolism: poor metabolisers (about 10% of caucasian populations), who 
excrete the drug unchanged and consequently suffer from cardiovascular 
effects, and extensive metabolisers who excrete debrisoquine metabolites 
(162). Poor metabolisers of a drug family have either a decreased content of a 
cytochrome P-450 isozyme, or a functionally altered enzyme (165-167). At 
present, there appear to be five drug families which exhibit genetic 
polymorphism in humans (Table 5). 
1.1.2 Proteins Associated with Cytochrome P-450-Dependent Oxidations 
1.1.2.1 NADPH-Cytochrome P-450 Reductase 
Since NADPH-cytochrome P-450 reductase is the only obligatory electron 
transfer protein for cytochrome P-450, it will be discussed here. The other 
proteins, NADH-cytochrome b5 reductase and cytochrome b5 will be discussed 
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TABLE 5 
HUMAN AND RAT LIVER CYTOCHROME$ P-450 ISOSYMES INVOLVED IN 







Specific cytochrome P-450 
involved in humans 
P-45009 
? 
* Compiled from reference 156,157,161 
t See references 119,122 and 157. 















with the fatty acid desaturases, since they form essential components of the 
fatty acid desaturase pathway. 
NADPH-cytochrome P-450 reductase accepts electrons from NADPH in 
preference to NADH. NADPH-cytochrome P-450 reductase donates electrons 
to cytochrome P-450, and a number of artificial electron acceptors, including 
cytochrome c (62, 168). The reduction of the cytochrome P-450 by NADPH 
proceeds via both one-electron equivalent, and two-electron equivalent 
mechanisms (62,169). NADPH-cytochrome P-450 reductase is a 
membrane-bound flavin protein with a molecular weight of about 77,000 
daltons, and contains one molecule each of FMD and FMN per molecule of the 
enzyme (32,170). NADPH-cytochrome P-450 reductase has been purified to 
homogeneity by several techniques including NADP-sepharose affinity 
chromatography (171 ). 
The interaction of NADPH-cytochrome P-450 reductase with both cytochrome 
P-450 and cytochrome b5 has already been discussed (Section 1.1.1.6). 
1.1.3 The Metabolism of Volatile Anaesthetic Agents by Hepatic 
Microsomal Cytochrome P-450 
The metabolism of halothane, methoxyflurane and enflurane by the different 
cytochrome P-450 isozymes and the metabolic pathways for these drugs have 
been studied (6,95, 172-183). In contrast, the role played by the cytochrome 
P-450 isozymes in the metabolism of isoflurane and the details of its metabolic 
pathway, remains to be resolved. 
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lsoflurane has been shown to be very resistant to biotransformation 
(1,191,192). In man, more than 95% of the administered dose of isoflurane was 
recovered unaltered, of which only 0.2% was recovered as urinary inorganic 
fluoride (1, 192). Mean peak serum inorganic fluoride concentration was only 
4.4 µM/L following six hours isoflurane anaesthesia in man (1,193). Metabolism 
of isoflurane in vivo to inorganic fluoride appears to be insufficient to cause renal 
dysfunction, so that nephrotoxicity is unlikely to be linked with isoflurane 
anaesthesia (192,194). 
The proposed pathways of isoflurane metabolism are illustrated in Figure 5. Of 
the proposed metabolites, inorganic fluoride has been identified in vitro and in 
vivo in both rats and humans (184,194). An additional metabolite, trifluoroacetic 
acid, has been found in the urine of humans following isoflurane anaesthesia 
(Figure 5) demonstrating that isoflurane is probably metabolised by the 
dechlorination pathway in humans (which is the pathway favoured by the 
quantum mechanical considerations of Loew et al) (7, 183,195). 
At the time of initiation of our studies, the only evidence suggesting that 
cytochrome P-450 might metabolise isoflurane arises from the enhanced rate of 
defluorination of the anaesthetic in hepatic microsomes following phenobarbital 
and ethanol (or isozianid) pretreatment of rats (179,184). However, in contrast 
to the in vitro results, phenobarbital pretreatment of rats had no effect on the 
extent of isoflurane defluorination in vivo (184,186,187). 3-Methylcholanthrene 
































































































































































































































































































































































































































Since it is not apparent which enzyme(s) defluorinate isoflurane, and there is 
only a single report of the identity of the metabolites (195), our study of the 
metabolism of isoflurane by cytochrome P-450 was undertaken to (i) identify 
the enzyme(s) catalysing the defluorination of isoflurane and (ii) to confirm the 
identity of the products of isoflurane metabolism in human and rat hepatic 
microsomes. 
Besides the involvement of cytochrome P-450 in the metabolism of anaesthetic 
agents, there is also evidence that halothane, methoxyflurane and enflurane 
interact with hepatic microsomal ~9-desaturase. For this reason, further studies 
on isoflurane in hepatic microsomes focussed on its interaction with the fatty 
acid desaturases and some of the other enzymes involved in fatty acid 
metabolism. Some of our studies were extended to include halothane, 
methoxyflurane and enflurane. The next sections, therefore, discuss the 
pathways of fatty acid metabolism in hepatic microsomes. 
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1.2 FATTY ACID METABOLISM 
1.2.1 Fatty Acids 
There are three families of polyunsaturated fatty acids which arise from 18 
carbon fatty acid precursors, and these are described by the position of the 
nearest double bond from the methyl end of the molecule (Figure 6) (196-198) : 
i) The n-9 family arises from stearic acid (Table 6) which is not an essential 
fatty acid as it can be synthesised by the fatty acid synthetase pathway 
from acetate in mammalian systems (196,199). 
ii) The n-6 family arises from the dietary intake of linoleic acid which cannot 
be synthesised in animals; in plants oleic acid can be desaturated by the 
A 12-desaturase to form linoleic acid (Table 6) (196). The A 12-desaturase 
activity was lost in vertebrates and invertebrates during metazoan 
evolution (200). Linoleic acid is, therefore, an essential fatty acid in 
mammals. Another fatty acid member of the n-6 family is arachidonic 
acid (Figure 6), which is the most abundant fatty acid in cell membranes 
and the most important precursor of eicosanoid biosynthesis (201 ). 
Arachidonic acid can either be obtained directly from the diet or it can be 
synthesised from linoleic acid (Figure 6). 
iii) The n-3 family arises from dietary a-linolenic acid. The n-3 family of fatty 
acids is essential in that it cannot be synthesised by animal tissues, but is 
of a different class to the n-6 family and is found mainly in highly 







































































































































































































































































































































































































































































































































18:3, M,9, 12 
18:3, M,12,15 
18:3, M trans, 9 cis, 12 cis 
20:3, A8, 11, 14 
20:3, M,8, 11 
20:4, M,8,11,14 
20:5, M,8, 11, 14, 17 
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Fatty acids were first found to be essential constituents of the diet by Burr and 
Burr in 1929 (203), and have been considered to have the same nutritional 
status as vitamins (202). Some of the symptoms ascribed to a lack of essential 
fatty acids in the diet include dermititis, impaired growth and increased water 
consumption (204). 
Fatty acids are thought to be essential components of the diet for two reasons 
(198,199,202) : 
i) Fatty acids are major constituents of cell membranes and exert control 
over the structural integrity of the membrane. In this capacity, fatty acids 
regulate the functioning of membrane-bound proteins and enzymes 
whose activity is dependent on the nature of the surrounding membrane 
lipids (204-208). 
ii) Fatty acids are essential precursors of the eicosanoids, prostaglandins, 
thromboxanes, and leukotrienes which influence many cellular 
reactions (201 ). 
Members of the n-6 family of fatty acids which can relieve the symptoms of 
essential fatty acid deficiency are linoleic acid, found in many vegetable seed 
oils, and arachidonic acid, obtained predominately from animal foods (199). 
Another fatty acid which has been found to relieve some of the symptoms of 
essential fatty acid deficiency is columbinic acid, which is found in columbine 
seeds (205,209). It has been suggested that columbinic acid may function as 
linoleic acid or arachidonic acid in epidermal tissues thus relieving some of the 
essential fatty acid deficiency symptoms related to the skin (204). 
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The important function of fatty acids in the formation and maintenance of 
cellular membranes is strongly suggested by many features of the nature of 
essential fatty acid deficiency disease, such as dermititis and water permeability 
of the skin (197,205,209). 
Fatty acids are found in the lipid component of cellular membranes and play an 
important role in determining the physical and chemical properties of 
membranes (206,207). The fatty acid composition of the lipid component of 
cellular membranes is the net result of complex interrelations of a number of 
enzyme systems, as well as the composition of dietary fatty acids, most of 
which are important factors in controlling membrane fluidity (205,206,208). The 
most important lipid components of microsomal membranes are the 
phospholipids. 
1.2.2 Phospholipids 
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Fatty acid R1, is usually saturated, e.g. stearic acid or palmitic acid, whereas R2 
is usually unsaturated, predominently arachidonic acid, linoleic acid or oleic 
acid, but will vary depending on dietary intake of fatty acids and tissue 
(201,206-208). Phosphoric acid or, more usually, a phosphorylated base (X), 
may be esterified at the carbon position 3, forming phosphatidic acid 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine or 
phosphatidylinositol. The phospholipid content of microsomal membranes is 
shown in Table 7. 
The arrangement of the lipid components of microsomal membrane depends 
on the amphipathic nature of the phospholipids (206,207). The polar head 
contains the phosphorylated base, and the fatty acid forms the hydrophobic tail. 
The membranes are arranged in bilayers with the polar heads being exposed to 
the cytoplasmic surface. The fatty acid composition of the hydrophobic portion 
of the phospholipid will determine the nature of the hydrophobic interactions 
and consequently membrane fluidity (206,207). 
Some of the enzymes responsible for regulating fatty acid homeostasis and the 
fatty acid composition of cellular membranes are the acyltransferases, 
phospholipases, fatty acid desaturases and fatty acid elongases. The formation 
of the CoA derivative of the fatty acids, which forms the substrate for these 
enzymes, is catalysed by the long-chain acyl-CoA synthetase These enzymes 
play an essential role in the pathways of fatty acid metabolism (Figure 7) and will 



















These lipids form about 30% of the content of the microsomal membrane which also contains small 




















































































































































































































































































































































































































































1.2.3 Long-Chain Acyl-CoA Synthetase 
The long-chain acyl-CoA synthetase activates fatty acids as follows: 
acyl-CoA 
fatty acid + CoA + ATP -+ acyl-CoA + AMP + PPj ....... (4) 
synthetase 
The long-chain acyl-CoA synthetase is a membrane-bound enzyme found in 
microsomes, peroxisomes and mitochondria (211 ). It has been purified from rat 
hepatic microsomes and shown to consist of identical subunits (28,000 daltons) 
which combine to form a catalytic unit of 168,000 daltons (212). Fatty acids of 
carbon chain length 1 O to 18 are activated to CoA derivatives at approximately 
equal rates, but the rate decreases for longer or shorter chain length fatty acids 
(213). The mechanism of action of the long-chain acyl-CoA synthetase is 
proposed to follow Bi Uni Uni Bi Ping Pong kinetics (214,215). The 
enzyme-bound intermediate has been isolated and contains equimolar amounts 
of adenylate and fatty acid bound to the enzyme (216). 
1.2.4 Acyl-CoA Hydrolase 
Acyl-CoA hydrolase catalyses the hydrolysis of the acyl-CoA ester bond (217). 
This enzyme has a high specificity for fatty acids containing 16 or 18 carbon 
atoms, and prefers substrates in the micellar form* (218). The acyl-CoA 
hydrolases are found in most mammalian tissues and the hepatic 
*Because of the amphipathic nature of fatty acids and the CoA derivatives 
thereof, they are only slightly soluble in aqueous medium and, above a certain 
concentration, tend to aggregate to form micelles. 
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microsomal enzyme has a molecular weight of 59,000 daltons (217). The 
presence of an acyl-CoA hydrolase within the cell suggests that an 
accumulation of acyl-CoA derivatives may not be desired (219). However, the 
mechanism of regulation of acyl-CoA metabolism is not as yet fully 
understood (219). 
1.2.5 The Acyltransferases 
This group of enzymes catalyses the esterification of fatty acids into 
phospholipids; the specific enzymes are named according to the phospholipid 
acceptor into which the fatty acid is incorporated. For example, 
1-acyl-sn-glycero-3-phosphate acyltransferase and 1-acyl-sn-glycero-3-
phosphatidylcholine acyltransferase esterify a fatty acid into the 2 position of 
1-acyl-sn-glycero-3-phosphate (lysophosphatidic acid) and 1-acyl-sn-glycero-
3-phosphatidylcholine (lysolecithin), respectively (220). The enzymes 
responsible for acylating the 1 carbon position of phospholipids have a high 
specificity for stearic and palmitic acids and a far lower specific activity than the 
enzymes acylating the 2-carbon position (221-223). It has been suggested that 
the relative activities of the acyltransferases towards different acyl-acceptors 
and donors are responsible for the non-random distribution of fatty acids in 
membranes (224). Consequently the different specificities of the enzymes 
towards different donors and acceptors has been extensively studied, especially 
with regard to the acylation of the 2-carbon position of phospholipids. In rat 
hepatic microsomes, arachidonic acid is the prefered acyl donor for 
1-acyl-sn-glycero-3-phosphatidylcholine acyltransferase (225); the mono- and 
diene fatty acids are esterified by the 1-acyl-sn-glycero-3-phosphate 
acyltransferase (222). Other fatty acids for which 1-acyl-sn-glycero-3-phosphate 
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and 1-acyl-sn-glycero-3-phosphatidylcholine acyltransferases show high activity, 
are linoleic, a- and -y-linolenic, eicosa-8, 11, 14-trienoic and eicosa-
5,8, 11, 14, 17-pentanoic acids. 1-acyl-sn-glycero-3-phosphatidylcholine 
acyltransferase has very low affinity for the long chain fatty acids, viz: 22:2, 
ti13,16, 22:3, ti13,16,19, and 22:4, ti?,10,13,16; palmitic and stearic acids do 
not act as acyl donors for the 1-acyl-sn-glycero-3-phosphate or 
1-acyl-sn-glycero-3-phosphatidylcholine acyltransferases (222). Lastly, the 
polar head group of the acyl acceptor also plays a role in determining the 
activity of the acyltransferases, e.g. phosphatidylcholine > ethanolamine (224). 
The 1-acyl-sn-glycero-3-phosphatidylcholine and 1-acyl-sn-glycero-3-phosphate 
acyltransferases are found tightly bound to the endoplasmic reticulum and have 
been partially purified from rat hepatic microsomes (226-228) and bovine brain 
microsomes (229). 
1.2.6 Phospholipases 
The phospholipases are a group of enzymes which catalyse the hydrolysis of 
phospholipids. There are a number of phospholipases which have been 
classified according to the position at which they attack phospholipids as 
illustrated in Figure 8. 
It has been established that the phospholipases play an important regulatory 
role in eicosanoid biosynthesis (230,231). The rate limiting step in 
prostaglandin biosynthesis is generally thought to be the release of the fatty 
acid precursor from the membrane phospholipid by phospholipase A2. The 
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activation is not a simple enzyme-catalysed deacylaction by phospholipase A2, 
but is the result of a chain of reactions resulting in the activation of 
phospholipase A2 (232,233). The polyunsaturated fatty acid, usually 
arachidonic acid, thus released is available for eicosanoid biosynthesis. The 
regulatory role of the phospholipases in eicosanoid biosynthesis is currently 
under intensive investigation. The chain of events from the stimulation of the 
cell to phospholipase A2 activation is complex and has been extensively 
reviewed (210,230,232 and references cited therein). 
Phospholipase A2 has been found in almost every tissue or cell type 
investigated and is not restricted to a single subcellular site (232,234). 
Phospholipase A2 catalyses the release of a fatty acid from the carbon 2 
position of phospholipids, such as phosphatidylcholine and 
phosphatidylethanolamine and has an absolute requirement for calcium (234). 
In rat liver, phospholipase A2 activity is found in plasma membranes, 
endoplasmic reticulum, golgi membranes, mitochondria and lysosymes; it 
occurs as both a membrane-bound and soluble form (230,234). Phospholipase 
A2 has been isolated from, for example, spleen, mitochondria, 
polymorphonucleocytes, and erythrocytes. The molecular weight and substrate 
specificity of phospholipase A2 for a particular phospholipid varies. For 
example, rat spleen phospholipase A2 has a specificity for 
phosphatidylethanolamine whereas that from sheep erythrocyte showed a 
preference for C-22, mono- and di-unsaturated fatty acids in 
phosphatidylcholine and phosphatidylethanolamine (234). Although the precise 
specificity of the reaction varies depending on the source of the enzymes, 
presumably each enzyme has a specific role to play in lipid metabolism and 
eicosanoid biosynthesis in mammals. 
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1.2. 7 Fatty Acid Desaturases 
The fatty acid desaturases are a group of membrane-bound enzymes which 
introduce a double bond into fatty acids (197,198). The fatty acid desaturases 
are defined by the position in the fatty acid chain in which a double bond is 
introduced with respect to the carboxylic acid end of the molecule, viz: the 
A6-desaturase introduces a double bond between carbon 6 and 7, the 
A9-desaturase between carbon 9 and 10, and the A5-desaturase between 
carbon 5 and 6, from the carboxylic acid end of the molecule. The fatty acid 
desaturases are the terminal oxidase of an electron transport chain requiring 
cytochrome b5, NADH-cytochrome b5 reductase, oxygen and NADH for activity 
(235-242). The flow of electrons is from NADH via NADH cytochrome b5 
reductase and cytochrome b5 to the terminal fatty acid desaturase as follows 
(see also Figure 1): 
NADH ___. NADH-CytochroMe Kls ___. :ytochror,e Kls --+ =-o.,;ty o.c:ci --+ 0
2 
Reciucto.se 
, Indico. tes t::',ectron Flow 




Further requirements for desaturation are a lipid-rich environment and a 
cytosolic factor (243-249). The lipid appears to play a structural role in 
desaturation, but the role of the cytosolic factor remains uncertain (244,247). 
Fatty acid desaturation is inhibited by cyanide, but not by carbon monoxide; 
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thus the fatty acid desaturases were first referred to as the "cyanide-sensitive 
factors" (235). 
The overall reaction scheme for the desaturation of fatty acids is : 
fatty acid 
acyl-CoA + 0 2 + NADH + H + 
.... desaturated acyl-CoA + NAO+ + 2H20 .... (5) 
desaturase 
The thioester remains intact during desaturation of the fatty acid substrate; the 
rate-limiting step of the A9- and A6-desaturases is the desaturation step 
(250-252). 
The A9-, AS-, and A5-desaturases have been shown to be different enzymes by 
immunochemical techniques and by isolation of the A9- and A6-desaturases 
(253-255). Although both these enzymes have been isolated, the purification 
has proved difficult to reproduce and this has hamper.ed research into the 
structure and function of these enzymes. 
1.2.7.1 A9-Desaturase 
The A9-desaturase was the first of the fatty acid desaturases to be investigated. 
The A9-desaturase accepts unsaturated fatty acids of chain-length 12 to 19 
carbons; the maximum rate of desaturation being for fatty acids of 16 to 19 
chain-length, with an abrupt cut-off at 20 (251 ). The preferred substrate for the 
A9-desaturase is stearic acid (198). The product of the A9-desaturation of 
stearic is oleic acid; further metabolism of oleic acid does not occur except 
where the essential fatty acids, linoleic acid or a-linolenic acid, are lacking, in 
which case there is a build-up of mead acid instead of arachidonic acid in the 
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cell (Figure 6, Table 6), (197,204,256). The ratio of mead acid to arachidonic 
acid is thought to be an indicator of essential fatty acid deficiency (triene to 
tetraene ratio) (198,252,256). 
The physiological roles of the t9-desaturase have been proposed to be as 
follows: 
i) to reduce the melting point of the saturated fatty acids to allow for easier 
transport (198). 
ii) to maintain the correct levels of oleic acid within the cell and hence the 
physical integrity of the membrane (198,257). 
iii) in the biosynthesis of triacylglycerol. In this role, the t9-desaturase is 
involved in carbohydrate-lipid conversion and energy metabolism (257). 
The t9-desaturase has been isolated from rat liver (251,254) and hen liver 
microsomes (258,259). Purification of rat liver t9-desaturase was achieved by a 
sequence of extractions of contaminating proteins, followed by solubilisation of 
the t9-desaturase in Triton X-1 GO-calcium deoxycholate. The enzyme is 
extremley unstable, however, and loses activity on detergent solubilisation 
(261 ). Nevertheless, the cDNA for rat hepatic t9-desaturase has recently been 
constructed, from which the protein sequence was deduced (260). 
Rat liver t9-desaturase is a single polypeptide of 41,500 daltons, containing one 
molecule of non-haem iron which is necessary for catalytic activity (254,262). 
The t9-desaturase contains a high percentage of hydrophobic residues (62%) 
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indicating that it is deeply embedded in the hydrophobic region of the 
membrane bilayer, possibly with only the hydrophilic catalytic site exposed 
(198,260,262). In the absence of lipid or detergent, the protein tends to form 
high molecular weight aggregates which suggests that the lipid required for 
activity serves to provide binding sites for the hydrophobic region of the enzyme 
(262). 
The apparent Km for the A9-desaturation of stearoyl-CoA when the purified 
enzyme is reconstituted with cytochrome b5, NADH-cytochrome b5 reductase, 
egg lecithin liposomes, and NADH, is 4-5 µM (262). From inhibition studies 
using unsaturated acids of different configurations, (cis- or trans-isomers), and 
from the similarity between the Km for the A9-desaturation of stearoyl-CoA and 
the Ki for the inhibition of this reaction by oleoyl-CoA (4.5 µM) in the purified 
reconstituted system, it is suggested that upon interaction of stearoyl-CoA with 
the A9-desaturase, stearoyl-CoA assumes a conformation similar to that of 
oleate, viz: a gauche conformation (251,262). The mechanism of desaturation 
of the A9-desaturase does not involve an oxygenation but rather an extraction of 
the D-hydrogens, which is the rate-limiting step of the overall reaction (250,251). 
1.2.7.2 The A6- and AS-Desaturases 
The physiological substrates for the A6- and A5-desaturase are primarily 
unsaturated fatty acids of the n-6 and n-3 fatty acid families, and the n-9 family 
only in cases of essential fatty acid deficiency, as already discussed (197). Of 
the physiological substrates for the A6-desaturase, a-linolenic acid is 
desaturated at a greater rate than linoleic acid, which is desaturated at a greater 
rate than oleic acid (197,198,237). 
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The physiological role of the ti6- and ti5-desaturases is the biosynthesis of 
polyunsaturated fatty acids which (i) form components of membrane 
phospholipids necessary for maintaining the physical integrity of the membrane 
and (ii) are the precursors of eicosanoid biosynthesis (198,201,257). 
The ti6-desaturase is far more readily solubilised in detergents than the 
ti9-desaturase, suggesting that the ti6-desaturase is not as deeply embedded in 
the microsomal membrane (263). However, only Okayasu et al have reported 
the successful purification of the enzyme (255). After initial detergent 
solubilisation, the ti6-desaturase was purified by ion exchange chromatography 
followed by cytochrome b5 affinity chromatography (255). The purified enzyme 
has a molecular weight of ca. 65,000 daltons. As in the case of the 
li9-desaturase, the ti6-desaturase is a single polypeptide chain containing one 
atom of non-haem iron, which is required for catalytic activity (255). The 
li6-desaturase contains only 49% hydrophobic residues compared with the 62% 
of the ti9-desaturase; this is a further indication that the ti9-desaturase is more 
hydrophobic than the ti6-desaturase (see also 237,255,261). Both the ti6- and 
ti9-desaturases appear to be located on the cytoplasmic side of the 
endoplasmic reticulum (264,265). 
The apparent Km for the desaturation of linoleoyl-CoA by the ti6-desaturase, 
using the purified reconstituted system, was 45 µM, and the Vmax value was 
83 nmol/mg protein/min (255). In hepatic microsomes, reported apparent Km 
values for the desaturation of linoleic acid varied from 0.2 µM to 160 µM 
(266-270). 
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The A6-desaturase can accommodate a wider variety of chain lengths than the 
A9-desaturase, although the optimum activity is for C-18 fatty acids (271,272). 
The increasing activity with the greater number of double bonds (oleic acid 
< linoleic acid < o-linolenic acid) would indicate that the higher activity is due to 
the increased curvature of the molecule (198,269). The active centre of the 
A6-desaturase cannot bind stearoyl-CoA and thus appears to be significantly 
different from that of the A9-desaturase (237,255,269). The A6-desaturase 
appears to recognise the chain length as well as the number of double bonds 
(272). 
In rat hepatic microsomes, the A5-desaturase shows activity towards 
eicosa-8, 11, 14-trienoic in two forms: (i) as the CoA derivative of the fatty acid 
and (ii) the fatty acid esterified in phospholipids (273,274). Separate enzymes 
for the two reactions have not been identified and both activities have been 
found following partial purification of the protein by detergent solubilisation 
(274). The lack of requirement for CoA rules out any possibility that the 
desaturation measured is a multiple enzyme reaction, viz: release of the fatty 
acid substrate from the phospholipid (phospholipase), followed by CoA 
esterification (acyl CoA-synthetase), desaturation and finally transfer of the fatty 
acid back to the phospholipid (acyltransferase) (Figure 7). Similarly, the 
A 12-desaturase in plants and bacteria has also been reported to desaturate 
oleoyl-CoA as well as oleic acid esterified in phospholipids (275). There are no 
reports on the structure of the A5-desaturases as isolation to homogeneity has 
not been achieved (274). 
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1.2.7.3 Factors which Stimulate Fatty Acid Desaturase Activity in Vitro 
On reconstitution of the purified A9- or A6-desaturase with cytochrome b5, 
NADH-cytochrome b5 reductase, lipid, NADH and oxygen, the reaction does 
not have an absolute requirement for a cytosolic factor. A cytosolic factor 
stimulates the A9-, A6- and A5-desaturase activities in hepatic microsomes in 
vitro, however (245-249). The activities of the A9-, A6- and A5-desaturases are 
lost on repeated washing of crude microsomal extracts, and can be restored on 
addition of the cytosolic factor (276). A crude extract of the factor has been 
prepared from cytosol and comprises both a lipid and a protein component 
(246). The precise role of this factor is uncertain (247), although it has been 
suggested that it plays a role in product removal (277). 
A stimulatory effect on the activities of the A9- and A5-desaturases, but not the 
A6-desaturase was observed with BSA (247,249). There is, however, a single 
report where the activity of the A6-desaturase was increased by ca. 50% in 
unwashed microsomes (276). BSA can activate or inhibit the other enzymes 
which utilise acyl-CoA esters as substrates, viz: the acylhydrolases, elongases 
and acyltransferases, depending on a complex set of circumstances relating in 
part to the critical micellar concentration* and Km values of the enzymes 
(218,278,279). The activation of the A9-desaturase by BSA observed by 
Jeffcoat et al has been proposed to result from the greater availability of the 
acyl-CoA for A9-desaturation (280); BSA inhibits the formation of micelles from 
the fatty acid substrate (218,278,279). 
* The critical micellar concentration of a fatty acid or Co A derivative thereof, is 
the concentration in aqueous medium above which it aggregates to form 
micelles. 
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1.2.7.4 Other Fatty Acid Desaturases 
Besides the A9-, A6-, and A5-desaturases, AS-and A4-desaturases have been 
reported in mammals (198,281,282). The A4-desaturase shows activity primarily 
towards members of the n-3 family, giving rise to 22:6, A4,7,10,13,16,19, a 
structural component of brain tissue (201 ). The AS- and A4-desaturases are not 
active in the liver and are found in specialised tissues such as testis, adrenal 
and brain tissue; little is known about them (198,282,283). 
1.2.7.5 Regulation of Fatty Acid Desaturation in Vivo 
The activity of the fatty acid desaturases in vivo appears to be regulated by the 
nutritional and hormonal status of the animal, although the exact mechanism of 
control is not fully understood (197,257). The A9-desaturase has a very short 
half life in vivo (4 hr), and is induced in response to specific dietary 
manipulations, e.g. carbohydrate intake (252,257,260). Levels of the 
A9-desaturase are thought to respond to the metabolic requirements of the cell, 
and control is closely linked to that of carbohydrate metabolism (257,284). 
Since the A6- and A5-desaturases are unaffected by dietary intake of 
carbohydrate (Table 8), it appears that the A9-desaturase is regulated by a 
mechanism different from that of the A6- and A5-desaturases (208,257). This is 
in accord with their different physiological roles: the A9-desaturase is involved in 
carbohydrate-lipid and energy metabolism whereas the A6- and A5-desaturases 
are on the synthetic pathway for molecules which have specific physiological 











THE EFFECTS OF BASIC DIETARY INTAKE ON 
A9-, AS-AND A5-DESATURASE ACTIVITY 
EFFECT ON FATTY ACID DESATURASE ACTIVITY 
A9-Desaturase M-Desaturase As-Desaturase 
increases unaffected unaffected 
unaffected increases increases 
decreases decreases increases 
decreases decreases increases 
increases decreases 










Considerable research has focussed on the effects of dietary fats on the activity 
of these enzymes, possibly due to concern over increased consumption of 
processed oils by humans (295). Much of this research is on the effects of 
isomers of the naturally occurring fatty acids on membrane composition, fatty 
acid desaturation in vivo and the interaction of these isomers with the fatty acid 
desaturases in vitro (296-301 ). Many of these studies on the effects of isomers 
of naturally occurring fatty acids on the fatty acid desaturases indicate that, 
although the fatty acid isomers have varying effects on the activity of the fatty 
acid desaturase, they usually disturb essential fatty acid metabolism by 
increasing the minimum requirement for linoleic acid in the diet (302-304). 
Since, during processing of many vegetable oils, isomerisation of the naturally 
occurring cis-unsaturated fatty acids occurs, the dietary intake of such fatty 
acids in processed oils may play a central role in regulating essential fatty acid 
metabolism. 
Besides dietary control of the fatty acid desaturases, a number of hormonal 
factors affect the activity of these enzymes (198,252,305-308). For example, an 
animal in an experimental diabetic state shows decreased ~9- and 
~6-desaturase activities; insulin is known to increase the ~9-desaturase activity 
(198,252,305-308). Other factors which affect the activity of the fatty acid 
desaturases include drugs, such as the glucocorticoids and the 
anti-inflammatory drug, ebselen (309,388), and ethanol (311,388). Ebselen 
inhibits the ~9-desaturase by disrupting electron transfer from NADH to 
NADH-cytochrome b5 reductase (388). Dietary ethanol reduces the activities of 
the ~9-, ~6- and ~5-desaturases and alters the acyl composition of subcellular 
membranes. This suggests that the change in cell morphology observed after 
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ethanol consumption results from the change in membrane structure and may 
be related to the change in activity of the desaturases (311 ,312). 
1.2.7.6 The Interaction of Anaesthetic Agents with the Fatty Acid 
Desaturases 
The volatile anaesthetic agents, halothane, methoxyflurane and enflurane have 
been reported to interact with A9-desaturase (313,314). These drugs did not 
inhibit the conversion of stearate to oleate. However, the interaction of these 
volatile anaesthetic agents with the A9-desaturase was demonstrated by their 
ability to stimulate cyanide-sensitive electron flow from NADH to oxygen. 
The stimulation of electron flow from NADH to oxygen by these anaesthetic 
agents is measured in hepatic microsomes as follows: cytochrome b5 is fully 
reduced by a limited quantity of NADH, and once the NADH supply is 
exhausted, the pseudo first order rate constant for the re-oxidation of 
cytochrome b5 is measured. The rate of electron flow can be measured in the 
absence and presence of the CoA derivative of a fatty acid or of a compound 
which stimulates the rate to above that of the background rate. The role of 
either cytochrome P-450 or the fatty acid desaturases in the stimulation of 
electron flow can be established through the use of inhibitors (carbon monoxide 
for cytochrome P-450 or cyanide for the fatty acid desaturases). The complete 
inhibition by cyanide of the increased electron flow mediated by a compound 
suggests interaction of the compound exclusively with the cyanide-sensitive 
factors, which include the A9-, A6-, and A5-desaturases. The stimulated electron 
flow resulting from the interaction of a compound with the cyanide-sensitive 
factors does not necessarily mean that it is binding to the substrate-binding site 
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of the enzyme(s); for example, p-cresol has been suggested to stimulate 
electron flow by increasing the production of active oxygen species (315). 
Several local anaesthetic agents have been reported to interact with the 
A9-desaturase, including dibucaine, propianolol and tetracaine; these 
anaesthetic agents inhibited the conversion of stearic acid to oleic acid by 
A9-desaturase in microsomes from tetrahymena (316). 
1.2.7.7 Distribution of the Fatty Acid Desaturases 
Fatty acid desaturase activity has been demonstrated in the livers of many 
species, including rats, mice and humans (237,317-319). One exception is the 
cat family, which lacks A6-desaturase activity (320). Human hepatic 
microsomes have A6-desaturase activity and desaturate both a-linolenic acid 
and linoleic acid (317). The A5-desaturase activity in human hepatic 
microsomes is far lower than that found in rat hepatic microsomes (317). 
Although the liver is the main site of the fatty acid desaturases, these enzymes 
are present in other tissues. For example, A9- and A6-desaturase activities have 
been demonstrated in rat kidney (321) and testis (323); bovine mammary 
glands and the sarcoplasmic reticulum of rabbit muscle both have 
A9-desaturase activity (324,325), and rat adrenal gland has a very active 
A6-desaturase (326). In contrast, rat and human epidermal tissue lack both A6-
and A5-desaturase activities (327,328) and human platelets have low A6- and 
A5-desaturase activities (329). Transformed cells, e.g. Morris hepatoma cells 
and adrenocarcinomas show greatly reduced A9- and A6-desaturase activities 
(330-333). 
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1.2.8 Fatty Acid Chain Elongation 
Fatty acid chain elongation involves the condensation of malonyl-CoA with an 
acyl-CoA in a four step reaction (Figure 9) (334,335). The fatty acid chain 
elongation is a different system from de novo fatty acid synthetase, although the 
reactions catalysed are very similar (335). Fatty acid chain elongation takes 
place in four steps thought to be calalysed by different enzymes (336): the first 
step in the elongation is a condensation of acyl-CoA and malonyl-CoA to form a 
.B-keto-acyl CoA (Figure 9). This step is reported to be the rate limiting step of 
the reaction (334,335). The second step is a reduction catalysed by .B-keto 
acyl-CoA reductase, requiring reducing equivalents; NADH and NADPH can 
act as electron donors via either cytochrome b5 and/or NADPH-cytochrome 
P-450 reductase (198,337-339). The third step is a dehydration by .B-hydroxy 
acyl-CoA dehydrase, followed by reduction by trans-2-enol-CoA reductase, 
giving rise to acyl-CoA, elongated by 2 carbons. The enzymes of this pathway 
have not been isolated, but are known to be localised on the microsomal 
membrane (340). 
The relative rates of fatty acid desaturation and elongation for each of the fatty 
acid families have been measured by Bernert and Sprecher (341 ). Within a fatty 
acid family, the rate of elongation is far greater than the rate of desaturation, the 
latter being the rate limiting step in their metabolism (341 ). However, in vivo the 
situation could be different, depending on the availability of the different fatty 






























































































































































































































































































































1.2.9 Proteins Associated with Fatty Acid Desaturations and Chain 
Elongation 
1.2.9.1 Cytochrome b5 
Cytochrome b5 is an essential factor in A9- and A6-desaturations in rat hepatic 
microsomes (239,240) and in the purified reconstituted systems (254,255). 
Cytochrome b5 also participates in the reduction of cytochrome P-450 during 
drug oxidation (see Section 1.1.1.6) and in the chain elongation of fatty acids 
(see Section 1.2.8). Cytochrome b5 is an amphipathic molecule with a 
molecular weight of 16,000 daltons (342). The complete amino acid sequence 
is known; it includes a hydrophobic sequence of 40 amino acid residues which 
attach the protein to the microsomal membrane, which is predominately a helix 
in secondary structure, and a hydrophilic catalytic region containing 80 amino 
acid residues which is located on the cytoplasmic surface of the endoplasmic 
reticulum (244,342,390). The polar region is also highly helical, but not all o 
helix (390). The two sections are joined by a short unstructured sequence. The 
haem crevice is located in the hydrophilic portion of the molecule and the haem 
is orientated so that one proprionyl side chain is at the surface of the molecule 
(346,347). 
Cytochrome b5 is easily purified by detergent solubilisation, ammonium sulfate 
precipitation and DEAE ion exchange chromatography (343). The reduced 
(ferrous) form of the protein has an absorption peak at 424 nm which shifts to 
409 nm in the oxidised (ferric) form. It has recently been cloned and assigned 
to a specific gene locus in both rats and humans (391 ). 
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1.2.9.2 NADH-Cytochrome b5 Reductase 
NADH-cytochrome b5 reductase is an amphipathic protein attached to the 
cytosolic surface of the endoplasmic reticulum (344,345). NADH-cytochrome 
b5 reductase accepts electrons from NADH in preference to NADPH (371 ). 
NADH-cytochrome b5 reductase has been purified; it has a molecular weight of 
about 43,000 daltons and contains 1 equivalent of flavin per mol of protein 
(344,345). 
The interaction of cytochrome b5 with both NADH-cytochrome b5 reductase 
and t9-desaturase has been studied (346). The proteins involved in the 
microsomal electron transport chain undergo translational and rotational 
diffusion in the phospholipid bilayer to produce productive protein-protein 
contacts (346). The interaction of cytochrome b5 with NADH-cytochrome b5 
reductase is thought to take place via complementary charge-pair interactions 
involving carboxylic side chains of glutamic acid residues and the single 
exposed haem proprionate group (347). 
1.2.10 The Role of Fatty Acids in the Biosynthesis of the 
Eicosanoids, Prostaglandins, Thromboxanes, Leukotrienes 
and other Derivatives of Carbon-20 Unsaturated Fatty Acids 
The eicosanoids are a family of chemically related lipids having a wide variety of 
different biological activities which modulate practically every function of the 
body (348,349). The eicosanoids are formed in response to a wide variety of 
hormonal and non-hormonal stimuli from their fatty acid precursors, which are 
released from specific fatty acid pools (348). The eicosanoids act locally and 
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virtually always in competition with other prostanoids and usually stimulate or 
inhibit key cellular processes (348). 
The common fatty acid precursors of the eicosanoids are arachidonic acid, 
dihomogammalinolenic acid ( eicosa-8, 11, 14-trienoic acid) and eicosa-
5,8, 11, 14, 17-pentaenoic acid which can be formed from the essential fatty acids 
linoleic acid or a-linolenic acid through the pathways illustrated in Figure 10, or 
can be ingested as a food constituent (201 ). Of these precursors, arachidonic 
acid predominates in cellular pools and consequently gives rise to the widest 
variety and largest amounts of eicosanoids including the prostaglandins of the 2 
series (Figure 10) (348,350,351). Considerable attention has been focussed on 
the chemistry, pharmacology and physiology of the products of arachidonic 
acid over the last decade and this field has been extensively reviewed (for 
example, 352-354 and refs. cited therein). 
Eicosa-5,8, 11, 14, 17-pentaenoic acid, found predominently in fish oils, is the 
precursor of the eicosanoids which include the 3-series of prostaglandins 
(Figure 10). However, eicosa-5,8, 11, 14, 17-pentaenoic acid is a poor substrate 
for cyclo-oxygenase, the enzyme catalysing the initial step in eicosanoid 
biosynthesis (Figure 10) (319,348). Consequently, the 3-series of 
prostaglandins are produced in exceedingly small amounts and are not thought 
to play an important physiological role (319), although it has been suggested 
that the 3-series of prostaglandins may have antithrombotic potential (348) and 
may play a role in preventing ischaemic heart disease (356). 
The 1-series of eicosanoids are derived from dihomogammalinolenic acid 




























































































































































































































































































































































































































































































































































produced in small amounts compared to the 2-series, probably because of the 
small amounts of dihomogammalinolenic acid found in most cellular 
membranes (351,357). The membranes of vesicular glands, however, contain a 
large amount of dihomogammalinolenic acid from which the very high quantities 
of PGE1 found in semen of man, sheep and baboon are derived (201). The 
variety of eicosanoid products from dihomogammalinolenic acid is not as great 
as those from arachidonic acid; the absence of a t5-double bond renders this 
compound incapable of conversion into the leukotriene series (351). The 
intermediates in thromboxane synthesis from dihomogammalinolenic acid, 
PGH1, and PGG1, are poor substrates for thromboxane synthetase so TXA1 is 
a product of very minor consequence (201,351). 
The increased biosynthesis of the eicosanoids occurs on reaction to a stimulus, 
such as neurotransmitters (e.g. norephinephrine), neuropeptides (e.g. 
somatostasin), various humeral agents (e.g. braydikin), hyperosmolar stimuli 
and even mechanical strain (349). These stimuli control eicosanoid 
biosynthesis by regulating the release of the fatty acid precursor from the 
membrane by phospholipase A2 (348) *. Subsequent reactions involve either 
cyclo-oxygenase or lipoxygenase which are the enzymes catalysing the initial 
steps in the formation of the numerous products shown in Figure 10. 
Not all eicosanoid products are formed in every tissue in the body; their 
distribution depends not only on the fatty acid content of subcellular 
* Another source of the fatty acid precursors for eicosanoid biosynthesis is 
thought to be the inositides. The inositides contain primarily arachidonic acid 
and stearic acid. The fatty acid precursor is released from the inositides by the 
action of phospholipase C (Figure 8) and diacylglycerol lipase (354). This 
reaction is known as the inositol effect (354). 
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membranes, but also on the relative activities of cyclo-oxygenase and 
lipoxygenase in the various tissues (349,351). 
Because the biological actions of eicosanoids encompass such a wide 
spectrum of effects, research in this field has made important contributions to a 
better understanding of diseases such as cardiovascular disease, thrombotic 
disease, immunity and inflamation, reproduction, nephrology, pulmonary 
disease, gastroenterology and metabolic disorders (357). Many commonly 
prescribed drugs exert their therapeutic effects through inhibition of eicosanoid 
biosynthesis. For example, phospholipase A2 is inhibited by the 
glucocorticoids and the antimalarial drug, mepacrine; cyclo-oxygenase is 
inhibited by aspirin and non-steroidal anti-inflammatory drugs, such as 
indomethacin, which extend their effect through inhibition of the synthesis of 
PGE2, the prostaglandin which is the causitive agent of erythema, oedema and 
pain associated with inflammation (319,349,358). 
1.3 AIMS OF THIS PROJECT 
In order to obtain a better understanding of the hepatic metabolism of isoflurane 
and the effects of this drug on liver processes, the interaction of this anaesthetic 
agent with the cytochrome P-450 and fatty acid desaturase enzyme systems in 
the liver were studied. These two enzyme systems were chosen for the 
following reasons: 
i) Cytochrome P-450 was chosen since all fluorinated volatile anaesthetic 
agents are known to be metabolised by the cytochrome P-450 enzyme 
system. 
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ii) The fatty acid desaturases or cyanide-sensitive factors were chosen 
since several volatile anaesthetic agents have been shown to interact 
with the A9-desaturase (313,314) with unknown physiological 
consequences. 
Firstly, the metabolism of isoflurane by hepatic microsomal cytochrome P-450 
was investigated in order to 
i) establish whether hepatic microsomal cytochrome P-450(s) catalyse(s) 
the defluorination of isoflurane in rat hepatic microsomes, and if so, 
which isozyme(s) of cytochrome P-450 are active in this transformation. 
This study involves the use of inhibitors and inducing agents specific for 
isozymes of cytochrome P-450. 
ii) elucidate the pathways of isoflurane metabolism in rat and human 
hepatic microsomes by identification of metabolites. 
Secondly, the interaction of isoflurane with the cyanide-sensitive factors was 
studied as follows: 
i) the stimulation of the cyanide-sensitive re-oxidation of cytochrome b5 in 
hepatic microsomes was used to assess whether isoflurane interacts 
with one or more cyanide-sensitive factor. 
ii) the effect of isoflurane on the activity of the A9-, A6- and A5-desaturases 
toward natural fatty acid substrates was assessed. 
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Since our initial results showed that isoflurane selectively inhibited the 
A6-desaturation of linoleic acid, further studies focussed on an attempt to 
characterise the interaction of isoflurane with the A6-desaturase. While in 
persuit of this goal, we realised that accurate measurement of the kinetics and 
activity of the A6-desaturase is more complicated than generally appreciated. It 
was therefore necessary to backtrack and re-investigate the assay system for 
the A6-desaturase in hepatic microsomes. This assay is complicated by the 
presence of other enzymes competing for the acyl-CoA substrate of the 
A6-desaturase, and several other factors. In an attempt to elucidate the 
underlying kinetics of the A6-desaturase, we investigated the effect of the 
following on apparent A6-desaturase activity: 
i) the presence and concentration of endogenous unlabelled linoleic acid in 
the hepatic microsomes - (was it sufficient to affect A6-desaturase 
activity?). 
ii) the activity of phospholipase A2 - (was it sufficient to release significant 
amounts of free linoleic acid to affect apparent A6-desaturase activity?). 
iii) kinetic data for the acyl-CoA synthetase and lysophospholipid 
acyltransferases - (was the former truely rapid and pre-equilibrium, and 
thus of insignificant effect on the A6-desaturase? Did the latter effectively 
compete with the A6-desaturase for acyl-CoA substrate?). 
The influence of these on the apparent A6-desaturase activity, and inhibition 
thereof by isoflurane, were assessed experimentally and the results of this 
complex system were assessed by computer modelling of a multi-enzyme 




2.1.1 Materials Used to Study the Interaction of lsoflurane with Hepatic 
Microsomal Cytochrome P-450 
lsoflurane was a gift from Dr Julien Biebuyck, Bell Laboratories, U.S.A., and 
from Abbott Laboratories, Transvaal, R.S.A. Pregnenolone-16a-carbonitrile was 
a gift from Searle Laboratories, Chicago, IL., U.S.A. Sodium phenobarbital and 
.B-naphthoflavone were obtained from Maybaker, Port Elizabeth, R.S.A. and 
Aldrich Chemical Co., Milwaukee, WI., U.S.A., respectively. lsocitrate 
dehydrogenase was from Sigma Chemicals, St. Louis, MO., U.S.A. NADH, 
NADPH, NADP and the components of the glucose 6-phosphate-dependent 
NADPH-generating system were purchased from Bayer-Miles, Cape Town, 
R.S.A. Sodium fluoride, trifluoroacetic acid, DL-isocitric acid and hydrogen 
peroxide were obtained from Merck Chemicals, Darmstadt, FDR. 
Trifluoroacetaldehyde hydrate was from ICN Pharmaceuticals, Plainview, NY, 
U.S.A. Metyrapone (2-methyl-1,2-bis-(3-pyridyl)-1-propane) was a gift from 
Ciba-Geigy Ltd, Basie, Switzerland. Cylinders of compressed gases were 
supplied by Afrox Ltd, Cape Town, R.S.A. All other chemicals were analytical 
grade reagents supplied by Merck Chemicals, Darmstadt, FDR or BDH 
Chemicals Limited, Poole, England. Water was distilled and deionized. 
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2.1.2 Materials Used to Study the Interaction of Anaesthetic Agents with 
the Enzymes of Fatty Acid Metabolism 
The vitamin mixture used in the high-carbohydrate diet was constituted from 
vitamins received as a gift from Roche (Pty) Ltd., lsando, Transvaal. Cornflour, 
when used instead of dextrin in the diet, was purchased from African Products 
(Pty) Ltd., Bellville, Cape, RS.A. Halothane was obtained from ICI South African 
Pharmaceuticals Ltd, Johannesburg, RS.A. and methoxyflurane and enflurane 
from Abbott Laboratories, Transvaal, RS.A. Radiochemicals for the fatty acid 
desaturase, acyl-CoA synthetase and lysophospholipid acyltransferase assays 
were purchased from Amersham International pie, Buckinghamshire, U.K. The 
relevant fatty acids and the methyl and Co A esters thereof, as well as 
glutathione, NADH, ATP and CoA were from Sigma Chemicals, St Louis, MO., 
U.S.A. 
Butylated hydroxytoluene was from Marine Oil Refineries of Africa Ltd, 
Simonstown, RS.A. and BSA from Bayer-Miles, Cape Town, RS.A. All solvents 
and acids used in the acyl-CoA synthetase, fatty acid desaturase and 
lysophospholipid acyltransferase assays were analytical reagent grade supplied 
by Merck Chemicals, Darmstadt, FDR, and Holpro Analytics (Pty) Ltd, 
Johannesburg, RS.A. Boron trifluoride-methanol, nicotinamide, 
2, 7-dichlorofluorescein were from Merck Chemicals. 
HPLC supplies were obtained as follows: Zorbax ODS and Golden Series 
columns were from Dupont, Wilmington, DEL., U.S.A., the Spherisorb column 
was from Phase Separations Ltd, U.K.; solvents were purchased from 
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Rathburn Chemicals Ltd, Walkenburn, Scotland and phosphoric acid was from 
Fischer Scientific Co., Pittsburg, PA., U.S.A. 
The solvents and phosphoric acid were filtered through Millipore filters 
0.45 and/or 0.22 µm pore size (HVLP 025 00 and/or GVMP 025 00) supplied 
by Millipore Corp., Bedford, Mass., U.S.A. The C-18 saturation column kit 
which was used as a pre-column, was purchased from Supelco Inc., Bellefonte, 
PA., U.S.A. 
Gas chromatography supplies were obtained as follows: GP 10% SP-2330 or 
100 / 120 ChromasorbR W AW was supplied by Supelco Inc., Bellefonte, PA., 
U.S.A. Nitrogen and hydrogen were extra high purity from Afrox Ltd, Cape 
Town, R.S.A. 
The solvent for liquid scintillation counting, ready-solv, TM EP, was purchased 
from Beckman Instruments, Cape Town, R.S.A. 
All other reagents, e.g. the salts used in buffer solutions, etc., were analytical 
reagent grade supplied by Merck Chemicals, Darmstadt, FDR, Holpro Analytics 
(Pty) Ltd, Johannesburg, R.S.A. or BDH Chemicals Limited, Poole, England. 
Gases were supplied by Afrox Ltd, Cape Town, R.S.A. Water was distilled and 
deionized. 
2.1.3 Instrumentation 
For all spectral studies, a Beckman 5230 or a Pye-Unicam SP 1800 UV-visible 
scanning spectrophotometer was used. The thermostatically controlled 
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compartment adjacent to the photomultiplier designed to accommodate turbid 
samples, was used for spectral assays on microsomal samples. 
Fluoride ion concentration was measured using an Orion specific ion fluoride 
electrode (model 94-09) in conjunction with an Orion reference electrode 
(model 90-01-00) attached to a Radiometer model 22 pH meter. 
For all HPLC separations, a Dupont 870 pump module and a series 8800 
gradient controller were used. The fatty acids were detected using a Dupont 
refractive index detector connected to a Perkin-Elmer R100 recorder. Fractions 
(2 ml) were collected directly into scintillation vials on a LKB 2112 Redirac 
fraction collector. 
Fatty acid methyl esters were separated by gas chromatography, using a 
Packard 428-series gas chromatograph with a model 907 flame ionisation 
detector and Hewlett Packard 3390A integrator. 
For liquid scintillation counting, samples were dissolved in Ready-solv TM EP 
(1 O ml) and counted in a Packard Tricarb 4640 liquid scintillation counter. 
For all analyses of enzyme kinetic data and construction of overlay plots, a Miad 
personal computer and programs entitled 'Enzfitter' and 'Quattro Pro' were 
used. 'Enzfitter' is a program for non-linear regression analysis by Robin J. 
Leatherbarrow, published by Elsevier Science Publishers BV, P.O. Box 1527, 




2.2.1 Treatment of Animals and Isolation of Hepatic Microsomes 
2.2.1.1 Treatment of Animals 
Male Long Evans rats were maintained on a diet of Epol laboratory chow 
(protein minimum 20%, fat 2.5%, fibre maximum 6%, calcium 1.8, phosphorus 
0.7%; obtained from Epol Ltd, Johannesburg, R.S.A.) and water, unless 
otherwise indicated. These rats were used at a weight of 190 ± 10 g for all 
studies. 
2.2.1.1a Induction of Cytochrome P-450 
Groups of 3 - 8 rats were used for each experiment. .B-Naphthoflavone was 
administered as a single intraperitoneal injection (80 mg/kg in corn oil) 36 hr 
before sacrifice (364). Phenobarbital and pregnenolone-16a-carbonitrile were 
administered intraperitoneally at doses of 80 mg/kg/day in saline and 
50 mg/kg/day in corn oil, respectively, for three consecutive days (364). The 
animals, including control animals which did not receive any pretreatment, were 
starved for 16 hr before sacrifice by cervical fracture; livers were removed 
immediately for preparation of subcellular fractions. 
2.2.1.1b Induction of Fatty Acid Desaturases 
Groups of 2 male Long Evans rats were fed diets to induce the '19- and 
'16-desaturases as follows: 3 days prior to use, the animals were starved for 
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24 hr, and, for induction of the t.6-desaturase, re-fed a diet of Epol laboratory 
chow (normal diet) for 48 hr; for induction of the t.9-desaturase, the animals 
were re-fed a high-carbohydrate diet containing dextrin or cornflour 126 g, 
sucrose 30 g, cellulose 4 g, casein 30 g, NaCl 4 g, KCI 2 g, choline chloride 
0.2 g and vitamin mixture 6 g (vitamin A, 2.5 g (325 000 I.U./g), vitamin D, 
2.0 g (200 000 1.U./g), vitamin B2, (Riboflavin) 0.5 g, niacin 7.5 g and 
pantothenic acid 1 g, made up to a total of 500 g with dextrin or cornflour) 
(314). 
2.2.1.2 Human Liver 
Human liver samples from three human organ transplant donors were obtained 
within 20 min of death, but before cessation of the circulation. Liver 1 was from 
a 52 year-old female motor vehicle accident victim and was used only for 
hepatic microsomal cytochrome P-450 determination (Section 2.2.2.1) and 
assessment of the metabolism of trifluoroacetaldehyde by hepatic cytosol 
(Section 2.2.2.7). Liver 2 was from a 47 year-old female who died of brain 
haemorrhage, and was stored at -80°C for 2 days before use. Liver 3 was 
from a 25 year-old male assault victim. Livers 2 and 3 were used to determine 
cytochrome P-450 levels (Section 2.2.2.1 ), to assess the in vitro metabolism of 
isoflurane in hepatic microsomes (Sections 2.2.2.3 and 2.2.2.6), and for the 
metabolism of trifluoroacetaldehyde by cytosol (Section 2.2.2.7). The histology 
of livers 2 and 3 was found to be normal. 
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2.2.1.3 Preparation of Hepatic Microsomes 
Hepatic microsomes were isolated in one of two different ways: 
2.2.1.3a Method A 
Microsomes were isolated from rat or human livers by differential 
ultracentrifugation essentially as described by Holtzman and Carr (359). The 
following modification was introduced for human liver: approximately 
80 - 150 g of human liver was minced in a Toshiba meat grinder MT-300 prior 
to homogenisation. Subsequent steps (as described by Holtzman and Carr 
(359)) were carried out in an identical manner for both human and rat liver. The 
human or rat liver was homogenised in 3 volumes 0.02 M Tris - 0.15 M KCI, 
pH 7.4 per gram of wet liver weight. Cell debris and mitochondria were 
removed by centrifugation at 1 O,OOOg for 15 min using a Beckman JA-20 rotor 
in a Beckman J2-21 centrifuge. The microsomes were sedimented from the 
supernatant by centrifugation at 105,000g for 1 hr using a Beckman Type 65, 
50Ti or 70Ti rotor in a Beckman L-8 ultracentrifuge. The supernatant was used 
in experiments where cytosol was required (Section 2.2.2.7). The microsomes 
were resuspended in 0.02 M Tris-HCI, pH 7.4, and pelleted by centrifugation 
for 45 min at 105,000g. The washed microsomes were resuspended in 0.02 M 
Tris-HCI, pH 7.4, and assayed for protein by the method of Lowry et al (360) as 
modified by Chaykin (361 ), using BSA as a standard. Microsomal suspensions 
were used at 2 or 4 mg protein/ml, unless otherwise stated. Anaesthetic 
agents were introduced into microsomal suspensions by vortex mixing for 
30 sec prior to the addition of the other components necessary for the assay. 
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2.2.1.3b Method B 
Microsomes were isolated from rat liver by differential ultracentrifugation in a 
buffer containing sucrose, 0.25 M; KCI, 0.15 M; GSH, 1.5 mM; potassium 
phosphate, 0.05 M; MgCl2, 5 mM; EDTA, 4 mM, pH 7.4, essentially as 
described by Mahfouz (297). The method used was as described for Method A 
except that the microsomes from the first 105,000g spin were not washed, but 
were resuspended in the above buffer by using gentle agitation to separate the 
microsomal pellet from the clear glycogen with a vortex mixer, followed by 
homogenisation. The protein concentration was determined as described for 
Method A. 
2.2.2 METHODS USED IN THE STUDY OF THE IN VITRO METABOLISM 
OF ISOFLURANE BY RAT AND HUMAN HEPATIC MICROSOMES 
2.2.2.1 Determination of Cytochrome P-450 Concentration in Hepatic 
Microsomes 
The concentration of cytochrome P-450 was determined by measuring the 
difference spectrum between carbon monoxide plus sodium dithionite reduced 
microsomes (2 mg protein/ml, prepared by Method A) versus sodium 
dithionite reduced microsomes (2 mg protein/ml) as described by Omura and 
Sato (36). Samples were assayed within 1 min of dithionite addition. The 
extinction coefficient of 91 cm-1 mM-1 for the difference in absorbance 
between 450 and 490 nm was used to calculate the cytochrome P-450 
concentration (36). 
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2.2.2.2 NADPH Oxidation 
The rate of NADPH oxidation in rat hepatic microsomes was measured 
spectrally at 30°C. Rat hepatic microsomes (2 mg protein/ml, prepared by 
Method A), were vortexed for 30 sec with 16 mM isoflurane. The reaction was 
initiated by the addition of 0.12 mM NADPH and the decrease in absorbance at 
340 nm due to NADPH oxidation was recorded spectrally against a reaction 
blank containing only hepatic microsomal suspension. NADPH oxidation was 
measured both in the absence and presence of C0:02 (80:20,v /v) and 
corrected for any non-cytochrome P-450 dependent NADPH oxidation 
according to the method of Stripp et al (362). Carbon monoxide and oxygen 
flow were controlled by Matheson Gas Products model 7600 flow meters. The 
mixture of gases was bubbled through the microsomal suspension for 30 sec at 
a flow rate of 20 ml/min prior to the addition of isoflurane and NADPH. 
2.2.2.3 Measurement of Fluoride Ion Production from lsoflurane in 
Hepatic Microsomes 
Unless otherwise stated, rat or human hepatic microsomes (5 ml, prepared by 
Method A) at a concentration of 4 mg protein/ml, were incubated with 32 mM 
isoflurane and NADPH-generating system (0.8 mM NADP, 14.8 mM glucose 
6-phosphate, 1 U /ml glucose 6-phosphate dehydrogenase and 1 O mM 
MgCl2), 2 mM nicotinamide and 0.4 mM EDTA. The reaction proceeded at 
30°C with shaking at 60 cycles/min, for times ranging from o to 30 min. The 
reaction was stopped by freezing in liquid nitrogen. Reaction mixtures were 
dried by lyophilisation or rotary evaporation and resuspended in 0.5 ml TISAB 
IV* for measurement of the concentration of fluoride ion. The electrodes were 
*TISAB IV contained 1 M Tris - 0.05 M sodium tartrate adjusted to pH 5.0 with 
HCI to give a final pH of 6.5 when mixed with the dried reaction mixture. 
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allowed to equilibrate for approximately 5 min before each reading. The slow 
response was thought to be due to the low concentration of fluoride and high 
concentration of protein in the solution. At concentrations above 1 x 10-5 µM 
of fluoride, and in the absence of protein, the slow response was not observed. 
Standard curves were drawn up using samples of hepatic microsomes (5 ml) 
containing four to six known concentrations of sodium fluoride ranging from 
2 - 20 µM. The fluoride standards were dried and assayed in exactly the same 
manner as the reaction mixtures. Standard curves drawn up in this way were 
compared to standard curves for fluoride plus 1 O mM MgCl2. These solutions 
(5 ml) were lyophilised and dissolved in 0.5 ml TISAB IV as described for 
reaction samples. MgCl2 was the only component of the NADPH-generating 
system shown to affect the reading of the fluoride electrode. 
To measure the extent to which NADH supported the metabolism of isoflurane, 
5 ml rat hepatic microsomes (4 mg protein/ml, prepared by Method A) were 
incubated with shaking at 30°C for 0, or 5 min with 32 mM isoflurane, 0.2 mM 
EDTA, 1 mM nicotinamide and 1 mM NADH or NADPH. The production of 
fluoride ion was measured as described above using a standard curve 
constructed in the absence of MgCl2. 
2.2.2.4 Identification of Organofluorine Metabolites of lsoflurane in 
Rat Hepatic Microsomes 
Hepatic microsomes from phenobarbital-pretreated rats (100 ml at 2 mg 
microsomal protein/ml, prepared by Method A) were incubated with 16 mM 
isoflurane, 0.2 mM EDTA, 1 mM nicotinamide, and NADPH-generating system 
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(0.4 mM NADP, 7.4 mM glucose 6-phosphate, 0.5 U/ml glucose 6-phosphate 
dehydrogenase, 5 mM MgCl2), for 30 min at 30°C with shaking. Incubated 
reaction mixtures lacking NADPH-generating system, were used as a control. 
Zero-time samples were prepared in the same way as reaction mixtures, without 
incubation. Reaction mixtures were assayed for trifluoroacetic acid or 
trifluoroacetaldehyde. 
2.2.2.4a Identification of Trifluoroacetic Acid 
Extraction and thin layer chromatography of trifluoroacetic acid from the 
microsomal incubation was carried out by modification of the method of 
Hitt .eL.ill (195). After incubation, the reaction mixture was extracted once with 
chloroform:methanol (1:1,v/v) and the extract discarded. The aqueous layer 
was acidified to pH 2 - 3 with concentrated sulfuric acid and extracted with 
100 ml diethyl ether. The extract was discarded and the aqueous layer was 
further acidified to a pH of between 0.2 - 0.3 with concentrated sulfuric acid 
and the trifluoroacetic acid was extracted from the aqueous layer thrice with 
20 ml diethyl ether*. 
The extracts were concentrated under a stream of nitrogen and 
chromatographed on silica gel thin layer chromatography plates (Merck, glass 
backed 20 cm x 20 cm x 0.2 mm without fluorescent indicator) developed in 
ethanol:chloroform:ammonium hydroxide (5:2:1,v/v/v). Spots were identified 
by spraying with a solution of 0.5% bromothymol blue in 80% methanol; this 
solution was treated before use with 1.0 M sodium hydroxide until it just turned 
blue. Trifluoroacetic acid at concentrations of 0.063 mM and 130 mM was 
added to 100 ml hepatic microsomes, and taken through the above extraction 
procedures. 
*The pK of trifluoroacetic acid is 0.23 (363). 
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2.2.2.4b Identification of Trifluoroacetaldehyde 
Trifluoroacetaldehyde in microsomal incubation mixtures was oxidised to 
trifluoroacetic acid as described by Costa et al (364). To 100 ml of reaction 
mixture, 1.33 ml 10% w/v NaOH, and 10 ml 0.1 M potassium permanganate 
were added. After the solution was acidified with 2 M sulfuric acid, sodium 
bisulfite (5% w /v) was added until all excess potassium permanganate was 
reduced. The precipitated protein was removed by centrifugation for 10 min at 
2000g in the MSE 6L centrifuge using the rotor head 62303. The pH was 
reduced to pH 2 - 3. Further extractions with diethyl ether and the 
identification of trifluoroacetic acid were carried out as described above 
(Section 2.2.2.4a). Trifluoroacetaldehyde (0.063 mM and 0.43 mM) was 
added to hepatic microsomes and taken through the oxidation, extraction and 
identification procedures described above. 
2.2.2.5 
" 
Measurement of Organofluorine Metabolites of lsoflurane in 
Rat and Human Hepatic Microsomes 
The method reported by Soltis and Gandolfi (365) (which provided for the 
analysis of total fluorinated metabolites from volatile anaesthetic agents) was 
tested in order to find a sensitive method for quantitating the organofluorine 
metabolites of isoflurane in vitro. Known quantities of trifluoroethanol 
(0.25 µmol), trifluoroacetic acid (0.25 µmol), trifluoroacetaldehyde (0.25 µmol) 
and sodium trifluoroacetate (0.25 µmol) were added to 0.5 ml water, buffer 
(0.02 M Tris-HCI, pH 7.4), microsomes (2 mg/ml, prepared by Method A), or 
urine. Halothane (20 mM) and fluroxene (15 mM) were added to water or 
microsomes. To each sample, 50 µI of 0.1 M NaOH was added, and the 
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mixture was dried by lyophilisation. The dried material was fused with 
15-20 mg sodium at high temperatures. Following sodium fusion, excess 
sodium was removed by the addition of 50 µI methanol and the solution was 
neutralised by the addition of 2.0 ml water plus 0.5 ml of 6 M potassium 
acetate, pH 6.0. An aliquot (0.5 ml) of the neutralised solution was added to 
TISAB IV, and the fluoride concentration determined. Standards of known 
concentrations of sodium fluoride (10 - 100 µM) were added to a solution 
(neutralising solution) containing 50 µI methanol, 2.0 ml water and 0.5 ml 6 M 
potassium acetate, pH 6.0. An aliquot of these neutralising solutions 
containing known concentrations of sodium fluoride, was added to TISAB IV 
and the fluoride levels were measured and used as standards. 
2.2.2.6 Total Fluoride Analysis 
Since the method of Soltis and Gandolfi was shown to be unsatisfactory for 
measurement of some of the organofluorine metabolites of isoflurane, the 
modifications outlined in the following sections were introduced in order to 
measure trifluoroacetic acid and trifluoroacetaldehyde. 
2.2.2.6a The Measurement of Trifluoroacetic acid from lsoflurane in 
Rat and Human Hepatic Microsomes (Method A, Figure 11) 
Rat or human hepatic microsomes (2 mg protein/ml) were incubated with 
16 mM isoflurane, 0.2 mM EDTA, 1 mM nicotinamide and a glucose 
6-phosphate-dependent NADPH-generating system (0.4 mM NADP, 7.4 mM 













































































































































































































































































































































































































































































5 mM MgCl2)*. 
After 15 min incubation at 30 • C with shaking at 60 cycles/min, 10 ml of the 
reaction mixture was removed and lyophilised to dryness for fluoride ion 
analysis. A further 1 O ml was removed, the pH was adjusted by the addition of 
50 µI 0.1 M NaOH and 0.5 ml of 4 M ammonium hydroxide (Method A, 
Figure 11), and the sample was lyophilised to dryness for analysis of total 
non-volatile fluoride. The fluoride ion analysis was carried out as already 
described (Section 2.2.2.3). Standard curves were drawn up as described in 
Section 2.2.2.3, excepting that sodium fluoride (2 - 20 µM) was added to 10 ml 
hepatic microsomes containing 5 mM MgCl2 which was lyophilised and 
reconstituted in 0.5 ml TISAB IV. 
For total fluoride analysis, the dried precipitate was fused with 50 - 60 mg 
sodium, neutralised, and a 0.5 ml aliquot used for fluoride analysis as 
previously described (Section 2.2.2.5). Aliquots of standard solutions of 
sodium fluoride (6.4 - 31.8 µM) and trifluoroacetic acid (2.6 - 12. 7 µM) added 
to hepatic microsomes and taken through the same procedure, were used to 
draw up standard curves to quantify the results. 
*For trifluoroacetic acid determination, a glucose 6-phosphate-dependent 
NADPH-generating system was used, but for the trifluoroacetaldehyde 
determination an isocitrate-dependent NADPH-generating system was used. It 
was thought that the aldehyde moiety of the glucose molecule which is present 
in concentrations far exceeding those of trifluoroacetaldehyde, might interfere 
with the assay. 
2.2.2.6b 
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The Measurement of Trifluoroacetaldehyde from lsoflurane in 
Rat Hepatic Microsomes (Methods B and C, Figure 11) 
Rat hepatic microsomes (2 mg/ml) were incubated with 16 mM isoflurane, 
0.2 mM EDTA, 1 mM nicotinamide and an isocitrate-dependent 
NADPH-generating system (0.4 mM NADP, 6.4 mM isocitric acid, 0.2 U/ml 
isocitrate dehydrogenase and 5 mM MgCl2) at 30°C with shaking at 
60 cycles/min. After 15 min, a 10 ml aliquot was lyophilised and used for 
fluoride ion analysis. A second and third 10 ml aliquot were lyophilised with 
(Method B, Figure 11) or without (Method C, Figure 11) 200 µI phenylhydrazine 
(0.1 mM, final concentration). The total non-volatile fluoride content was 
determined by sodium fusion (Section 2.2.2.5). Standards of sodium fluoride 
(6.4 - 47.7 µM fluoride, final concentration) and trifluoroacetaldehyde 
(2.6 - 19.1 µM trifluoroacetaldehyde, final concentration) were added to rat 
hepatic microsomes, taken through the same procedure and used to draw up 
standard curves to quantify the results. 
2.2.2.7 The Metabolism of Trifluoroacetaldehyde by Rat and Human 
Liver Cytosol 
The metabolism of trifluoroacetaldehyde by rat and human liver cytosol was 
assessed as follows: hepatic postmicrosomal supernatant (70-100 ml) was 
incubated with 7.5 mM NAO, 1 mM nicotinamide with, or without 0.1 or 1.6 mM 
trifluoroacetaldehyde for 30 min. Reaction mixtures were extracted and 
subjected to thin layer chromatography as already described (Section 2.2.2.4a). 
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2.2.2.8 Assay for Hydrogen Peroxide Production 
Hepatic microsomes (3.0 ml) from phenobarbital-pretreated rats (2 mg 
protein/ml, prepared by Method A) were incubated with 16 mM isoflurane, 
NADPH-generating system (0.4 mM NADP, 6.4 mM isocitric acid, 0.2 U/ml 
isocitrate dehydrogenase and 5 mM MgCl2), EDTA (0.1 mM) and nicotinamide 
(1 mM). Following incubation for 15 min, hydrogen peroxide was determined 
using a slight modification of the method of Hildebrandt et al (366). The 
reaction was terminated as follows: aliquots (1.5 ml) of the incubation mixture 
were treated with 1.5 ml of 5% (w /v) trichloroacetic acid and the precipitated 
protein was removed by centrifugation at 2000g for 10 min in an MSE 6L 
centrifuge using rotor head 62303. In zero-time samples, reaction mixtures 
were prepared in the same way and the reaction terminated immediately. To 
2 ml of the supernatant, 0.2 ml of 1 O mM ferroammonium sulphate was 
added, followed exactly 2 min later by the addition of 0.1 ml of 2.5 mM 
potassium thiocyanate. The absorbance at 480 nm was measured exactly 
4 min after the last addition. Standards of hydrogen peroxide added to hepatic 
microsomes and taken through the same procedure were used to prepare 
standard curves from which the hydrogen peroxide concentration was 
determined. 
Alternatively, hydrogen peroxide was determined by the catalase-methanol 
method (367). Incubation mixtures of hepatic microsomes (3.0 ml) from 
phenobarbital-pretreated rats (2 mg/ml, prepared by Method A) included 
2000 U/ml catalase and 50 mM methanol as well as 16 mM isoflurane, 
NADPH-generating system (0.4 mM NADP, 7.4 mM glucose 6-phosphate, 
0.5 U/ml glucose 6-phosphate dehydrogenase and 5 mM MgCl2), 0.2 mM 
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EDTA and 1 mM nicotinamide. After incubation for 15 min at 30°C with 
shaking, the reaction was terminated by the addition of 1.5 ml of the incubation 
medium to 1.5 ml ice cold 15% w /v trichloroacetic acid. The precipitated 
protein was removed by centrifugation for 10 min at 2000g, as described 
above. The supernatant (1.5 ml) was mixed with 1.5 ml Nash reagent, stirred 
and heated at 58°C for 8 min. The solution was allowed to cool to room 
temperature before the absorbance was read at 412 nm. An extinction 
coefficient of 17.8 cm-1 mM-1 at 412 nm was used to calculate the hydrogen 
peroxide concentration (395). 
2.2.3 METHODS USED TO STUDY THE INTERACTION OF ISOFLURANE 
WITH HEPATIC MICROSOMAL CYANIDE-SENSITIVE FACTORS 
2.2.3.1 Measurement of the Re-oxidation of Hepatic Microsomal 
Cytochrome b5 
The re-oxidation of cytochrome b5 in hepatic microsomes was measured 
spectrally essentially as described by Oshino et al (236). Complete reduction 
of cytochrome b5 in 3.0 ml hepatic microsomes (1.5 mg protein/ml, prepared 
by Method A (Section 2.2.1.3a) and induced for either t.6- or the t.9-desaturase 
activity) was achieved with NADH (1 - 5 µM). Once the supply of NADH was 
exhausted, the pseudo-first order kinetics for the re-oxidation of cytochrome b5 
were monitored spectrally against a reference containing only microsomes. 
The difference in absorbance between 424 nm and 409 nm with time was used 
to calculate the pseudo-first order rate constant for the auto-oxidation of 
cytochrome b5. The pseudo-first order rate constant for the re-oxidation of 
cytochrome b5 in the presence of 12 µM stearoyl-CoA, 12 µM linoleoyl-CoA 
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and 13.3 mM isoflurane was determined in the same way. Linoleoyl-CoA and 
stearoyl-CoA were added immediately after the NADH, but the isoflurane was 
vortexed into the microsomes for 30 sec prior to the addition of NADH. 
2.2.3.2 Assay for Microsomal A6- and AS-Desaturase Activities 
Incubation conditions are described for A5- and AB-desaturase activities. Two 
different assays for the AB-desaturase are described here: a modification of the 
method of Mahfouz (297) (Method 1) and an HPLC assay method devised in 
our laboratory (Method 2). Method 2 was extended to measure the 
AB-desaturation of c:r-linolenic acid and the A5-desaturation of 
eicosa-8, 11, 14-trienoic acid. 
2.2.3.2a Incubation Conditions for Assay of Microsomal AS- and 
A6-Desaturase Activities 
Assays for hepatic microsomal AB- and A5-desaturases were established in our 
laboratory based on the method described by Mahfouz (297) and 
Mahfouz et al (304). Incubation conditions were the same for the 
measurement of the activities of AB- and A5-desaturases except for 
concentrations such as those of microsomal protein, substrate and BSA, and 
incubation times; these varied depending on the enzyme activity measured, 
and are outlined below. For the AB-desaturation of linoleic acid, hepatic 
microsomes (0.5 mg protein/ml, prepared by Method B (Section 2.2.1.3b), 
unless otherwise stated) from rats fed a normal diet were used. Reaction 
mixtures contained a 0.05 M phosphate buffer, pH 7.4, 0.15 M KCI, 0.25 M 
sucrose, 1.5 mM GSH, 5 mM MgCl2, 4 mM EDTA, 7.5 mM ATP, 1 mM CoA, 
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2.6 mM NADH, 40 mM KF, 0.33 mM nicotinamide, BSA (115 or 11.5 µg/µg 
fatty acid added) and (1-14c] linoleic acid (0.45 - 10.9 nmol, 26 - 632 nCi) in a 
final volume of 1.0 ml hepatic microsomes. Incubations were at 35 ·c with 
shaking at 60 cycles/min for O and 10 min, unless otherwise stated. For the 
fl6-desaturation of a-linolenic acid, the reaction mixtures were identical to those 
above except that the radiolabelled fatty acid substrate was (1-14c] a-linolenic 
acid (0.45 - 10.9 nmol, 25 - 613 nCi), the microsomal protein concentration 
was 0.5 mg/ml and the reaction time was O and 7 min, unless otherwise 
stated. For the fl5-desaturation of eicosa-8, 11, 14-trienoic acid, the radiolabelled 
fatty acid substrate was [2-14c] eicosa-8, 11, 14-trienoic acid (0.3 - 1.6 nmol, 
3.6 - 19.0 nCi), the microsomal protein concentration was 0.25 mg protein/ml 
and the reaction time was O and 10 min, unless otherwise stated. When the 
fl6- or fl5-desaturase activity was determined in the presence of anaesthetic 
agents, the anaesthetic agent was suspended in the hepatic microsomes 
(1 - 2 mg protein/ml) by vortex mixing for 30 sec prior to the addition of the 
remaining components of the incubation mixture. 
Separation and quantitation of the fatty acid substrates and products of the fl5-
and fl6-desaturation reactions were achieved by TLC after saponification of 
membrane phospholipids and methylation of the free fatty acid substrates and 
products as described by Mahfouz (297) (Method 1 ); or by HPLC following 
saponification of membrane phospholipids, a method devised in our laboratory 
(Table 9) (Method 2). The similarities and differences between the two assay 
methods are summarised in Table 9. 
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TABLE 9 
SUMMARY OF THE SIMILARITIES AND DIFFERENCES BETWEEN 
THE TWO METHODS OF ASSAY FOR THE t6-DESATURASE 














fication at 85 ° C for 
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(Same as Method 1) 
At 60°C for 30 min 
under argon 
None 
HPLC of free fatty 
acids 




Method 1: Saponification of Membrane Phospholipids 
followed by Methylation and the Separation of the Fatty Acid 
Substrate and Product of the t.6-Desaturase Reaction 
The t.6-desaturase reaction (Section 2.2.3.2a) was terminated by the addition of 
an equal volume (1 ml) of 5% HCI in methanol. The method of Mahfouz (297) 
was modified in that free fatty acid carriers (2 mg each of linoleic and -y-linolenic 
acids) were added prior to methylation, instead of after as methylated fatty 
acids. Microsomal fatty acids were extracted, saponified and methylated as 
described by Mahfouz (297,304). Finally, the fatty acid methyl esters were 
resuspended in 150 µI petroleum ether (bp 60 - 80°C) and stored at -20°C 
under nitrogen prior to separation by TLC (within 48 hr). 
The thin layer chromatography plates (Merck aluminium or glass-backed silica 
gel 60 (20 cm x 20 cm x 0.2 mm) without fluorescent agent) were dipped in 
10% aqueous silver nitrate, air dried, and activated at 110°C for 30 min. 
Alternatively, the separation of the fatty acid methyl esters was carried out on 
glass plates which were covered with a slurry of 50% silica gel H in 10% 
aqueous silver nitrate, air dried and activated for 30 min at 110°C. To each 
plate, 1 O µI samples of the fatty acid methyl ester mixtures were applied. The 
plates were developed in chloroform:methanol (100:2,v/v) and the separated 
fatty acid methyl ester bands were identified under ultraviolet light after spraying 
lightly with a solution of 0. 1 % 2, 7-dichlorofluorescein in ethanol. The methyl 
esters of linoleic and -y-linolenic acids were identified by comparison of the Rt 
value with those of authentic methyl ester standards. The bands of methylated 
fatty acids were cut (aluminium-backed plates) or scraped (glass-backed 
plates) into counting vials, suspended in 10 ml ready-solv TM EP for liquid 
scintillation counting (Section 2.1.3). 
2.2.3.2c 
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Method 2: Saponification of Membrane Phospholipids and 
Separation of Free Fatty Acids by HPLC 
The t.5- and t.6-desaturase reactions were terminated by addition of an equal 
volume (1 ml) of 10% potassium hydroxide in methanol containing 0.005% 
butylated hydroxytoluene. Fatty acid carriers were added to facilitate detection 
by change in refractive index, viz: 1 mg each of the following: linoleic and 
-y-linolenic acids for the t.6-desaturation of linoleic acid; a-linolenic acid for the 
t.6-desaturation of a-linolenic acid; eicosa-8, 11, 14-trienoic acid and arachidonic 
acid for the t.5-desaturation of eicosa-8, 11, 14-trienoic acid. The reaction 
mixtures were saponified for 30 min at 60 ° C under argon, acidified and 
extracted thrice with 2 ml hexane. The free fatty acids were dried under a 
stream of nitrogen at ca. 45°C, resuspended in 0.5 ml methanol, filtered 
through a 0.45 µm filter (Millipore hydrophilic durapore) and stored under liquid 
nitrogen. Under these conditions, the fatty acids were stable for at least three to 
six weeks. 
The free fatty acids were separated by HPLC using a modification of the method 
of Aveldano et al (368). The free fatty acids (50 µI) were applied to one of 
three HPLC columns: Zorbax ODS (25 cm x 0.45 cm), Zorbax Golden Series 
(8 cm x 0.62 cm, 3 µm pore size) or Spherisorb ODS (25 cm x 0.45 cm, 10 µm 
pore size). The columns were equilibrated with acetonitrile:30 mM phosphoric 
acid (65:35,v/v). The Zorbax ODS column was equilibrated at 35°C and the 
Zorbax Golden Series and Spherisorb ODS columns were equilibrated at room 
temperature. The columns were run at a flow rate of 2 ml/min. After each run, 
the column was washed with acetonitrile (100%) before re-equilibration in 
acetonitrile:30 mM phosphoric acid (65:35, v /v). Fractions (2 ml) were 
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collected directly into scintillation vials and mixed with 1 O ml of Beckman 
Ready-Solv TM EP for liquid scintillation counting (Section 2.1.3). The free fatty 
acids were identified by comparison of their elution profiles* with authentic 
samples of appropriate free fatty acids. 
2.2.3.2d Enzyme Activity Calculations for the Fatty Acid Desaturases 
used in Both Assay Methods 
The fatty acid desaturase activity can be expressed as the ratio: 
dpm of product 
dpm of product + dpm of substrate 
This parameter corrects for variations in the recovery of radioactive fatty acids 
during the extraction procedures. Since the total number of counts on 
termination of the reaction, i.e. the dpm in substrate + dpm in product, 
represents the initial substrate concentration, the ratio can be expressed as 
follows: 
dpm of product 
dpm of substrate+ dpm of product 
concentration of product 
initial substrate concentration 
then, product formed (µM) = concentration of product x initial substrate 
initial substrate concentration concentration (µM) 
In the zero time samples, the dpm of the fatty acid product was 50 ± 10 which 
was comparable to the observed background counts. By subtracting ratios 
calculated for zero time samples, the small contribution of the background 
counts to the activity was eliminated. This was only possible when the specific 
* The elution profiles for the different fatty acids are illustrated in the results 
(Figure 18). 
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activity of the r1-14c] linoleic acid was the same throughout, i.e. substrate 
concentration was uniform. Where substrate concentration varied, the average 
background counts were subtracted from each sample counted. 
2.2.3.3 Assay for Microsomal f.9-Desaturase Activity in Hepatic 
Microsomes 
The activity of the f.9-desaturase in hepatic microsomes (prepared by 
Method A, Section 2.2.1.3a) was measured essentially as described by Oshino 
et al (235). Hepatic microsomes (1.0 mg protein) were incubated with 40 µM 
r1-14c] stearoyl-CoA (12 nCi), 1 mM NADH or NADPH, with, or without 
16 mM isoflurane, in a volume of 0.5 ml 0.02 M Tris-HCI, pH 7.4, for 10 min at 
30°C with shaking. The reaction was terminated with 0.5 ml 10% potassium 
hydroxide in methanol, and fatty acid carriers (2 mg each of stearate and 
oleate) were added. 
The reaction mixtures were saponified at so·c for 30 min under nitrogen, 
acidified and extracted thrice with 2 ml petroleum ether (bp 60 - 80°C). The 
extracts were evaporated to dryness under nitrogen at ca. 45 • C and the fatty 
acids were methylated using boron trifluoride (14% w/v in methanol) (369). 
The fatty acids, suspended in 5 ml boron trifluoride, were heated at 1oo·c for 
15 min under nitrogen. The samples were cooled before 1 ml of water was 
added, and the methylated fatty acids were extracted thrice with hexane. The 
methylated fatty acids were taken to dryness under a stream of nitrogen at ca. 
45°C and redissolved in 100 µI petroleum ether (bp 40 - 60°C). The methyl 
esters of stearate and oleate were separated by argentation thin layer 
chromatography. Silica gel thin layer chromatography plates (Merck, 
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glass-backed 20 cm x 20 cm x 0.2 mm) were lightly sprayed with an 
aqueous solution of 10% silver nitrate, air dried and activated at 110°C. The 
plates were developed in diethyl ether:n-hexane (1 :9, v /v) and the spots located 
by spraying with water; methyl stearate and methyl oleate were identified by 
comparison of the Rt values with authentic standards. The spots were scraped 
into counting vials and the radioactivity of the labelled stearate and oleate 
fractions were determined using liquid scintillation counting (Section 2.1.3). 
2.2.3.4 Quantification of the Endogenous Free Fatty Acids present in 
Hepatic Microsomes 
The endogenous free fatty acids in hepatic microsomes from rats fed a normal 
diet were extracted as follows: to 2 ml of hepatic microsomes (7 - 11 mg 
protein/ml, prepared by Method B (Section 2.2.1.3b)) 1 µI [1-14cJ oleic acid 
(3.5 nmol, 57.4 nCi) or 1 µI [1-14c] linoleic acid (1.8 nmol, 106 nCi) was 
added as a radiolabelled standard. The microsomes were acidified to a pH of 
about 1 with HCI and extracted with 33 ml hexane:2-propanol (3:2,v /v) (370). * 
The extract was filtered and taken to dryness by rotary evaporation. The 
residue was dissolved in 0.5 ml chloroform:methanol (2:1,v/v) and the whole 
sample was applied to silica gel thin layer chromatography plates (Merck, 
glass-backed 20 cm x 20 cm x 0.2 mm, without fluorescent agent), which 
had been activated at 11 O ° C for 30 min. The microsomal extract was applied 
across the central 15 m of the plate, and authentic standards of a free fatty acid 
(linoleic acid), phospholipid (phosphatidylcholine) and neutral lipid (olive oil) 
were applied to both sides of the plates. The plates were developed in 
*This extraction procedure gave ca. 100% yield of free fatty acids. 
99 
petroleum ether (bp 40 - 60 ° C) :diethyl ether:glacial acetic acid (90: 10: 1, 
v /v /v) (297). 
The free fatty acids were located under ultraviolet light after spraying the sides 
of the developed plates (viz: the lanes containing the standards) with 0.2% 
2, 7-dichlorofluorescein in ethanol. The central band with an Rt value 
corresponding to that of the free fatty acid standard was scraped off and 
extracted thrice with 1 O ml chloroform:methanol (2: 1, v /v). The extract was 
taken to dryness by rotary evaporation, and the residue suspended in 1 ml 
chloroform:methanol (2:1,v /v). 
The fatty acids were methylated using boron trifluoride according to the method 
of McIntosh et al (369) (Section 2.2.3.3). The extracts were resuspended in 
200 µI iso-octane. These samples were stored in liquid nitrogen until they could 
be separated and quantitated by gas chromatography (Section 2.1.3). The 
recovery of the radiolabelled fatty acid was determined at several stages of the 
procedure and used to correct for any loss of free fatty acid which occurred 
during the lengthy extraction and chromatographic procedures. When 
[ 1-14c] linoleic acid was used as an internal standard, the yield of 
[1-14c] linoleic acid was calculated from the dpm and specific activity, and 
subtracted from the final concentration of free linoleic acid in the microsomes. 
2.2.3.5 Quantification of the Total Fatty Acid Content of the Lipid 
Fraction of the Hepatic Microsomal Membrane 
Hepatic microsomes (0.5 ml of 4 - 7 mg microsomal protein/ml, induced for 
ti6-desaturase activity and prepared by Method B (Section 2.2.1.3b)), plus 1 µI 
[1-14c] oleic acid (3.5 nmol, 57.4 nCi) were saponified as follows: to the 
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microsomes, an equal volume (0.5 ml) of 10% potassium hydroxide in 
methanol and butylated hydroxytoluene (0.005%) was added and this mixture 
was heated at 60 ° C for 30 min under argon. Following saponification, the 
microsomes were acidified with HCI and extracted thrice with 2 ml hexane. The 
hexane extracts were evaporated to dryness under a stream of nitrogen and the 
residue was resuspended in 1 ml chloroform:methanol, (2:1,v/v). A 10 µI 
sample was counted to estimate the recovery of the [ 1-14c] oleic acid 
(recovery was greater than 90%). The fatty acids were methylated using boron 
trifluoride as described above (Section 2.2.3.3) and resuspended in 0.5 ml 
iso-octane. The methylated fatty acids were stored in liquid nitrogen until they 
could be analysed by gas chromatography. 
2.2.3.6 Separation and Quantitation of Fatty Acids by Gas 
Chromatography 
Methyl esters of free fatty acids were separated by gas chromatography as 
described by Pugh and Kates (371 ). A glass column (1.8 metre x 0.25 cm), 
packed with GP 10% SP-2330 on 100/120 Chromosorb W AW (Supelco, Inc.) 
was run at a temperature of 200°C with nitrogen (20 ml/min) as the carrier gas. 
The injector temperature was 220 ° C and the detector temperature 230 ° C. 
The fatty acid methyl esters were identified by comparison of retention times 
with those of authentic standards. Standard curves were obtained using known 
concentrations of fatty acid standards (0.13 - 0.66 mM) which were methylated 
by the boron trifluoride-methanol procedure (Section 2.2.3.3). 
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The standards curves were used to quantitate the free fatty acid concentration 
in hepatic microsomes. 
2.2.3.7 Assay for Microsomal Phospholipase A2 Activity 
Phospholipase A2 activity was assessed in hepatic microsomes (prepared by 
Method B (Section 2.2.1.3b)) isolated from rats induced for A6-desaturase 
activity. The solvents (toluene and ethanol) from a 5 µI volume of radiolabelled 
L-3-phosphatidylcholine (1-palmitoyl-2-[1-14c] linoleoyl-phosphatidycholine, 
10. 7 nmol, 128 nCi) were removed under a stream of argon at room 
temperature. The L-3-phosphatidylcholine was resuspended (by vortexing) in 
0.1 ml of a 0.05 M phosphate buffer pH 7.4, containing 0.25 M sucrose, 
0.15 M KCI, 1 mM GSH, 5 mM MgCl2 and 0.4 mM EDTA. To this was added 
0.1 ml hepatic microsomes (0.5 mg/ml) and the mixture was incubated with 
shaking for O or 1 O min at 35 ° C. The concentration of EDTA in some samples 
was 5.0 mM. The reaction was terminated by the addition of an equal volume 
of 5% HCI in methanol (0.2 ml) plus butylated hydroxytoluene (0.005%). The 
microsomal lipids were extracted in chloroform:methanol (2:1,v/v) as described 
by Felch (372) and separated from the fatty acid fraction by TLC using the 
solvent system described in Section 2.2.3.4 (297). 
2.2.3.8 Measurement of Acyl-CoA Synthetase and Lysophospholipid 
Acyltransferase Activities in Hepatic Microsomes 
The following sections describe methods used to assess the activity of the 
acyl-CoA synthetase and lysophospholipid acyltransferases in hepatic 
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microsomes under conditions used to investigate the effect of isoflurane on the 
A6-desaturase .. 
Reaction mixtures were identical to those used to measure hepatic microsomal 
A6-desaturase activity (Section 2.2.3.2a) and were incubated at 35°C with 
shaking for O to 7 min. Subsequent steps were designed to obtain the best 
possible separation of neutral lipids, fatty acids, acyl-CoA esters and 
phospholipids. 
2.2.3.Ba Extraction and Separation of Microsomal Phospholipids, 
Neutral Lipids, Fatty Acids and Acyl-CoA Esters 
Two different extraction and chromatographic procedures were applied: the 
first (Method A) separated neutral lipids from fatty acids and phospholipids plus 
acyl-CoA, the second (Method B), separated acyl-CoA, fatty acids and 
phospholipids. 
Method A: the reaction (Section 2.2.3.2a) was terminated with an equal volume 
of 5% HCI in methanol (1.0 ml) containing butylated hydroxytoluene (0.005%). 
The mixture was extracted essentially as described by Folch (372): once with 
3 ml of chloroform:methanol (2:1,v/v) and then twice with 3 ml of chloroform. 
The extracts were pooled and the volume reduced to approximately 0.5 ml 
under a stream of nitrogen at ca. 45 ° C. 
The extracts were stored in liquid nitrogen prior to the separation of the 
constituent lipid classes by TLC as follows: an aliquot (50 µI) was applied to 
TLC plates (Merck aluminium-backed silica gel, 20 cm x 20 cm x 0.2 mm) 
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which had been activated at 110°C for 30 min under a stream of nitrogen. The 
plates were developed in petroleum ether (bp 40 - 60 ° C):diethyl ether:glacial 
acetic acid (90:10:1,v/v/v) containing 0.005% butylated hydroxytoluene (297). 
The bands corresponding to the phospholipids, neutral lipids and fatty acids 
were located under ultraviolet light after spraying with 2, 7-dichlorofluorescein 
and the Rt values were compared with those of authentic standards. The 
standards used were free fatty acid, linoleic acid; neutral lipid, olive oil and 
phospholipid, phosphatidylcholine. Identification of the phospholipid was 
facilitated by the use of molybdenum blue spray (373). Once the lipid classes 
had been identified, the corresponding bands were cut out and the radioactivity 
associated with each lipid fraction determined by liquid scintillation counting 
(Section 2. 1.3). 
Method B: The reaction (Section 2.2.3.2a) was terminated by the addition of 
4 ml diethyl ether containing 0.25 mg butylated hydroxytoluene. All steps in 
the extraction procedure were carried out under argon or nitrogen. The fatty 
acids were extracted twice into 4 ml diethyl ether. These extracts were pooled 
and the volume recorded. An aliquot (0.5 ml) of the diethyl extracts was 
removed and the radioactivity determined by liquid scintillation counting 
(Section 2. 1.3) 
The phospholipid and fatty acyl-CoA fractions remained in the aqueous layer 
and were separated into organic and aqueous phases essentially as described 
by Lands (374). To the aqueous layer, 4 ml chloroform:methanol (1 :4,v/v) 
containing 0.005% butylated hydroxtoluene was added, followed by 9 ml 
chloroform:methanol (4: 1,v /v) containing 0.005% butylated hydroxytoluene, 
and the mixture was vortex mixed. Four ml water was added to wash the 
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non-lipid material from the organic phase. The organic phase 
(chloroform:methanol) was removed and the volume of both phases recorded. 
An aliquot (0.5 ml) of the organic and aqueous phases was used for liquid 
scintillation counting (Section 2.1.3). This method of separation of the 
substrates and products of the acyl-CoA synthetase and lysophospholipid 
acyltransferases is referred to as the assay by differential organic extractions. 
Radioactive standards were taken through the extraction procedure described 
above to assess the percentage recovery and to determine the distribution of 
the fatty acid, phospholipids and acyl-CoA in the fractions. The standards used 
were fatty acid, r1-14c] linoleic acid (1.8 nmol, 106 nCi); phospholipid, 
1-palmitoyl-2-[1-14C] linoleoyl-phosphatidylcholine (2.2 nmol, 26 nCi) and 
acyl-CoA, r1-14c] palmitoyl-CoA (0.86 nmol, 50 nCi). 
The organic phases (diethyl ether and chloroform:methanol) were taken to 
dryness under a stream of nitrogen; the residue was resuspended in 0.5 ml 
chloroform:methanol (2: 1, v /v). These samples were stored under liquid 
nitrogen until their purity could be assessed by TLC. A 50 µI aliquot of sample 
was applied to the TLC plate (Merck aluminium-backed silica gel, 
20 cm x 20 cm x 0.2 mm activated at 11 O ° C for 30 min) under a stream of 
nitrogen. The plates were developed in chloroform:methanol:glacial acetic acid 
(66:34:1,v/v/v) containing 0.005% butylated hydroxytoluene*. The bands 
corresponding to the free fatty acid were located under ultraviolet light after 
spraying with 2,7-dichlorofluoresein; the phospholipid bands were identified 
using Molybdenum blue spray and the acyl-CoA band was identified using 
nitroprusside (after treatment with 10% KOH in methanol to split the 
*This solvent system is an adaption of those reported by Emilsson and Sundler 
(398) and was shown to give optimum separation. 
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thioester bond) (375). The phospholipid fractions were further identified by 
comparison of their Rt values with those of authentic standards of 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, 
phosphatic acid and lysophosphatidylcholine. Bands were cut out and counted 
by liquid scintillation counting (Section 2.1.3). 
2.2.3.Sb Enzyme Activity Calculations 
The activity of the acyl-CoA synthetase was calculated as the ratio of dpm fatty 
acyl-CoA/total dpm recovered. This ratio corrects for recovery of the 
radioactivity in the extraction procedure. The amount of fatty acyl-CoA 
produced (µM) can be calculated from this ratio and specific activity. The 
concentration of fatty acyl-CoA recovered was corrected for yield of fatty 
acyl-CoA standards on extraction. 
The activity of the lysophospholipid acyltransferases was calculated in the same 
way as above from the corrected yield of phospholipid. 
2.2.3.9 Calculations and Statistical Analyses 
Reported values are means ± standard deviations. For the study of the 
metabolism of isoflurane by cytochrome P-450 (Section 3.1 ), assays were 
performed in triplicate on at least two or more preparations of hepatic 
microsomes from the pooled livers of three to six rats. For the rest of the results 
(Section 3.2), assays were in triplicate from two or three preparations, and 
occasionally one preparation, of hepatic microsomes using the pooled livers of 
two rats. The total number of determinations reported accompany the results in 
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brackets. Unless otherwise stated, the means are from two or more 
preparations of microsomes. Daily activity measurements of the fatty acid 
desaturases varied, however, so that the results of more than one day could not 
be averaged. In these cases, the results from one day are reported and were 
chosen so that they were representative of all those obtained on that aspect of 
the research. When the results of a single, but representative day are reported, 
this is stated in the text. The Students t-test was utilised to calculate significant 
differences between means. 
Since calculation of the activity of the fatty acid desaturases, acyl-CoA 
synthetase and lysophospholipid acyltransferases is based on substrate 
concentration (Sections 2.2.3.2d and 2.2.3.Sb) and in the course of the 
experiments, endogenous substrate was found in the microsomes, the activity 
of these enzymes was corrected for endogenous substrate as outlined by Segel 
(376). All substrate concentrations are substrate added plus endogenous 
substrate and enzyme rates reported are corrected for the effect of endogenous 
substrate concentration on specific activity, unless otherwise noted. 
2.2.3.10 Presentation of Kinetic Data 
The kinetic data for the microsomal enzyme reactions were plotted according to 
the method described by Segel for assays using radiolabelled substrate in the 
presence of endogenous substrate, i.e. the rate was corrected for endogenous 
substrate and the substrate concentration used was that of added plus 
endogenous substrate (376). 
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Plots of rate versus substrate concentration, Lineweaver-Burk and 
Eadie-Hofstee plots, were constructed from the experimentally determined data 
points using a Miad personal computer and the 'Enzfitter' program 
(Section 2.1.3). Where experimental data points in Lineweaver-Burk plots and 
Eadie-Hofstee plots looked as if they were linear, these lines were calculated 
and drawn using the 'Enzfitter' program. Where possible, apparent Km and 
Vmax values were calculated from the Michaelis-Menten equation using the 
'Enzfitter' program. 
2.2.3.11 Computer Modelling of the A6-Desaturase Reaction 
A simplified reaction scheme for the A6-desaturase and other fatty acid 
metabolising enzymes was devised (shown in Figure 38). This reaction scheme 
was simulated using the SLAM II Version 3.0 program on a Univac model 1180 
or a Vax 6000-330 computer. The formation of products with time was 
monitored over 5 min and compared with that obtained experimentally. For 
each computer run, the simulated data were compared to the experimentally 
determined data for substrate disappearance or product formation as a function 
of time by constructing overlay plots using a Miad personal computer and 
Quattro Pro. 
The rate constants in the models were adjusted until the data from the simulated 
reaction scheme modelled the experimental data for substrate disappearance 
and product formation versus time for all three enzymes. Once the data from 
the simulated reaction scheme as a function of time compared favourably with 
the experimentally determined data for fatty acid disappearance, acyl-CoA 
formation, AS-desaturation and acylation of phospholipids, the constants were 
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used to simulate the reaction scheme at different concentrations of fatty acid 
substrate. Fatty acid substrate concentrations were taken as added fatty acid 
plus endogenous fatty acid. The reaction rate in µM product formed/min was 
calculated from the amount of product formed at 3 minutes from the output of 
the simulated reaction scheme, and compared to that obtained experimentally 
in hepatic microsomes for the acyl-CoA synthetase, ti6-desaturase and 
lysophospholipid acyltransferase at the different substrate concentrations used. 
Concentrations of enzymes and other factors, such as lysophospholipid, were 
obtained or calculated from the literature. 
2.2.3.12 Desaturase System 
Details of several aspects of the SLAM model for the desaturase enzyme 
system are given in this section. The abbreviations used and SLAM definitions 
are given immediately below (Section 2.2.3.12.1 ). The differential equations 
(Section 2. 2.3. 12.4) are identified and defined in SLAM -acceptable language. 
The variables (Section 2.2.3.12.2) and parameters (Section 2.2.3.12.3) are 
given. The values of the variables and initial and final values of the parameters 
are given in the Results and Discussion. 




Added + endogenous fatty acid 





c* Coenzyme A (CoA) 
E1 Acyl-CoA synthetase SS(2) 
FE1 Complex of F and E 1 SS(3) 
FC CoA derivative of F SS(4) 
E2 t:.6-Desaturase SS(5) 
FCE2 Complex of F, C and E2 SS(6) 
ut Fatty acid product of the desaturation of F 
UC CoA derivative of U SS(7) 
L Lysolecithin SS(8) 
E3 Lysophospholipid acyltransferase SS(9) 
UCLE3 Complex of UC, L and E3 SS(10) 
PU Phospholipid containing U at 2- position SS(11) 
FCLE3 Complex of FC, Land E3 SS(12) 
PF Phospholipid containing F at 2- position SS(13) 
* C was present in a large excess and the decay of its concentration was not 
monitered in the modelled reaction scheme (Figure 38). 












































dE * -1 00(14) 
dt 





F, E1, FE1, FC, E2, FCE2, UC, L, E3, UCLE3, PU, FCLE3, PF, NAOH, 02. 
2.2.3.12.3 Parameters 
2.2.3.12.4 Differential Equations 
1) dF 
dt 
00(1) = k2*SS(3) + k13*SS(4) - k1SS(1)*SS(2) 
2) dE1 
dt 
00(2) = k2*SS(3) + k3*SS(3) - k1 *SS(1)*SS(2) - k14*SS(2) 
3) dFE1 
dt 




= k3[FE1] + k5[FCE2] + k11[FCLE3] -k4[FC][E2]-
k1o[FC][E3][L] - k13[FC] 




00(5) = k5*SS(6) + k5*SS(6) - k4 *SS(4)*SS(5) - k15*SS(5) 
6) dFCE2 
dt 
00(6) = k4*SS(4)*SS(5) - k5*SS(6) - k5*SS(6) 
7) dUC 
dt 
00(7) = k5*SS(6) + kg*SS(10) - k7*SS(8)*SS(9)*8S(7) 
8) dl 
dt 
= kg[UCLE3] + k11 [FCLE3] - k7[L][E3][UC] -
k1o[FC][L][E3] 




= (kg + k9)[UCLE3] + (k11 + k12)[FCLE3] -
k7[UC][E3][L] - k1o[FC][E3][L] - k15[E3] 
00(9) = kg*SS(10) + k9*SS(10) + k11*SS(12) + k12*SS(12)-
k7*S8(7)*SS(8)*SS(9) - k1o*SS(4)*SS(9)*S8(8) -
k15*SS(9) 
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14) dE * -1 
dt 
= k7*SS(7)*SS(8)*8S(9) - kg*SS(10) - kg*SS(10) 
= kg[UCLE3] 
= kg*SS(10) 
= k1o*SS(4)*SS(8)*8S(9) - k11 *SS(12) - k12*SS(12) 
= k12*SS(12) 
00(14) = k14*SS(2) 










The results presented herein fall into two sections: 
i) an investigation of the metabolism of isoflurane by cytochrome P-450 
(Section 3. 1); and 
ii) the interaction of isoflurane and other anaesthetic agents with the 
cyanide-sensitive factors, focussing on the fatty acid desaturases. These 
results are followed by an attempt to characterise the interaction of 
isoflurane with the A6-desaturase, and this study includes an 
investigation into reactions and other factors which may influence 
accurate measurement of the activity of the A6-desaturase in hepatic 
microsomes (Section 3.2). 
3.1 THE METABOLISM OF ISOFLURANE BY THE CYTOCHROME P-450 
DRUG METABOLISM PATHWAY 
The metabolism of isoflurane by rat cytochrome P-450 was measured in hepatic 
microsomes in two ways:-
i) indirectly, by the stimulation of CO-inhibitable NADPH oxidation by 
isoflurane; and 
ii) directly, by fluoride ion production from isoflurane in the presence of a 
NAO PH-generating system and EDT A. 
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Using both these methods, the rates of isoflurane metabolism were assessed in 
microsomes from rats pretreated with inducing agents specific for isozymes of 
cytochrome P-450 which are members of the gene families I, II and Ill. 
3.1.1 Rates of the CO-inhibitable NADPH Oxidation in the Presence of 
lsoflurane in Rat Hepatic Microsomes 
The results of the indirect measurement of the metabolism of isoflurane in 
hepatic microsomes from rats pretreated with inducing agents for the different 
cytochrome P-450 isozymes are presented in Table 10. Pretreatment of rats 
with phenobarbital, ,B-napthoflavone and pregnenolone-160-carbonitrile gave 
increased levels of cytochrome P-450 which were significantly greater (P < 0.01) 
than the corresponding levels in control microsomes (Table 10). Initial reaction 
rates, which were linear for two to three minutes, were utilised in the calculation 
of rates of NADPH oxidation. The rate of CO-inhibitable NADPH oxidation in the 
presence of isoflurane was decreased or unchanged per mg microsomal 
protein and per nmol cytochrome P-450 following .B-naphthoflavone and 
pregnenolone-160-carbonitrile induction and was increased significantly 
(P < 0.01) following phenobarbital induction of cytochrome P-450 (Table 10). 
3.1.2 Fluoride Ion Production from lsoflurane in Rat Hepatic Microsomes 
Fluoride ion production following incubation of rat hepatic microsomes with 
isoflurane, NADPH-generating system and EDTA was at or below the limit of 
detection of the fluoride electrode. Therefore, fluoride ion concentration was 
elevated by lyophilisation of reaction mixtures. In spite of a resulting ten- to 
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TABLE 10 
THE EFFECT OF INDUCTION ON THE CO-INHIBITABLE NADPH OXIDATION 










0.95 ± 0.08 (6) 
1.22 ± 0.09 (6) t 
1.73±0.16(12) t 
2.02 ± 0.26 (6) t 
CO-inhibitable NADPH Oxidation * 
(nmol/mg protein/min) (nmol/nmol cytochrome 
P-450/min) 
1.9 ± 0.2 (12) 2.0 ± 0.2 
1.1 ± 0.4 (20)t 0.9 ± 0.4 t 
1.4 ± 1.1 (24) 1.1 ±0.6 t 
5.7 ± 0.4 (20)t 2.8 ± 0.4 t 
* In reaction mixtures containing hepatic microsomes (2 mg microsomal protein/ml 0.02 M Tris-HCI, 
pH 7.4), isoflurane (16 mM), NADPH (0.12 mM). The values are corrected for non-cytochrome 
P-450-dependent rates of NADPH oxidation measured in identical reaction mixtures in which the 
microsomes had been bubbled with C0:02 (80:20, v /v) for 30 sec. 
t Differs significantly from corresponding value for microsomes from untreated rats (P < 0.01 ). 
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twenty-fold increase in fluoride concentration, the levels of fluoride measured 
were still below the linear portion of the standard curve (data not shown). 
During the course of our experiments, we realised that lyophilisation designed 
to increase the concentration of fluoride ten- or twenty-fold, also increased the 
final concentration of MgCl2 (from the NADPH-generating system), resulting in 
interference with the fluoride determination. The effects of increasing 
concentrations of MgCl2 on the fluoride reading in phenobarbital-induced 
hepatic microsomes (2 mg protein/ml) incubated with NADPH (1 mM), 
nicotinamide (1 mM) and EDTA (0.2 mM), are shown in Table 11. It was 
accordingly necessary to draw up a standard curve for fluoride determination in 
the presence of MgCl2, in order to correct for the effect of MgCl2 on the fluoride 
reading. Standard curves of fluoride concentration versus millivolt reading 
obtained in the presence and absence of MgCl2 are illustrated in Figure 12. 
Other components of the NADPH-generating system were shown not to 
interfere with the fluoride reading, including glucose 6-phosphate and glucose 
6-phosphate dehydrogenase (Results not shown). 
Fluoride ion production from isoflurane as a function of time in rat liver 
microsomes from the differently pretreated animals, is illustrated in Figure 13. 
The reported fluoride content has been corrected for the levels of fluoride in 
zero-time samples consisting of hepatic microsomes (4 mg protein/ml) and 
isoflurane (32 mM). Negligible levels of fluoride ion ( < 1.0 pmol/mg 
microsomal protein/min) were found when the NADPH-generating system was 
excluded from reaction mixtures (Results not shown). In subsequent 
experiments, production of fluoride ion from isoflurane was assessed after 




THE EFFECT OF MgCl2 CONCENTRATION ON THE DETERMINATION 
OF FLUORIDE ION FROM ISOFLURANE IN RAT HEPATIC MICROSOMES 
[MgCl2] [MgCl2] Apparent Fluoride 
in Reaction Mixture in Solution for Fluoride Production 
(mM)* Determination (nmol fluoride/mg protein/min) 
(mM) t 
None None 178.0 ± 42.0 
0.2 4 150.0 ± 46.0 
20 11.6 ± 2.6 
5 100 5.2 ± 2.0 
In reaction mixtures containing 10 ml hepatic microsomes (2 mg microsomal protein/ml 0.02 M 
Tris-HCI, pH 7.4), isoflurane (16 mM), NADPH (1.0 mM), EDTA (0.2 mM), and nicotinamide 
(1.0 mM). Cytochrome P-450 content of hepatic microsomes was 2.83 ± 0.48 
nmol/mg microsomal protein. 
t 10 ml reaction mixture lyophilised and resuspended in 0.5 ml TISAB IV. Therefore, concentration 











Standard curves of fluoride concentration versus millivolt reading in 
the presence (•) and absence (e) of MgCl2 (5.0 mM). 















































































































































































































































untreated, and 5 min incubation for microsomes from phenobarbital- and 
pregnenolone-16a-carbonitrile-treated rats, unless otherwise stated (Figure 13). 
For microsomes from phenobarbital-pretreated rats, this was on the linear 
portion of the time curve. For microsomes from untreated and 
.B-naphthoflavone-preatreated rats, we used the shortest time over which we 
could accurately measure fluoride production, without being able to acertain 
that fluoride production was linear over this time period. This was a 
compromise that was not fully satisfactory, but we could find no alternative. 
A comparison of the production of fluoride ion from isoflurane by microsomes 
from differently pretreated rats is shown in Table 12. Pretreatment of rats with 
.B-naphthoflavone did not affect fluoride ion production from isofiurane per mg 
microsomal protein (Table 12). In contrast, both pregnenolone-16a-carbonitrile 
and phenobarbital pretreatment of rats significantly increased the production of 
fluoride ion per mg microsomal protein from isoflurane (P < 0.01) (Table 12). 
Fluoride ion production per nmol cytochrome P-450 was unchanged following 
.B-naphthoflavone induction but was increased significantly following 
pregnenolone-16a-carbonitrile and phenobarbital treatment (P < 0.01) 
(Table 12). 
It was possible to calculate Km and Vmax values for the production of fluoride 
ion from isoflurane only in microsomes from phenobarbital- and 
pregnenolone-16a-carbonitrile-induced rats. In view of the extremely low levels 
of fluoride ion produced from isoflurane in hepatic microsomes from 
.B-naphthoflavone-pretreated and untreated rats (Table 12), it was not possible 
to determine Km and Vmax values for the defluorination of isoflurane in 
microsomes from these rats.· Lineweaver-Burk plots for the defluorination of 
isoflurane in microsomes from phenobarbital- and pregnenolone-16a-
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TABLE 12 
THE EFFECT OF INDUCTION ON THE FLUORIDE ION PRODUCTION 
FROM ISOFLURANE IN RAT HEPATIC MICROSOMES 
Production of Fluoride Ion* 
Induction Cytochrome P-450 
of Rats (nmol/mg protein) 
(pmol/mg protein/min) (pmol/nmol cytochrome 
P-450/min) 
None 0.95 ± 0.08 (6) 16 ± 5 (12) 18 ± 4 
/3-Naphthoflavone 1.22 ± 0.09 (6) t 18±4(12) 16 ± 7 
Pregnenolone-16a- 1.73 ± 0.16 (12) t 126 ± 18 (7) t 72 ± 9 t 
carbonitrile 
Phenobarbital 2.02 ± 0.26 (6) t 59 ± 10 (12) t 24 ± 4 t 
* In reaction mixtures containing hepatic microsomes (5 ml at 4 mg microsomal protein/ml 
0.02 Tris-HCI, pH 7.4), isoflurane (32 mM), EDTA (0.4 mM), nicotinamide (2 mM), NADP (0.8 mM), 
glucose 6-phosphate (14.8 mM), glucose 6-phosphate dehydrogenase (1.0 U/ml) and MgCl2 
(10.0 mM). 










Lineweaver-Burk plot for the detluorination of isoflurane in hepatic 
microsomes from phenobarbital-pretreated rats. 
Rate, rate of fluoride ion production expressed as a percentage of 













Lineweaver-Burk plot for the defluorination of isoflurane in hepatic 
microsomes from pregnenolone-160-carbonitrile-pretreated rats. 
Rate, nmol fluoride ion produced/mg microsomal protein/5 min; isoflurane 
concentration, mM. 
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carbonitrile-pretreated rats are illustrated in Figures 14 and 15, respectively. 
Since incubation times of 5 and 15 min were used in different experiments for 
the determination of the rate of fluoride ion production from isoflurane in 
microsomes from phenobarbital-pretreated rats, the reaction rate in the 
Lineweaver-Burk plot (Figure 14) is expressed as a percentage of the maximum 
rate. The rate of fluoride ion production expressed in this way was equivalent 
for both incubation times. The Km values for the defluorination of isoflurane in 
microsomes from phenobarbital- and pregnenolone-16a- carbonitrile-pretreated 
rats were 0.86 ± 0.05 mM for both types of pretreatment. The Vmax values 
were 40 and 115 pmol fluoride/mg microsomal protein/min (17 and 68 pmol 
fluoride/nmol cytochrome P-450/min) for phenobarbital and 
pregnenolone-16a-carbonitrile induction, respectively. 
The production of fluoride ion from isoflurane in hepatic microsomes from 
phenobarbital-pretreated rats was inhibited by both CO and metyrapone. The 
extent of the inhibition of fluoride ion production from isoflurane by C0:02 
(80:20),v/v) and metyrapone is shown in Table 13. 
The alternate electron donor, NADH, supported the defluorination of isoflurane 
in hepatic microsomes at a slightly lower rate than NADPH (Table 14). In the 
presence of both NADH and NADPH, the rate of defluorination of isoflurane in 
hepatic microsomes from phenobarbital-pretreated rats was significantly higher 
than in the presence of either electron donors alone (P<0.01) (Table 14). 
Metyrapone inhibited the NADH-supported defluorination of isoflurane to a 
greater extent than that supported by NADPH (Tables 13 and 14). 
Since the rate of isoflurane metabolism by cytochrome P-450 measured via 




THE EFFECT OF INHIBITORS OF CYTOCHROME P-450 ON THE DEFLUORINATION OF 
ISOFLURANE IN HEPATIC MICROSOMES FROM PHENOBARBITAL-PRETREATED RATS 
Additions* Fluoride Ion Production % Inhibition of 
(pmol/mg protein/min) Fluoride Ion Production 
None 35±3(15) 
C0:02 (80:20, v /v) 27 ± 5 (15) t 24 ± 15 
None 35 ± 4 (14) 
Metyrapone (3.4 mM) 22 ± (14) 9 t 37 ± 8 
To reaction mixtures containing hepatic microsomes (5 ml at 4 mg microsomal protein/ml 0.02 M 
Tris-HCI, pH 7.4), isoflurane (32 mM), EDTA (0.4 mM) glucose 6-phosphate (14.8 mM), glucose 
6-phosphate dehydrogenase (1.0 U/ml), NADP (0.8 mM), MgCl2 (10.0 mM) and nicotinamide 
(2.0 mM), incubated for 15 min at 30 °C. 




THE EFFECT OF ELECTRON DONOR AND METYRAPONE ON THE DEFLUORINATION OF 





NADH (1) + NADPH (1) 
NADH (1) + metyrapone (3.4) 
Fluoride Ion Production 
(pmol/mg protein/min.) 
193±40(8) 
141 ±41 (8) 
249 ± 24 (8) t 
19 ± 1 (4) t 
To reaction mixtures containing hepatic microsomes (5 ml at 4 mg microsomal protein/ml 0.02 M 
Tris-HCI, pH 7.4), EDTA (0.2 mM), nicotinamide (1 mM), and isoflurane (32 mM), incubated for 
5 min at 30 ° C. 
t Differs significantly from that in the presence of one electron donor, or in absence of inhibitor 
(P<0.01). 
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directly via fluoride ion production (compare Tables 10 and 12), the production 
of hydrogen peroxide during the metabolism of isoflurane was measured to see 
if the production of active oxygen species could account for the discrepancy 
between NADPH utilised and fluoride ion produced. 
3.1.3 Production of Hydrogen Peroxide in Rat Hepatic Microsomes 
A number of factors were shown to influence the spectrophotometric 
measurement of hydrogen peroxide by the method of Hildebrandt (366) 
(Table 15). EDTA, glucose 6-phosphate-dependent NADPH-generating 
system and hepatic microsomes lowered the absorbance of known 
concentrations of hydrogen peroxide significantly (P<0.01), whereas isoflurane; 
nicotinamide and the isocitrate-dependent NADPH-generating system had no 
effect. Consequently, reaction conditions were selected which had minimal 
effect on the spectrophotometric measurement of hydrogen peroxide: the 
isocitrate-dependent NADPH-generating system was used, and EDTA 
concentration was reduced to 0.1 mM. 
The production of hydrogen peroxide was measured by two methods: the 
method of Hildebrandt (366) and the catalase-methanol method (367) 
(Table 16). Hepatic microsomes from phenobarbital-pretreated rats in the 
presence of NADPH-generating system, produced hydrogen peroxide 
(Table 16). The production of hydrogen peroxide was significantly lower 
following incubation of hepatic microsomes with NADPH generating system 
plus isoflurane (P<0.01); the results were the same for both methods of 
analysis (Table 16). lsoflurane in hepatic microsomes incubated without 
NADPH generating system, did not produce measureable amounts of hydrogen 
peroxide (Table 16). 
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TABLE 15 
THE EFFECTS OF REAGENTS OF THE REACTION MIXTURE ON THE SPECTROPHOTOMETRIC 
DETERMINATION OF HYDROGEN PEROXIDE DESCRIBED BY HILDEBRANDT (366) 
Medium containing Hydrogen Peroxide * 
Buffer 
Microsomes 
Microsomes + isoflurane 
Buffer + EDT A (0.2 mM) 
Microsomes + EDTA (0.2 mM) 
Buffer + glucose 6-phosphate-
dependent NADPH-generating system 
Buffer + isocitrate-dependent 
NADPH-generating system 
Buffer + EDTA (0.1 mM) + glucose 
6-phosphate-dependent NADPH-generating 
system 
Buffer + EDTA (0.2 mM) + glucose 
6-phosphate-dependent NADPH-generating 
system 













0.521 ± 0.031 
0.397 ± 0.023 t 
0.407 ± 0.011 
0.337 ± 0.012 t 
0.187 ± 0.010 t 
0.407 ± 0.012 t 
0.520 ± 0.016 
0.197 ± 0.026 t 
0.079 ± 0.012 t 
0.542 ± 0.032 
* Buffer, 0.02 M Tris-HCI, pH 7.4; Microsomes, hepatic microsomes from phenobarbital-pretreated rats 
at 2 mg microsomal protein/ml 0.02M Tris-HCI, pH 7.4; Glucose 6-phosphate-dependent 
NADPH-generating system, glucose 6-phosphate (7.4 mM), glucose 6-phosphate dehydrogenase 
(0.5 U/ml), MgCl2 (5 mM), nicotinamide (1 mM) and NADP (0.4 mM); lsocitrate-dependent 
NADPH-generating system, isocitric acid (6.4 mM), isocitrate dehydrogenase (0.2 U/ml), MgCl2 
(5 mM), nicotinamide (1 mM), and NADP (0.4 mM). Hydrogen peroxide concentration was 58 µM. 
t Differs significantly from the corresponding value for hydrogen peroxide in buffer or, where relevant, 
hydrogen peroxide plus microsomes (P<0.01). 
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TABLE 16 
THE EFFECT OF ISOFLURANE ON HEPATIC MICROSOMAL HYDROGEN PEROXIDE PRODUCTION 
* 
Additions to Method of Incubation Hydrogen Peroxide 
Hepatic Microsomes * Assay Time (nmol/mg protein/min) 
(from Phenobarbital- (min) 
pretreated Rats) 
lsoflurane + glucose 6-phosphate- Catalase-methanol 15 2.12 ± 0.13 (4) 
dependent NADPH-generating system 
Glucose 6-phosphate-dependent Catalase-methanol 15 5.19 ± 0.58 (4) t 
NADPH-generating system 
lsoflurane Catalase-methanol 15 0.06 ± 0.02 (4) 
lsoflurane + isocitrate-dependent Hildebrandt 5 3.08 ± 0.17 (3) t 
NADPH-generating system 2 2.89 ± 0.19 (3) t 
lsocitrate-dependent Hildebrandt 5 6.14 ± 0.07 (3) 
NADPH-generating system 2 5.06 ± 0.69 (3) 
The isocitrate-dependent NADPH-generating system, which contained EDTA (0.2 mM), sodium azide (0.2 mM), 
isocitric acid (6.4 mM), isocitrate dehydrogenase (0.2 U/ml), NADPH (0.4 mM), MgCl2 (5 mM) and nicotinamide 
(1.0 mM), was added to reaction mixtures of hepatic microsomes (2 mg microsomal protein/ml 0.02 M Tris-HCI, 
pH 7.4). 
The glucose 6-phosphate-dependent NADPH-generating system, which contained EDTA (0.1 mM), glucose 
6-phosphate (7.4 mM) glucose 6-phosphate dehydrogenase (0.5 U/ml), NADPH (0.4 mM), MgCl2 (5 mM) and 
nicotinamide (1.0 mM) was added to reaction mixtures of hepatic microsomes (2 mg microsomal protein/ml 0.02 M 
Tris-HCI, pH 7.4). 
lsoflurane concentration was 16 mM. 
t Differs significantly from the corresponding value in the absence of isoflurane (P<0.01). 
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3.1.4 The Metabolism of lsoflurane by Human Hepatic Microsomes 
The metabolism of isoflurane by human hepatic microsomes was measured 
directly by production of fluoride ion from isoflurane in the presence of EDT A 
and NADPH-generating system. The levels of fluoride ion produced following 
incubation of hepatic microsomes from human livers 2 and 3 with isoflurane, 
NADPH-generating system and EDTA are shown in Table 17, together with the 
concentrations of cytochrome P-450 found in all three livers. 
3.1.5 Detection of Fluorinated Metabolites using the Sodium Fusion Assay 
Three possible fluorinated metabolites of volatile fluorinated anaesthetic agents 
such as fluroxene, isoflurane and halothane, were subjected to the sodium 
fusion assay of Soltis and Gandfolfi (365). Since the decomposition of 
fluorinated compounds to fluoride ion is reported to depend on the medium 
(365), the yield of inorganic fluoride from these organofluorine metabolites was 
measured in various solutions and physiological fluids (Table 18). 
From the results presented in Table 18, it was apparent that the yield of 
inorganic fluorine from the fluorinated metabolites of volatile anaesthetic agents 
was not strikingly dependent on the physiological medium. The yield of 
inorganic fluoride did, however, show striking variation with the volatility of the 
metabolite during the sodium fusion assay; i.e., if a metabolite is volatile under 
the conditions of assay, e.g. trifluoroacetaldehyde and trifluoroethanol 
(Table 18), it is removed during the lyophilisation step in the assay. If not, e.g., 










THE PRODUCTION OF FLUORIDE ION FROM ISOFLURANE BY 
HUMAN HEPATIC MICROSOMES 
Fluoride Ion Production* 
Cytochrome P-450 
(nmol/mg protein) (pmol/mg protein/min) (pmol/nmol 
cytochrome P-450) 
0.63, 0.64 (2) N.D. N.D. 
0.53, 0.56 (2) 25 ± 6 (4) 45 ± 11 
0.71, 0.74 (2) 27±10(4) 37 ± 14 
The reaction mixtures contained hepatic microsomes (4 mg microsomal protein/0.02 M 
Tris-HCI, pH 7.4), glucose 6-phosphate (14.8 mM), glucose 6-phosphate dehydrogenase 




RECOVERY OF FLUORINATED METABOLITES OF ANAESTHETIC AGENTS 



















Recovery of Fluorinated Metabolites 
as Inorganic Fluoride 
% 









31 ± 2 26 
22 ± 2 19 
25 ± 8 20 
22 ± 5 19 
100 ± 20 83 
120 ± 6 100 
96 ± 15 80 
100 ± 5 83 
100 ± 5 83 
* Concentrations of metabolites were adjusted to give a final concentration of 120 µM fluoride ion in 
assay medium assuming 100% recovery after sodium fusion. Assay was that of Soltis and 
Gandolfi (365). 
t 0.02 M, pH 7.4. 
§ At a concentration of 2 mg microsomal protein/ml in 0.02 M Tris-HCI, pH 7.4. Microsomes were 
from phenobarbital-pretreated rats. 
1 0.05 M, pH 7.4. 
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We adapted the sodium fusion assay of Soltis and Gandolfi to ensure that in a 
single sample, one of the fluorinated metabolites of isoflurane, viz: either 
trifluoroacetic acid or trifluoroacetaldehyde (Figures 5 and 11 ), was in a 
non-volatile form for quantitation. The results of the adaptions to the sodium 
fusion assay on the recovery of trifluoroacetic acid and trifluoroacetaldehyde 
are outlined in the following section, and have been reported elsewhere (396). 
Trifluoroacetic acid in physiological fluids was relatively volatile (ca. 20% 
recovery as fluoride), but sodium trifluoroacetate, the anionic form of the acid, 
was relatively non-volatile, giving a yield of approximately 80% (Table 18). 
Although sodium hydroxide was added to each sample before lyophilisation 
(Section 2.2.2.5), the amount of sodium hydroxide added was apparently 
insufficient to ensure complete ionisation of the free acid to sodium 
trifluoroacetate (Table 18). Complete ionisation of trifluoroacetic acid to the 
non-volatile form was achieved by the addition of ammonium hydroxide, as well 
as sodium hydroxide before lyophilisation, as in Method A (Figure 11 ). The 
recovery of inorganic fluoride from trifluoroacetic acid (50 µM) was 87 ± 10% 
(n = 5) under these conditions. 
Since trifluoroacetaldehyde, another potential metabolite of isoflurane, was 
volatile under these conditions and lost during lyophilisation (data not shown), 
Method A (Figure 11) selectively measured trifluoroacetic acid, even if 
trifluoroacetaldehyde was produced. 
The conversion of trifluoroacetaldehyde to a non-volatile form was achieved by 
the addition of phenylhydrazine (Method B, Figure 11), which forms a 
non-volatile phenylhydrazone with trifluoroacetaldehyde. Under these 
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conditions, since alkali was not added, trifluoroacetic acid remained volatile, and 
was removed by lyophilisation (data not shown). Therefore, Method B 
(Figure 11) selectively measured the organic fluoride from 
trifluoroacetaldehyde, even in the presence of trifluoroacetic acid. 
During the course of these experiments, it was observed that inorganic fluoride 
could be recovered from trifluoroacetaldehyde when added to hepatic 
microsomes in the absence of sodium hydroxide or ammonium hydroxide 
(Method C, Figure 11). Trifluoroacetaldehyde (22 µM), added to 10 ml hepatic 
microsomes (2 mg microsomal protein/ml), lyophilised and taken through the 
sodium fusion assay, yielded of 68.5 ± 13 µM (n=5) inorganic fluoride 
(103 ± 19% recovery). Under these conditions (Method C, Figure 11) 
trifluoroacetaldehyde binds, presumably as a Schiff base, to microsomal 
constituents. The high pH resulting from the addition of the sodium hydroxide 
and ammonium hydroxide to hepatic microsomes used to render trifluoroacetic 
acid non-volatile (Method A, Figure 11) breaks these bonds releasing volatile 
trifluoroacetaldehyde resulting in the selective recovery of trifluoroacetic acid. 
Thus, by altering the conditions under which the reaction mixtures were 
lyophilised, the sodium fusion assay was adapted to measure the organic 
fluoride from either trifluoroacetic acid or trifluoroacetaldehyde, as potential 
metabolites of isoflurane. 
As a control, the recovery of organic fluoride from isoflurane was also 
measured. lsoflurane (32 mM), which was vortexed into microsomes (5 ml at 
4 mg microsomal protein/ml) and lyophilised, yielded less than 
2.2 nmol fluoride/ml incubation mixture. Any contribution made by isoflurane 
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to the levels of total organic fluoride was corrected for by including isoflurane in 
the zero-time samples, the results of which were subtracted from incubated 
samples. 
3.1.6 Identification of the Organofluoride Metabolites of lsoflurane in Rat 
and Human Hepatic Microsomes 
Known concentrations of trifluoroacetic acid and sodium fluoride incubated with 
human liver microsomes (2 mg microsomal protein/ml) taken through 
lyophilisation (under conditions where trifluoroacetic acid is non-volatile 
(Method A, Figure 11 )) and sodium fusion, were used to draw up fluoride 
standard curves (Figure 16). As can be seen from Figure 16, sodium fluoride 
and trifluoroacetic acid gave rise to different standard curves indicating that the 
recovery of fluoride ion from hepatic microsomes was different for trifluoroacetic 
acid and sodium fluoride using the sodium fusion technique. Since both 
fluoride ion and trifluoroacetic acid were present in reaction mixtures, a single 
standard curve was selected for quantitation of fluoride, viz: that for fluoride ion 
(in the form of sodium fluoride) added to human hepatic microsomes and taken 
through the sodium fusion assay (Method A, Figure 16). 
In human liver, Method A was used for measurement of total non-volatile 
fluoride including trifluoroacetic acid (Table 19). The production of total 
non-volatile fluoride significantly exceeded that of fluoride ion (P < 0.01) in both 
human livers, suggesting that trifluoroacetic acid was produced in measurable 
quantities following incubation of isoflurane with human hepatic microsomes, 
NADPH-generating system and EDTA (Table 19). Only Method A was applied 
to human hepatic microsomes, since insufficient material was available for 











Standard curves of fluoride concentration versus millivolt reading for 
sodium fluoride ( • ) and trifluoroacetic acid (, ) added to human 
hepatic microsomes and taken through the modified sodium fusion 
assay (Method A, Figure 11), and for sodium fluoride in neutralising 
solution (a) added to TISAB IV (Section 2.2.2.6). 






A COMPARISON OF THE TOTAL NON-VOLATILE FLUORIDE AND FLUORIDE ION 
PRODUCTION FROM ISOFLURANE IN RAT AND HUMAN HEPATIC MICROSOMES 
Species 
Human Liver 2 









Identity of Metabolite 




T rifl uoroacetald ehyde 
Trifluoroacetaldehyde 
Fluoride Ion * Total Fluoride§ 
(nmol fluoride/mg microsomal 
protein/15 min) 
0.40 ± 0.17 (4) 2.5 ± 0.8 (3) t 
0.41 ± 0.07 (4) 0.9 ± 0.5 (5) t 
0.35 ± 0.10 (8) 0.2 ± 0.1 (8) 
0.35±0.10(8) 4.0 ± 2.0 (5) t 
0.35 ± 0.10 (8) 2.2 ± 1.4 (5) t 
In 10 ml of reaction mixture containing hepatic microsomes (2 mg microsomal protein/ml 0.02 M 
Tris-Hcl, pH 7.4), isoflurane (16 mM), EDTA (0.2 mM), nicotinamide (1 mM) and the glucose 
6-phosphate-dependent or isocitrate-dependent NADPH-generating system (see Section 2.2.2.6a). 
Total organic fluoride measured in zero-time samples (0.55 ± 0.31 nmol fluoride/mg microsomal 
protein) was subtracted from total organic fluoride in incubated samples. 
Significantly greater than fluoride ion production (P < 0.01 ). 
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Application of Method A to rat hepatic microsomes resulted in no measurable 
production of non-volatile organic fluoride, i.e. no trifluoroacetic acid (Table 19). 
Furthermore, trifluoroacetic acid was not produced in measurable amounts as 
assessed by thin layer chromatography following 30 min incubation of 
isoflurane, hepatic microsomes from phenobarbital-pretreated rats, 
NADPH-generating system and EDTA (limit of detection was 0.2 nmol/mg 
protein/30 min). Known amounts of trifluoroacetic acid (approximately 
equivalent to the yield of 60 nmol/100 ml of incubation mixture calculated from 
the fluoride ion production) added to incubation mixtures in which either the 
NADPH-generating system or isoflurane was omitted, were readily detected. 
Treatment of the rat liver incubation mixtures described above with KMn04, 
which oxidises acetaldehydes to the corresponding acetic acids, resulted in the 
production of a metabolite which chromatographed identically to trifluoroacetic 
acid (Rt = 0.58). Sufficient amounts of this metabolite were produced and 
extracted from reaction mixtures so that the product could be visually detected 
relative to reaction mixtures which had not been incubated, or to reaction 
mixtures incubated for 30 min without NADPH-generating system. The sodium 
fusion assay was used to confirm the identity of trifluoroacetaldehyde 
(Methods B and C, Figure 11) as a metabolite of isoflurane in rat hepatic 
microsomes and to attempt to quantitate the production of this metabolite of 
isoflurane. 
Known concentrations of trifluoroacetaldehyde and sodium fluoride were taken 
through lyophilisation and sodium fusion as described in Method B (Figure 11) 
and used to draw up fluoride standard curves (Figure 17). The standard curve 
obtained for trifluoroacetaldehyde differed from that for sodium fluoride 







Standard curves of fluoride concentration versus millivolt reading for 
sodium fluoride <•) and trifluoroacetaldehyde (") added to rat hepatic 
microsomes and taken through the modified sodium fusion assay 
(Method 8, Figure 11), and for sodium fluoride in neutralising 
solution (•) added to TISAB IV (Section 2.2.2.6). 
Fluoride concentration, µM on a logarithmic scale. 
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the recovery of fluoride ion from hepatic microsomes was different for 
trifluoroacetaldehyde and sodium fluoride using this technique. Since 
quantitation of fluoride was necessary when both trifluoroacetaldehyde and 
fluoride ion were present, a single standard curve, viz: that for fluoride ion 
(sodium fluoride) which was added to rat hepatic microsomes and taken 
through the sodium fusion assay (Method B, Figure 11), was utilised. Both 
Method B (Figure 11 ), in which trifluoroacetaldehyde was converted to a 
non-volatile phenylhydrazone, and Method C, in which trifluoroacetaldehyde 
was bound to cellular macromolecules, were applied to hepatic microsomes 
from phenobarbital-pretreated rats, following incubation with isoflurane 
(16 mM), EDTA and NADPH-generating system. The yields of non-volatile 
organic fluoride were significantly (P < 0.01) greater than the fluoride ion 
measured, or total non-volatile fluoride measured by Method A in which 
trifluoroacetic acid and not trifluoroacetaldehyde was recovered as a 
non-volatile metabolite (Table 19). 
The results of measurement of total fluorinated metabolites from isoflurane in rat 
and human hepatic microsomes suggested that in human hepatic microsomes 
from two transplant donors, isoflurane was converted to fluoride ion and 
trifluoroacetic acid. In contrast, in hepatic microsomes from 
phenobarbital-pretreated rats, isoflurane was converted to fluoride ion and 
trifluoroacetaldehyde. Furthermore, the trifluoroacetaldehyde produced from 
isoflurane in rat hepatic microsomes appears to bind tightly to microsomal 
macromolecules, presumably as a Schiff base. 
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3.1. 7 Oxidation of Trifluoroacetaldehyde by Rat and Human Hepatic 
Cytosol 
Rat liver cytosol from phenobarbital pretreated animals in the presence of 
NADH (7.5 mM) and nicotinamide (1 mM) did not measurably convert 
trifluoroacetaldehyde (1.6 mM) to trifluoroacetic acid (limit of detection 
15 nmol/ml/30 min), i.e. no trifluoroacetic acid was detected visually from the 
reaction mixtures following extraction and TLC. Similarly, post-microsomal 
supernatants from human liver 2 and 3 did not measurably convert 
trifluoroacetaldehyde to trifluoroacetic acid but that from human liver 1 did: 
trifluoroacetaldehyde was visually detected following extraction and TLC. 
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3.2 THE INTERACTION OF ISOFLURANE WITH RAT HEPATIC 
MICROSOMAL CYANIDE-SENSITIVE FACTORS 
The interaction of isoflurane with the cyanide-sensitive factors was investigated 
by assessing the activity of these factors in two different ways: 
i) indirectly, by measuring the increased flow of electrons to the 
cyanide-sensitive factors. This is achieved by measuring the increased 
rate of reoxidation of cytochrome b5, an essential component of the fatty 
acid desaturase electron transport pathway (239,240), as shown in the 
following reaction: 
_..esc. -:i ... d';. :ea 
The ability of cyanide to inhibit the observed increased rate of reoxidation 
of cytochrome b5 mediated by a compound, indicates metabolism by (or 
interaction of the compound with) the cyanide-sensitive factors and not 
with the enzymes of other pathways which also utlilise electron transfer 
from cytochrome b5 (Figure 2), but are unaffected by low concentrations 
of cyanide. 
ii) directly, by measuring the effect of isoflurane on fatty acid desaturase 
activity. 
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First, it was necessary to establish assay methods for the ~6-desaturase and 
some of the other fatty acid desaturases in our laboratory. 
3.2.1 Assay for Rat Hepatic Microsomal ~6-Desaturase Activity 
The activity of the ~6-desaturase was measured in reaction mixtures where the 
substrate was added as linoleic acid together with an acyl-CoA generating 
system (Section 2.2.3.2a). After the reaction, the microsomal lipids were 
saponified. This releases linoleate (substrate) and -y-linolenate (product) from 
acyl-CoA and lipid derivatives formed concommitant with the ~6-desaturation of 
linoleic acid in hepatic microsomes. Under these conditions, the fatty acid 
desaturase assay described here, and assays reported elsewhere (see e.g. 
267-270) measured a composite of reactions, which is illustrated in a simplified 
form as follows (see also Figure 7): 
Acyl-CoA 
Linoleic acid -+ 
synthetase 
Fatty acid 
Linoleoyl-CoA -+ "(-Linolenoyl-CoA 
desaturase 
Esterified into phospholipids (and other lipids) by 
the lysophospholipid acyltransferases 
(and other enzymes) 
Two different methods of assay were used to measure directly the activity of the 
hepatic microsomal ~6-desaturase. 
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3.2.1.1 Method 1 (Table 9) 
This method was based on that reported by Mahfouz (297) with one 
modification: the fatty acid carriers were added as the free fatty acids 
immediately upon termination of the reaction in contrast to the reported method, 
where the carriers were the fatty acyl methyl esters which were added after 
extraction and methylation, and immediately prior to separation by TLC (297). 
Separation of the methyl esters of the fatty acid substrate and product of the 
AB-desaturation of linoleic acid by Method 1 resulted in five UV-detectable spots 
(Table 20). Two of the five had Rt values corresponded to authentic standards 
of methyl linoleate and methyl -y-linolenate which chromatographed as single 
spots. The other three spots remained unidentified. Linoleic acid and 
-y-linolenic acid, added to hepatic microsomes and taken through the 
methylation and saponification procedures, also gave rise to five UV-detectable 
spots. These five spots were always present and had similar Rt values, 
irrespective of whether the TLC was run on Merck glass-backed or 
aluminium-backed silica gel plates, or glass-backed plates prepared in our 
laboratory from a slurry of silica gel H (Section 2.2.3.2b). Therefore, the five 
UV-detectable spots appeared to result from the methylation and saponification 
procedures, rather than the argentation TLC. Had the fatty acid carriers been 
added as the corresponding methyl esters just prior to the TLC, as in the 
reported method (297), it is possible that only the two spots corresponding to 
methyl linoleate and methyl -y-linolenate would have been detected visually 




THE DISTRIBUTION OF RADIOACTIVITY IN THE UV-DETECTABLE SPOTS 
FOLLOWING TLC OF THE METHYL ESTERS OF THE SUBSTRATE AND 
PRODUCT OF THE ~6-DESATURATION OF LINOLEIC ACID 
UV-Detectable Rt Value Radioactivity* 
Spot (% of total radioactivity recovered t) 
Unknown 1 0.77 4.6 ± 1.7 (9) 
Methyl linoleate 0.58 79.2 ± 2.4 (9) 
Methyl 'Y-linolenate 0.49 12.8 ± 3.2 (9) 
Unknown 2 0.20 2.5 ± 0.9 (9) 
Unknown 3 0.03 0.2 ± 0.2 (9) 
Values were taken from four different preparations of microsomes. The distribution of 
radioactivity between methyl linoleate and methyl -y-linolenate varied depending on (a) whether 
the reaction mixture was a zero time or incubated sample, an~ (b) incubation conditions, e.g. 
time, protein concentration. The data presented here are from reaction mixtures containing 0.5 
mg protein/ml, corrected substrate concentration of 4.7 µM linoleic acid, and were incubated 
for 10 min. 
t Of the radioactivity applied to the plates, 90 ± 1 % was recovered. The distribution of the 
radioactivity in the spots is expressed as a percentage of the recovered radioactivity. 
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Of the radioactivity applied to the TLC plates, 90 ± 1 % was recovered in the five 
UV-detectable spots. Of the recovered radioactivity, > 90% was in the spots 
corresponding to methyl linoleate and methyl 1-linolenate (Table 20). The 
distribution of radioactivity among the unidentified spots remained constant 
during the course of several experiments, and did not vary between zero-time 
and incubated reaction mixtures (Table 20). Therefore, we did not count the 
three extraneous spots and used only data from the methyl linoleate and methyl 
1-linolenate spots in our calculations. This method for the t.6-desaturase activity 
was used for some of the results presented herein; it is referred to as Method 1. 
3.2.1.2 Method 2 (Table 9) 
In Method 2, the step in Method 1 thought to give rise to the multiple spots 
following separation of the substrate and product, was eliminated, 
i.e., methylation of the fatty acids. The substrates and products of the reaction 
were separated as free fatty acids by HPLC. A chromatogram illustrating the 
separation of the fatty acid substrate and product of the t.6-desaturation of 
linoleic acid by HPLC is illustrated in Figure 18. Of the radioactivity applied to 
the column, 100 ± 2% was recovered in fractions which eluted at times 
corresponding to those of authentic standards of linoleic acid and 1-linolenic 
acid. This HPLC method was extended to measure the t.6-desaturation of 
a-linolenic and the t.5-desaturation of eicosa-8, 11, 14-trienoic acid. 
Chromatograms illustrating the separation of the substrates and products by 
HPLC for the last two reactions are also shown in Figure 18. The product of the 
t.6-desaturation of a-linolenic acid, octadeca-6,9, 12, 15-tetraenoic acid, was not 








































































































































































































































































































































































































































For the ti6-desaturation of a-linolenic acid, 100 ± 2% of the radioactivity applied 
to the column was recovered in two fractions: one eluted at a time 
corresponding to that of an authentic standard of a-linolenic acid and the other, 
which remained unidentified, was assumed to be 
octadeca-6, 19, 12, 15-tetraenoic acid. For the tis-desaturation of 
eicosa-8, 11, 14-trienoic acid, only ca. 90% of the radioactivity was recovered in 
fractions corresponding to authentic standards of the substrate and product, a 
low recovery compared to the recovery for the ti6-desaturase assays by this 
method. Since both the substrate and product of the tis-desaturation of 
eicosa-8, 11, 14-trienoic acid are substrates for cyclo-oxygenase (Figure 10), we 
investigated whether the low recovery of radioactivity following tis-desaturation 
of eicosa-8, 11, 14-trienoic acid could be accounted for by the formation of 
eicosanoids. No further radioactivity was found in any other fractions. The 
following percentage recoveries, 94 ± 5% (n=3), 92 ± 0% (n=2) and 85 ± 4% 
(n = 3) were calculated for zero time reaction mixtures, full reaction mixtures 
incubated for 10 min with and without NADH, respectively. Subsequently, the 
recovery of (2-14c] eicosa-8, 11, 14-trienoic acid from the H PLC column 
(Spherisorb ODS) was found to be 90 ± 2% (n =3), indicating that impurities in 
the substrate, rather than deficiencies in the chromatographic procedure 
resulted in the relatively low recovery of the radioactivity for the A5-desaturase 
assay. 
The chromatograms illustrated in Figure 18 were obtained after HPLC 
separation of the substrates and products of the A6- and A5-desaturases using 
a Zorbax ODS HPLC column (Section 2.2.3.2c). During the course of 
approximately five hundred chromatographic separations, the elution times 
gradually became shorter. Ultimately, separation of the substrate and product 
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of the AS-desaturation of a-linolenic acid was no longer achievable. The Zorbax 
ODS column could be replaced by a Spherisorb ODS column for assay of the 
AS-desaturation of linoleic acid and AS-desaturation of eicosa-8, 11, 14-trienoic 
acid. On the latter column, elution times for linoleic acid and -y-linolenic acid 
were 14 to 17 min and 10 to 12 min, respectively, and for eicosa-8, 11, 14-trienoic 
acid and arachidonic acid were 14 to 17 min and 10 to 12 min, respectively. 
The substrate and product of the AS-desaturation of a-linolenic acid were not 
fully resolved using the Spherisorb ODS column (elution times of 7 to 12 min 
and s to 8 min for substrate and product, respectively). Consequently, a 
Zorbax Golden Series column was used to assay the AS-desaturation of 
a-linolenic acid. Although initial studies of the AS-desaturation of linoleic acid 
and A5-de:saturation of eicosa-8, 11, 14-trienoic acid in hepatic microsomes were 
performed using the Zorbax ODS column, the bulk of the assays were 
conducted using the Spherisorb ODS column. 
The effects of microsomal protein concentration and time on the activity of the 
AS-desaturation of linoleic acid as measured by Method 1, are shown in 
Figure 19, and on A6- and A5-desaturase activities measured by Method 2, in 
Figures 20, 21 and 22. For the AS-desaturase, the rate of product formation 
was linear up to a protein concentration of 0.5 mg microsomal protein/ml for 
both substrates; for the A5-desaturase, the rate of product formation was linear 
up to a protein concentration of 0.25 mg microsomal protein/ml 
(Figures 20, 21 and 22). The AS-desaturase activity with linoleic acid as 
substrate was linear over a period of 10 min, but when a-linolenic acid was the 
substrate, the rate of product formation was linear for only 7 min 
(Figures 20 and 21 ). The A5-desaturase activity was linear over a time period 


























The effect of microsomal protein concentration (A) and time (B) on the 
li6-desaturation of linoleic acid measured using Method 1. 
Protein concentration, mg microsomal protein/ml reaction mixture 
(Section 2.2.3.2a); rate, µM -y-linolenic acid produced/min; -y-linolenic acid 
concentration, µM. Corrected substrate concentration was 4.7 µM. BSA 
concentration was 11.5 µg/ µg linoleic acid added. Results are from a 





























The effect of microsomal protein concentration (A) and time (B) on the 
As-desaturation of linoleic acid measured using Method 2. 
Protein concentration, mg microsomal protein/ml reaction mixture 
(Section 2.2.3.2a); rate, µM -y-linolenic acid produced/min; -y-linolenic acid 
concentration, µM. Corrected substrate concentration was 4. 7 µM. BSA 
concentration was 115 µg/µg linoleic acid added. Results are from a single 























The effect of microsomal protein concentration (A) and time (B) on the 
ts-desaturation of a-linolenic acid measured using Method 2. 
Protein concentration, mg microsomal protein/ml reaction mixture 
(Section 2.2.3.2a); rate, µM octadeca-6,9, 12, 15-tetraenoic acid 
produced/min; product concentration, µM octadeca-6,9, 12, 15-tetraenoic 
acid. Corrected substrate concentration was 2.1 µM. BSA concentration 
was 115 µg/µg linoleic acid added. Results are from a single preparation of 































The effect of microsomal protein concentration (A) and time (B) on the 
ts-desaturation of eicosa-8, 11, 14-trienoic acid measured using 
Method 2 
Protein concentration, mg microsomal protein/ml reaction mixture 
(Section 2.2.3.2a); rate, µM arachidonic acid produced/min; arachidonic 
acid concentration. µM. Corrected substrate concentration was O. 75 µM. 
BSA concentration was 115 µg/µg linoleic acid added. Results are from a 
single preparation of hepatic microsomes, but are typical of those from 
three preparations. 
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linoleic acid were identical for measurement of the t.6-desaturase activity by the 
Methods 1 and 2 (compare Figures 19 and 20). 
As previously reported (237), the t.5- and t.6-desaturase activities in hepatic 
microsomes required NADH (Table 21 ). In the absence of NADH, the activities 
were relatively low compared to those observed in the presence of NADH, 
especially for the t.6-desaturase, where rates were ~ 5% in the absence of 
NADH (Table 21 ). Interestingly, ca. 15% activity was observed for the 
t.5-desaturase in the absence of added NADH (Table 21 ). This result may have 
been an artifact or may represent the presence of a suitable endogenous 
electron donor for the t.5-desaturase in hepatic microsomes. 
Although the results of the measurement of the t.6-desaturase activity appeared 
to be comparable whether measured by Method 1 (TLC) or Method 2 (HPLC), 
the results from Method 2 were more reproducible. This is demonstrated by a 
comparison of the coefficients of variation of the two methods. For the analysis 
of a single reaction mixture for the t.6-desaturation of linoleic acid, the coefficient 
of variation was 3.5% (n = 6) for Method 1 and 0.3% (n = 5) for Method 2. 
Consequently, Method 2 was the preferred method for analysis, especially as 
the activity of the t.6-desaturase was low. 
During the course of our experiments, we became aware that endogenous free 
fatty acids are present in significant concentrations in hepatic microsomes 
(see e.g. 397). From results in our laboratory, the levels of free fatty acid 
substrates for the fatty acid desaturases were found to be sufficiently plentiful to 
affect the calculation of fatty acid desaturase activity by diluting out the specific 
activity of the radiolabelled substrate (see the following sections). 
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TABLE 21 
THE EFFECT OF NADH ON FATTY ACID DESATURASE ACTIVITY IN HEPATIC MICROSOMES 









Linoleic acid (1.8) 
a-Linolenic acid (1.8) 
Eicosa - 8, 11, 14 -




9.1 ± 0.5 
4.1 ± 5.1 
16.8 ± 5.3 
+ NADH 
(2.6 mM) 
202.0 ± 19.1 
92.9 ± 8.6 
109 ± 5.3 
Reaction mixtures contained hepatic microsomes (0.5 mg protein/ml for the M-desaturase, 
and 0.25 mg protein/ml for the As-desaturase) and BSA (115 µg/ µg free fatty acid substrate 
added). Incubations were for 10 min (for the M-desaturation of linoleic acid and the 
As-desaturation of eicosa-8, 11, 14-trienoic acid) or 7 min (M-desaturation of Q-linolenic acid) 
and assayed using Method 2. Corrected substrate concentrations were linoleic acid, 4.7 µM; 
a-linolenic acid, 2.1 µM; eicosa-8, 11, 14-trienoic acid, o. 75 µM. Other incubation conditions are 
given in the Methods. (Section 2.2.3.2a). 
t Results were from a single preparation of hepatic microsomes (n=3), but were typical of 
results obtained on two or more microsomal preparations. 
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3.2.2. Fatty Acid Content of Rat Hepatic Microsomes 
3.2.2.1. Analysis of the Fatty Acid Content of the Microsomal 
Membrane 
In order to establish the technique for fatty acid analysis in our laboratory, I 
initially measured the total fatty acid content of the microsomal membrane, 
including free fatty acid plus fatty acid covalently bound in microsomal lipids. 
Alkaline saponification of the microsomal membrane was used to hydrolyse the 
fatty acids from lipids; the resulting fatty acids were extracted, methylated and 
analysed by gas chromatography. A typical chromatogram illustrating the 
separation of the fatty acids of the microsomal membrane by gas 
chromatography is shown in Figure 23. The major fatty acids found in these 
membranes were quantitated and are listed in Table 22, together with their 
microsomal concentrations. Palmitic acid was also identified as one of the main 
fatty acid components of the microsomal membrane, but was not quantitated. 
Other unidentified fatty acids occurred in small amounts (Figure 23). There was 
a variation in the fatty acid content of the microsomal membrane from 
microsomal preparation to preparation. This was noticable especially for 
arachidonic acid, the level of which has been reported to be related to changes 
in daily dietary intake (197,206). These differences in the fatty acid content of 
the microsomal membrane may have influenced the activity of the 
f.6-desaturase (206). Whatever the cause, the observed daily variation in 
f.6-desaturase activity was substantial and has affected the way in which the 
results are presented herein, viz: the results obtained on more than one day 
could not always be averaged because of differing f.6-desaturase activity of the 
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Chromatogram illustrating the separation by gas chromatography of 
(A) the methyl esters of the fatty acids of hepatic microsomal 
membranes and (8) a mixture of fatty acid methyl ester standards. 
The fatty acids were detected by the change in flame ionisation potential 
(flFIP), Fatty acid peaks were identified as follows: 1: palmitic acid, 
2: stearic acid, 3: oleic acid, 4: linoleic acid, 5: a-linolenic acid, 




ANALYSIS OF THE TOTAL FATTY ACIDS CONTENT OF A PORTION OF THE 
RAT HEPATIC MICROSOMAL MEMBRANE 
Fatty Acid Fatty Acid Concentration (µM)* 
Experiment 1 Experiment 2 Experiment 3 
Stearic acid 76±18(3) 92 ± 21 (8) 148 ± 68 (7) 
Oleic acid 63 ± 46 (5) 73 ± 14 (3) 54 ± 6 (2) 
Linoleic acid 49 ± 8 (6) 59 ± 10 (10) 78±27(10) 
Eicosa - 8, 11, 14 - trienoic acid 5.1 ± 2.1 (6) 9.7 ± 4 (6) 6.7 ± 3 (6) 
Arachidonic acid 616 ± 84 (3) 85 ± 9 (5) 154 ± 55 (9) 
-y-Linolenic acid ND ND ND 
a-Linolenic acid ND ND ND 
* In hepatic microsomes at a concentration of 0.5 mg microsomal protein/ml. Total fatty acid 
concentration includes free fatty acids plus those esterified into lipids. Each experiment used a 
different preparation of hepatic microsomes from identically treated rats. 
ND = Not detected. 
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experiments 1 and 2 shown in Table 28 differed by a factor of 2 in the absence 
isoflurane. This extent of variability was typical of !16-desaturase activity in the 
absence of inhibitors. Therefore, the results of desaturase assays on a single, 
but representative microsomal preparation, are often reported. This data is 
generally supported by similar results on one or more other microsomal 
preparations. 
3.2.2.2. Analysis of the Free Fatty Acid Content of the Microsomal 
Membrane 
In contrast to the previous section (3.2.2.1 ), the fatty acids measured in this 
section were not esterified into lipids, but were non-covalently bound to the 
microsomal membrane and were, therefore, a potential source of endogenous 
fatty acid substrate for the fatty acid-metabolising enzymes including the fatty 
acid desaturases. These free fatty acids were extracted from microsomes 
(without saponification), separated from the phospholipids by TLC, methylated 
and then analysed by gas chromatography (Sections 2.2.3.4 and 2.2.3.6). A 
typical chromatogram illustrating the gas chromatographic separation of 
extracted microsomal fatty acid methyl esters is shown in Figure 24. Also 
shown is the chromatogram for fatty acid methyl ester standards (Figure 24 B). 
Quantitation of the microsomal free fatty acids on two to three microsomal 
preparations is shown in Table 23. It can be seen that linoleic acid, one of the 
substrates for the !16-desaturase, was present in amounts comparable with 
added linoleate concentrations used in the assay of the !16-desaturase (0.45 -
10.9 µM) (Table 23). The amount of free linoleic acid did not vary significantly 
(P>0.1) in three different preparations of hepatic microsomes. Similarly, the 
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Chromatogram illustrating the separation by gas chromatography of 
(A) the methyl esters of free fatty acids extracted from hepatic 
microsomes and (B) a mixture of fatty acid methyl ester standards. 
The fatty acids were detected by the change in flame ionization potential 
(AFIP). Fatty acid peaks were identified as follows: 1: palmitic acid, 
2: stearic acid, 3: oleic acid, 4: linoleic acid, 5: cr-linolenic acid, 
6: -y-linolenic acid, 7: eicosa-8, 11, 14-trienoic acid and 8: arachidonic acid. 
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TABLE 23 
ANALYSIS OF THE FREE FATTY ACID CONTENT OF RAT HEPATIC MICROSOMES 
Fatty Acid Free Fatty Acid Concentration (µM) * 
Experiment 1 Experiment 2 Experiment 3 
Linoleic acid 2.9 ± 0.8 (4) 3.1 ± 1.3 (6) 2.9 ± 0.9 (8) 
a-Linolenic acid 0.6 ± 0.4 (3) 0.4 ± 0.3 (3) 
"(-Linolenic acid 0.4 ± 0.1 (4) 0.7 ± 0.3 (2) 0.5 ± 0.1 (3) 
Eicosa - 8, 11, 14 - trienoic acid 0.4 ± 0.9 (4) 0.5 ± 0.1 (4) 
Arachidonic acid 2.0 ± 0.9 (4) 0.8 ± 0.1 (2) 
* In hepatic microsomes at a concentration of 0.5 mg microsomal protein/ml. Each experiment used a 
different preparation of hepatic microsomes from identically treated rats. 
--, 
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eicosa-8, 11, 14-trienoic acid, a substrate for the .t\5-desaturase, showed no 
significant variation in two preparations of hepatic microsomes (P > 0.1) (Table 
23). The concentrations of these fatty acids in hepatic microsomes were 
considerably lower than the free linoleic acid present (Table 23). Of the free 
fatty acids quantitated, only -y-linolenic acid and arachidonic acid showed 
significant daily variation (P < 0.01) (Table 23). 
The impact of endogenous substrate on the accurate calculation of enzymic 
reaction rates has been demonstrated clearly and elegantly by Segel (376). 
Therefore, as indicated in the Methods (Section 2.2.3.9), we have corrected the 
fatty acid desaturase, acyl-CoA synthetase and lysophospholipid 
acyltransferase activities for endogenous fatty acid concentrations. The effect 
of dilution of the added radiolabelled fatty acid substrate with endogenous 
unlabelled fatty acid on fatty acid desaturase activity is illustrated in Figure 25. 
Two different reaction rate versus substrate concentration curves were obtained 
for the .t\6-desaturase when the results were or were not corrected for 
endogenous substrate concentrations (Figure 25). The corresponding 
Lineweaver-Burk plots for these curves showed the substantial effect of 
correcting for endogenous substrate in calculation of enzyme activity on the 
apparent Km value for the enzyme (Figure 25). 
As a consequence of this striking effect of endogenous substrate levels on 
apparent fatty acid desaturase activity, all reaction rates and substrate 
concentrations for the fatty acid desaturases are reported as corrected values. 
To our knowledge no other investigators have corrected fatty acid desaturase 
activity measured with hepatic microsomes for endogenous substrate levels 




















The effect of correcting for endogenous substrate on the rate versus 
substrate concentration curve (A) and Lineweaver-Burk plot (8) for the 
b6-desaturation of linoleic acid in rat hepatic microsomes. Rate was 
calculated from the concentration of added + endogenous substrate 
(corrected) (X), and added substrate (uncorrected) (• ). Substrate 
concentration is that of added + endogenous substrate for corrected 
data (X) and added substrate for uncorrected data (•) 
Rate, µM [1-14q -y-linolenoyl-CoA + p-14q 2--y-linolenoyl-phospholipid 
formed/min; linoleic acid concentration, µM linoleic acid. BSA 
concentration was 115 µg/ µg linoleic acid added. b6-Desaturase activity 
was measured using Method 2. Curves and lines were drawn by Enzfitter 
(Section 2.2.3.10\ 
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concentration and is corrected for endogenous substrate. For the 
t.6-desaturation of o-linolenic acid, both reaction rates and substrate 
concentrations are reported as corrected values. The t.9-desaturase activity 
was determined using stearoyl-CoA as substrate so there was no need to 
correct for endogenous stearic acid levels. 
Since the same substrates and incubation conditions were used for 
measurement of acyl-CoA synthetase and lysophospholipid acyltransferase 
activities in hepatic microsomes, these rates were also corrected for 
endogenous fatty acid levels and are reported in this way. For the 
lysophospholipid acyltransferase, acyl-CoA is usually used as substrate (371 ), 
so activities reported in the literature do not correct for endogenous substrate. 
For a single report on activity of the acyl-CoA synthetase, the presence of 
endogenous fatty acids in hepatic microsomes was acknowledged, and the 
microsomes were treated in such a way as to remove these fatty acids (386). 
Besides this report, to our knowledge no other studied of the activity of the 
acyl-CoA synthetase in hepatic microsomes corrected for endogenous 
substrate. 
3.2.3 The Effect of lsoflurane on Indirect Assay for Fatty Acid Desaturase 
Activity in Rat Hepatic Microsomes 
Using the indirect method of assessment of activity of the fatty acid desaturases 
(the reoxidation of cytochrome b5), isoflurane was shown to interact with one or 
more of these enzymes: isoflurane significantly increased the pseudo first order 
rate constant for the re-oxidation of cytochrome b5 (P < 0.01) in hepatic 
microsomes from rats fed a high-carbohydrate diet (Table 24); potassium 
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TABLE 24 
THE EFFECT OF CYANIDE ON THE ISOFLURANE-STIMULATED RE-OXIDATION 
OF CYTOCHROME b5 IN HEPATIC MICROSOMES 
FROM RATS FED A HIGH-CARBOHYDRATE DIET 
Additions to Reaction Mixture* 
None 
KCN (0.5 mM) 
lsoflurane (13.3 mM) 
lsoflurane (13.3 mM) 
+ KCN (0.5 mM) 
Pseudo First Order Rate 
Constant for the Re-oxidation of 
Cytochrome b5 
( x 10-2 sec ·1) 
1.30 ± 0.06 (2) 
1.30 ± 0.01 (2) 
2.24 ± 0.38 (1 O) t 
1.32 ± 0.31 (5) § 
* Reaction mixtures contained 3.0 ml hepatic microsomes (1.5 mg microsomes protein/ml 0.02 M 
Tris - HCL, pH 7.4) and NADH (2.5 µM). 
t Differs significantly from the rate constant for no additions (P < 0.01 ). 
§ Differs significantly from the rate constant in the presence of isoflurane alone (P<0.01). 
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cyanide significantly decreased the pseudo first order rate constant for 
re-oxidation of cytochrome b5 in the presence of isoflurane (P < 0.01 ), but did 
not affect the reoxidation of cytochrome b5 in the absence of isoflurane 
(Table 24). Futher studies were aimed at investigating the effect of isoflurane 
on the fatty acid desaturases both indirectly, using the reoxidation of 
cytochrome b5 as an index of fatty acid desaturase activity, and directly, 
measuring drug effects on the desaturation of fatty acid substrates. 
3.2.3.1 The Effect of Diet and lsoflurane on the Indirect Assay for 
Fatty Acid Desaturase Activity 
The effect of diet on microsomal desaturase activity, as assessed by 
cytochrome b5 reoxidation, is given in Table 25. Stearoyl-CoA and 
linoleoyl-CoA were used as the substrates for the A9- and A6-desaturases, 
respectively, thus eliminating any interference from endogenous free fatty acid 
substrates. The high-carbohydrate diet was used to induce A9-desaturase 
activity (314). The induction of the A9-desaturase by a high-carbohydrate diet in 
our studies is confirmed by the significant increase in the pseudo first order rate 
constant for the re-oxidation of cytochrome b5 in the presence of stearoyl-CoA 
in hepatic microsomes from rats fed on a high-carbohydrate diet, compared to 
that in hepatic microsomes from rats fed a normal diet (P<0.01) (Table 25). In 
contrast, the pseudo first order rate constants for the re-oxidation of 
cytochrome b5 by linoleoyl-CoA in the hepatic microsomes from rats fed a 
normal diet and from rats fed a high-carbohydrate diet are similar (P > 0.1) 
(Table 25). The pseudo first order rate constant for the re-oxidation of 
cytochrome b5 in hepatic microsomes from rats fed a normal or a 
high-carbohydrate diet was increased significantly by isoflurane (P < 0.01 ). 
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TABLE 25 
THE EFFECT OF DIET ON THE STEAROYL-CoA, LINOLEOYL-CoA AND 
ISOFLURANE-STIMULATED RE-OXIDATION OF CYTOCHROME b5 IN 
RAT HEPATIC MICROSOMES 
Diet Additions to Reaction Mixture* 
HCD None 
Normal None 
HCD Stearoyl-CoA (12 µM) 
Normal Stearoyl-CoA (12 µM) 
HCD Linoleoyl-CoA (12 µM) 
Normal Linoleoyl-CoA (12 µM) 
HCD lsoflurane (13.3 mM) 
Normal lsoflurane (13.3 mM) 
Pseudo First Order Rate 
Constant for the Re-oxidation of 
Cytochrome b5 
( x 10-2 sec -1) 
1.30 ± 0.16 (7) 
1.50, 1.50 (2) 
6.87 ± 0.68 (4) t 
2.20, 2.42 (2) t 
1.90, 2.20 (2) t 
1.78, 1.80 (2) t 
2.24 ± 0.38 (10) t 
2.13 ± 0.12 (3) t 
HCD, High-carbohydrate diet 
* Reaction mixtures contained 3.0 ml hepatic microsomes (1.5 mg microsomes protein/ml 0.02 M 
Tris - HCI, pH 7.4) and NADH (2.5 µM). 
t Differs significantly from that in absence of additions to reaction mixture for identical dietary 
pretreatment (P < 0.01 ). 
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There was no difference in the effects of isoflurane in the microsomes from rats 
treated with the two diets in spite of the induction of the ti9-desaturase by the 
high-carbohydrate diet (P > 0.1) (Table 25). 
These results confirm that isoflurane stimulates electron transfer perhaps by 
interacting with a microsomal terminal oxidase. Since a high-carbohydrate diet 
did not increase the magnitude of the effect of isoflurane on cytochrome b5 
reoxidation (Table 25), isoflurane was probably not stimulating electron flow via 
the ti9-desaturase. To obtain more conclusive evidence on which fatty acid 
desaturase(s) could be involved, the effect of isoflurane on the desaturation of 
fatty acid substrates by the t.9-, t.6- and t.5-desaturases was studied. 
3.2.3.2 The Effect of lsoflurane on the Hepatic Microsomal 
ti9-Desaturation of Stearoyl-CoA 
The effect of isoflurane on the activity of the ti9-desaturase in hepatic 
microsomes from rats fed a high-carbohydrate diet, was investigated using 
electron donors NADH and NADPH. lsoflurane had no effect on the activity of 
the t.9-desaturase when the desaturation of stearoyl-CoA was supported by 
NADH (Table 26). However, isoflurane did slightly, and probably significantly, 
diminish the activity of the t.9-desaturase using NADPH as electron donor 





THE EFFECT OF ISOFLURANE ON THE A9-DESATURATION OF STEAROYL-CoA IN 












Activity of M-Desaturase § 
(nmol oleate/mg protein/min.) 
1.96 ± 0.08 (6) 
1.96 ± 0.18 (6) 
2.05 ± 0.36 (6) 
1.66 ± 0.10 (6) t 
To reaction mixtures containing hepatic microsomes (0.5 mg/ml, 0.02 M Tris-HCI, pH 7.4), 
stearoyl-CoA (40 µM, 12 nCi) and NADH or NADPH (1 mM), incubated for 1 O min at 30 °C. 
t Significantly different from that in the absence of isoflurane (P<0.05). 
§ The substrate was added as stearoyl-CoA so there was no need to correct the activity for 
endogenous substrate (Section 2.2.3.9). 
3.2.3.3 
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The Effect of lsoflurane on the Hepatic Microsomal 
AS-Desaturation of a-Linolenic Acid 
lsoflurane had no effect on the A6-desaturation of a-linolenic acid in hepatic 
microsomes from rats fed a normal diet: in the presence of 1 mM isoflurane *, 
the rate of A6-desaturation of a-linolenic acid was 0.22 ± 0.03 nmol 
octadeca-6,9, 12, 15-tetraenoic acid produced/mg protein/min compared to 
0.22 ± 0.01 nmol octadeca-6,9, 12, 15-tetraenoic acid produced/mg protein/ min 
in the absence of isoflurane. In these experiments, hepatic microsomes (0.5 mg 
protein/ml) were incubated with BSA (115 µg/ µg a-linolenic acid added) and 
[1-14c] a-linolenic acid (1.8 µM, 121 nCi) for 7 min as described in 
Section 2.2.3.2a. The corrected substrate concentration was 2.1. µM a-linolenic 
acid. 
3.2.3.4 The Effect of lsoflurane on the Hepatic · Microsomal 
AS-Desaturation of Eicosa-8, 11, 14-trienoic acid 
The effect of isoflurane on the activity of the A5-desaturase in hepatic 
microsomes from rats fed a normal diet is shown in Table 27. At low 
concentrations (0.4 mM - 2.0 mM), isoflurane had no effect on A5-desaturase 
activity in hepatic microsomes. However, at the highest concentration used 
(8.0 mM), isoflurane decreased the activity of the A5-desaturase in hepatic 
microsomes slightly, and significantly (P<0.05) (Table 27). 
* This concentration of isoflurane significantly inhibited the A6-desaturation of 




THE EFFECT OF ISOFLURANE ON THE AS-DESATURATION OF 








Activity of A5-Desaturase t 
(nmol arachidonic acid formed/mg protein/min) 
97.1 ± 3.2 
95.7 ± 6.9 
103.2 ± 6.9 
81.6 ± 4.8 § 
In reaction mixtures of hepatic microsomes (0.25 mg protein/ml) incubated as described in the 
methods (Section 2.2.3.2a) with BSA (115 µg/µg fatty acid substrate added), and 
[2-14C]-eicosa-8, 11, 14-trienoic acid (0.3 µM, 3.6 nCi) for 1 O min. The corrected substrate 
concentration was 0. 75 µM. 
t Results were from a single preparation of hepatic microsomes (n=3). 
§ Significantly different from that in the absence of isoflurane (P <0.05). 
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3.2.3.5 The Effect of lsoflurane on Hepatic Microsomal 
!\6-Desaturation of Linoleic acid 
The effect of isoflurane on hepatic microsomal !\6-desaturation of linoleic acid 
by two direct assay Methods is shown in Figure 26. lsoflurane was shown to 
inhibit the t6-desaturation of linoleic acid in a concentration-dependent manner. 
The inhibition was evident when either Method 1 or 2 was used to measure 
enzyme activity (Figure 26). The inhibition of the !\6-desaturase activity by 
isoflurane was observed at low isoflurane concentrations; half-maximal 
inhibition of the !\6-desaturase occurred at approximately 0.6 mM isoflurane 
(Figure 26). 
Since cyanide completely inhibited the stimulation of the reoxidation of 
cytochrome b5 by isoflurane at a concentration that inhibits fatty acid 
desaturase activity but not cytochrome P-450-dependent drug oxidations (235) 
(Table 24), electron flow to cytochrome P-450 appeared to play no direct role in 
the ability of isoflurane to stimulate microsomal electron transfer. However, it 
was not clear whether the cytochrome P-450-dependent metabolism of 
isoflurane could have resulted in products which affected the !\6-desaturase. To 
investigate this possibility, the effect of the specific inhibitors of 
cytochrome P-450, CO and metyrapone, on the !\6-desaturase in the presence 
and absence of isoflurane were assessed. 
Neither metyrapone nor C0:02 (80:20,v /v) significantly affected the extent to 
which isoflurane inhibited !\6-desaturase activity in hepatic microsomes (P > 0.1) 
(Table 28). The results with metyrapone are difficult to interpret since this 
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The effect of isoflurane concentration on the b~esaturation of 
linoleic acid measured using Method 2 (A) and Method 1 (8). 
lsoflurane concentration, mM. Results for Method 2 are from a single 
hepatic microsomal preparation (n=3). BSA concentration was 
115 (Method 1) and 11.5 (Method 2) µ.g/ µ.g fatty acid added. Corrected 
substrate concentration was 4. 7 µ.M. 
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TABLE 28 
THE EFFECT OF METYRAPONE AND C0:02 ON THE INHIBITION OF THE 










C0:02 (80:20, v /v) 
C0:02 (80:20, v /v) + 
isoflurane (0.8) 
Activity of M-Desaturase 
(pmol/mg protein/min) t 
EXPERIMENT 1 
269 ± 26 
188 ± 3 
195 ± 3 
177 ± 21 
EXPERIMENT 2 
148 ± 13 
109 ± 8 
135 ± 10 
88 ± 18 








* In reaction mixtures of hepatic microsomes (0.5 mg protein/ml) incubated as described in the 
methods (Section 2.2.3.2a), with BSA (115 µg/µg fatty acid substrate added), ([1-14q linoleic acid 
(1.8 µM, 106 nCi) for 10 min, and assayed using Method 2. The corrected substrate concentration 
was 4.7 µM linoleic acid. 
t Results were from a single preparation of hepatic microsomes (n=3). Experiment 1 was performed 
on a different preparation of microsomes from experiment 2. 
§ Significant from that in the absence of additions (P<0.05). 
1 Significantly different from that in the absence of isoflurane (P<0.01). 
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suggest that cytochrome P-450 played no role in the effect of isoflurane on 
t:.6-desaturase activity, viz: that the effect was not caused by a cytochrome 
P-450 metabolite of isoflurane. 
To investigate whether the inhibition of the t:.6-desaturation of linoleic acid by 
isoflurane was reversible, the following experiment was performed: hepatic 
microsomes were pre-incubated with or without isoflurane (0.8 mM) for 5 min at 
35 ° C (Table 29). In an attempt to remove the isoflurane, the microsomes were 
bubbled with air for 1 o min at o - 4 • C before incubation with the components 
necessary for t:.6-desaturase activity (Table 29). Microsomes without isoflurane 
were treated in the same manner. Inhibition of the t:.6-desaturase was not 
diminished significantly by the pretreatment (Table 29). 
The inhibition of the t:.6-desaturase activity by isoflurane was observed in 
hepatic microsomes whether or not the incubation mixture was bubbled with air 
(Table 29), which suggested that isoflurane (i) may not have been effectively 
removed by our procedure, or that (ii) isoflurane binding to its site of action may 
be tight - either reversible or essentially irreversible. 
3.2.3.6 The Interaction of Other Volatile Anaesthetic Agents with Rat 
Hepatic Microsomal t:.6-Desaturase 
The effect of the volatile anaesthetic agents, methoxyflurane, enflurane and 
halothane on the t:.6-desaturation of linoleic acid in hepatic microsomes from 
rats fed a normal diet, was investigated. None of the anaesthetic agents, 
including enflurane, a close structural analogue of isoflurane (Table 1 ), had a 




THE EFFECT OF PRE-INCUBATION WITH, AND SUBSEQUENT REMOVAL OF 
ISOFLURANE ON THE t.6-DESATURATION OF LINOLEIC ACID IN 
Pre-incubation * 















RAT HEPATIC MICROSOMES 
Bubbled with air or 
left on ice for 10 min 
Bubbled with air 
for 10 min 
Bubbled with air 
for 10 min 
Left on ice 
Left on ice 
Activity of 66-Desaturase 
(pmol/mg protein/min) § 
99 ± 29 
71 ± 51 
122 ± 3 
75±161 







Reaction mixture for pre-incubation contained hepatic microsomes (0.5 mg protein/ml), nicotinamide (1 mM), potassium 
fluoride (0.04 M) and bovine serum albumin (115 µg/µg fatty acid substrate added). Reaction mixtures were prepared 
from pre-incubated samples after they had been left on ice or bubbled with air for 10 min, and were incubated as 
described in the methods (Section 2.2.3.2a) with (1- 14C] linoleic acid (1.8 µmol, 106 nCi) with or without isoflurane (0.8 
mM) for 10 min. The corrected substrate concentration was 4.7 µM linoleic acid. Results were obtained using Method 2. 
t Additions made before pre-incubation. 
§ Results were from a single preparation of hepatic microsomes (n = 3), but were typical of results obtained from two 
microsomal preparations. 
,r Differs significantly from that in absence of isoflurane (P<0.01 ). 
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TABLE 30 
THE EFFECT OF ANAESTHETIC AGENTS ON THE ~6-DESATURATION OF 
LINOLEIC ACID IN RAT HEPATIC MICROSOMES 








% of Activity in Absence of 







* In reaction mixtures of hepatic microsomes (0.5 mg protein/ml) incubated as described in the 
methods (Section 2.2.3.3b) with bovine serum albumin (115 µg/µg fatty acid substrate added) and 
p-1 4C]-linoleic acid (1.8 µM, 106 nCi) for 10 min at 30° C, and assayed using Method 1 (Section 
2.2.3.2b). The corrected substrate concentration was 4.7 µM linoleic acid. 
t Results were for a single preparation of microsomes (n =3-4). 
§ Differs significantly from that in absence of additions (P <0.01 ). 
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at which isoflurane inhibited AS-desaturase activity (Table 30). lsoflurane 
(0.4 mM) was included as a positive control. 
3.2.4. Kinetic Data for Hepatic Microsomal A6-Desaturase in the Presence 
and Absence of lsoflurane 
AS-Desaturation of linoleic acid was measured at two different BSA 
concentrations in the presence and absence of isoflurane. Lineweaver-Burk 
plots for the AS-desaturation of linoleic acid in the presence and absence of 
isoflurane at both BSA concentrations are illustrated in Figures 27 and 28. 
The inhibition of the AS-desaturase by isoflurane was evident at both BSA 
concentrations. 
Kinetic data for the AS-desaturation of et-linolenic acid at the lower BSA 
concentration (11.5 µg BSA/ µg free fatty acid added) is illustrated in Figure 29. 
The kinetic data confirmed that isoflurane did not inhibit of the AS-desaturation 
of this substrate (Figure 29). 
The kinetic data for the inhibition of the AS-desaturase in hepatic microsomes 
was measured under conditions where the AS-desaturase activity is probably 
influenced by a number of other enzymatic reactions (Figure 7). Further 
experiments were aimed at clarifying the role of other reactions, which are 
shown in Figure 7, in the AS-desaturase assay in hepatic microsomes. It was, 
therefore, necessary to measure the activity of phospholipase A2, acyl-CoA 
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Lineweaver-Burk plot of the As-desaturation of linoleic acid in the 
presence <• ) and absence (X} of isoflurane (2 mM) in rat hepatic 
microsomes at the low BSA concentration. 
Rate, µM p-14q 1'-linolenoyl-CoA + 2-p-14q 1'-linolenoyl-phospholipid 
formed/min; linoleic acid concentration, µM linoleic acid. BSA 
concentration was 11.5 µg/µg linoleic acid added. A6-Desaturase activity 
was measured using Method 2. Data represents the average of that 
obtained in triplicate from three preparations of hepatic microsomes. Lines 












Lineweaver-Burk plot of the AFH:tesaturation of linoleic acid in the 
presence (• ) and absence (X) of isoflurane (2 mM) in rat hepatic 
microsomes at the high BSA concentration. 
Rate, µM p-14q 1'-linolenoyl-CoA + 2-[i-14q 1'-linolenoyl-phospholipid 
formed/min; linoleic acid concentration, µM linoleic acid. BSA 
concentration was 115 µg/µg linoleic acid added. 66-Desaturase activity 
was measured using Method 2. Data represents the average of that 
obtained in triplicate from two preparations of hepatic microsomes. Lines 















Lineweaver-Burk plot of the 66-desaturation of o:-linolenic acid in the 
presence (• ) and absence (X) of isoflurane (0.8 mM) in rat hepatic 
microsomes at the low BSA concentration. 
Rate, µM [1-14C] octa-6,9, 12, 15-decatetraenoyl-CoA + 2-[1-14C] octa-
6,9, 12, 15-decatetraenoyl-phospholipid formed/min; a-linolenic acid 
concentration, µM a-linolenic acid. BSA concentration was 11.5 µg/µg 
a-linolenic acid added. fi6-Desaturase activity was measured using 
Method 2. Results are from a single preparation of hepatic microsomes, 
but are representative of those obtained from two preparations. Line was 
drawn by Enzfitter (Section 2.2.3.10). 
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3.2.5 Measurement of Reactions Which Could Influence the 
3.2.5.1 
ti6-Desaturase Activity in Hepatic Microsomes Under the Conditions 
of Our Experiments 
Phospholipase A2 Activity in Rat Hepatic Microsomes 
Phospholipase A2 activity was measured in hepatic microsomes which 
contained EDTA (4 µM) (Section 2.2.3.7); EDTA acts as a scavenger of calcium 
ions, an essential component for phospholipase A2 activity (234). The 
phospholipase A2 activity measured under these conditions was extremely low 
compared to the ti6-desaturase substrate concentration, viz: 0.035 ± 0.014 µM 
(1-14c] linoleic acid was released from the radiolabelled phospholipid over a 
period of 1 O min, compared to the substrate concentration range of 
3.4 to 10.8 µM, which includes endogenous substrate. Therefore, linoleic acid 
released from phospholipids during the ti6-desaturase incubation time was 
unlikely to significantly dilute the radiolabelled plus endogenous substrate. No 
further activity measurements on phospholipase A2 were attempted since 
phospholipase A2 activity appeared too low to influence the measurement of 
the ti6-desaturase activity in hepatic microsomes. 
3.2.5.2 Separation of Fatty Acid (Substrate), Phospholipid and 
Acyl-CoA (Products) for Measurement of Activity of Fatty 
Acid-Metabolising Enzymes in Rat Hepatic Microsomes 
In order to measure the activity of acyl-CoA synthetase and lysophospholipid 
acyltransferase in hepatic microsomes, separation of the radiolabelled fatty 
acid, acyl-CoA and phospholipid in good yield, had to be achieved. This 
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section outlines the results of the techniques used in the attempt to achieve this 
separation. A number of different literature methods were attempted for the 
separation of the three types of compounds mentioned. Although literature 
methods are well established for measuring one of the three components, our 
difficulties reflected trying to measure all three concurrently in the same reaction 
mixture. The methods attempted are outlined in Table 31. The reasons why the 
methods were unsuitable for our purposes are also given. 
The first four methods cited in Table 31 were unsuitable in that they did not 
achieve separation of the requisite lipid classes in good yield. The fourth 
method did achieve separation using extraction plus TLC, but was rejected in 
view of the development of the final method which gave satisfactory results by a 
shorter method involving differential extraction without chromatography. Useful 
data was obtained from Method A (Section 2.2.3.Ba) which is a combination of 
the first two methods in Table 31, and Method B (Section 2.2.3.Ba) which is the 
last method in Table 31. The latter Method is referred to as the method of 
differential organic extraction. 
Although the Method A was unsuitable for separation of fatty acids, acyl-CoA 
and phospholipids, it did, nevertheless, separate neutral lipids from 
phospholipids, acyl-CoA and fatty acids (Rt values for neutral lipid, fatty acid, 
and phospholipid plus acyl-CoA were 0.44, 0.22 and 0, respectively). This 
enabled us to establish that only a small amount ( < 5%) of the radiolabelled 
linoleic acid added to reaction mixtures was incorporated into neutral lipids 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The method developed to separate fatty acid, acyl-CoA and phospholipid 
involved differential extraction of the components (final method in Table 31 
(adapted from 374,392)) as follows: first, the fatty acid was extracted from 
reaction mixtures into diethyl ether, and then the phospholipids into 
chloroform:methanol*; the acyl-CoA remained primarily in the aqueous layer. 
The total recovery of radioactivity from reaction mixtures in all three fractions 
was 89.0 ± 5.6% (n = 20). 
The amount of overlap of the components in the organic phases was assessed 
by following the distribution of radioactivity in the three phases on extraction of 
radioactive standards from hepatic microsomes (Table 32). 
The fatty acid standard, [1-14c] linoleic acid was extracted measurably only into 
diethyl ether. Overall recovery was excellent (ca. 90%). The acyl-CoA 
standard, [1-14c] palmitoyl-CoA remained exclusively ( > 95%) in the aqueous 
layer when extracted from buffer. However, only approximately 65% of the 
acyl-CoA remained in the aqueous layer when the acyl-CoA standard was 
extracted from hepatic microsomes (Table 32); the remainder was extracted 
into the diethyl ether layer. The recovery of radioactive acyl-CoA in the diethyl 
ether layer does not appear to reflect enzymic hydrolysis of the acyl-CoA by 
hepatic microsomal acyl-CoA hydrolase since the use of heat-treated 
microsomes did not alter the separation pattern (Table 32). 
The phospholipid was also found in significant amounts in two phases: 
ca. 75% of the phospholipid was extracted into chloroform:methanol, while 
ca. 20% extracted with diethyl ether and thus would be co-extracted with fatty 
acid. 
* Using this method, the final proportions of chloroform and methanol in the 
extract are unknown. Therefore, it will be referred to as the 




RECOVERY OF RADIOACTIVITY ASSOCIATED WITH RADIOACTIVE STANDARDS IN 
THE THREE PHASES USED FOR MEASUREMENT OF PRODUCT FORMATION DURING ASSAY 
FOR LYSOPHOSPHOLIPID ACYLTRANSFERASE AND ACYL-CoA SYNTHETASE ACTIVITY 
Radioactive 
Standard* 
[1-14C] Unoleic acid 
in hepatic microsomes 





in microsomes which 






















% Recovery t Total 
% Recovery t 
89.3 ± 5.6 (5) 89.3 (5) 
None 
None >95 (3) 
>95 (3) 
32.3 ± 10.1 (5) 
None 90.2 (5) 
58.5 ± 10.3 (5) 
32.6 ± 10.5 (4) 
None 90.4 ± 8.1 (4) 
56.7 ± 8.5 (4) 
22.4 ± 3.7 (5) 
92.9 (5) 
70.5 ± 7.0 (5) 
The radioactive standard was extracted from the medium described above as outlined in Section 2.2.3.Ba, Method B 
t Expressed as a percentage of the radioactivity added to the medium. 
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After incubation of hepatic microsomes with [ 1-14c] linoleic acid 
(Section 2.2.3.8), the total radioactivity recovered in the three phases was 
89 ± 5.6%; the amount of radioactivity in each phase varied with substrate 
concentration, viz: 20 - 60%, 8 - 30% and 30 - 60% of the radioactivity 
recovered was in the diethyl ether, chloroform:methanol and aqueous phases, 
respectively. This reflected that the disappearance of substrate and formation 
of products was dependent on substrate concentration. In contrast, within each 
organic phase, the distribution of the radioactivity, which was analysed by TLC, 
was independent of substrate concentration (data not shown). This showed 
that the overlap of fatty acid, acyl-CoA and phospholipid within the organic 
phases was independent of substrate concentration. Therefore, a simple 
correction for the loss of acyl-CoA and phospholipid into the diethyl ether phase 
can be made. In all further experiments, the yields of fatty acid, acyl-CoA and 
phospholipid were corrected for the recoveries seen in Table 32, as follows: 
i) radioactivity recovered in chloroform:methanol was equal to 76% of the 
recovered phospholipids and was corrected accordingly to yield 100% 
(Table 32). 
ii) radioactivity recovered in aqueous phase was equal to 65% of the 
acyl-CoA and was corrected accordingly to yield 100% (Table 32). 
Where necessary, the amount of substrate remaining (free fatty acid) was 
calculated from the radioactivity associated with the diethyl ether phase minus 
the amount of radioactivity associated with the acyl-CoA and phospholipid in 
this phase. 
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Following incubation of [1-14cJ linoleic acid with hepatic microsomes 
(Section 2.2.3.Sa), TLC analysis of the diethyl ether and chloroform:methanol 
phases was also performed. Since hydrolysis of the thioester bond has been 
reported to occurr during TLC of acyl-CoA, this TLC analysis was not used to 
quantitate fatty acid, acyl-CoA and phospholipid during assay for acyl-CoA 
synthetase and lysophospholipid acyltransferase activity, but only to analyse 
the distribution of the radioactivity in organic phases after incubation and 
extraction, in particular, the distribution of the radioactivity in the different 
phospholipids. In contrast to the TLC system mentioned in the first method in 
Table 31 (petroleum ether:diethyl ether:glacial acetic acid; 90:10:1, v/v/v), this 
TLC system (chloroform:methanol:glacial acetic acid; 66:34:1; v/v/v), achieved 
separation of the acyl-CoA from the phospholipid and fatty acid (Section 
2.2.3.Sa, Method B). Authentic standards of linoleoyl-CoA, linoleic acid 
phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol were 
used to analyse the TLC system; the acyl-CoA and phospholipids were further 
identified using the nitroprusside and molubdenum blue sprays, respectively 
(Section 2.2.3.Sa) (373,375). 
Of the radioactivity recovered in the diethyl ether phase, ca. 77% was 
associated with the fatty acid fraction (Table 33). Together the acyl-CoA and 
phospholipid contributed the remaining 20% of the radioactivity recovered in 
this phase (Table 33). The acyl-CoA recovered in the diethyl ether phase after 
TLC of this phase (Table 33) was considerably less than that associated with 
acyl-CoA standard ([1-14cJ palmitoyl-CoA) extracted from microsomes into the 
same phase (Table 32), suggesting that splitting of the thioester bond during 









TLC ANALYSIS OF ORGANIC EXTRACTS OF REACTION MIXTURES 
FOR MEASUREMENT OF LYSOPHOSPOLIPID ACYL TRANSFERASE AND 





















% Radioactivity Recovered 
in Corresponding 
Organic Phase t 
14.3±11.4(7) 
8.6 ± 4.3 (7) 
77.1 ± 13.0 (7) 
0 
69.7 ± 4.8 (15) 
0 
8.2 ± 2.9 (15) 
21.9 ± 4.9 (15) 
* In reaction mixtures of hepatic microsomes (0.5 mg protein/ml) incubated as described in the Methods (Section 2.2.3.2a), 
with BSA (115 µg;µg fatty acid substrate added), ([1- 14C) linoleic acid (1.8 µM, 106 nCi) for 3 min, and analysed using 
differential organic extractions and TLC (Section 2.2.3.8a, Method 8). Corrected substrate concentration was 4.7 µM 
t Total recovery of added radioactivity in all three phases (diethyl ether, chloroform:methanol plus aqueous) was 
89 ± 5.6% (20); the distribution of the radioactivity recovered in the different phases was dependent on the initial 
substrate concentration, but was in the following ranges: 20 - 60% in the diethyl ether phase, 8 - 30% in the 
chloroform:methanol phase and 30 - 60% in the aqueous phase. The distribution of radioactivity within a phase was 
independent of substrate concentration (data not shown) 
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was not performed. However, since > 90% of the radioactivity associated with 
the standards (1-14c] linoleic acid and 1-palmitoyl-2-[1-14c] 
linoleoylphosphatidylcholine was recovered in the organic phases (Table 32), it 
was assumed that neither the fatty acid nor the phospholipid contributed to the 
radioactivity in the aqueous layer of reaction mixtures (after diethyl ether and 
chloroform:methanol extraction). Therefore, the radioactivity in the aqueous 
phase was assumed to be acyl-CoA. 
In the chloroform:methanol phase, approximately 80% of the radioactivity 
recovered in this phase was associated with the phospholipid 
(phosphatidylcholine plus phosphatidylethanolamine); the remaining 
radioactivity was recovered as fatty acid (which may be released from 
phospholipid during chromatography), but not acyl-CoA (Table 33). The 
radioactivity associated with the phospholipid was recovered primarily as 
phosphatidylcholine; a small amount of radioactivity was also associated with 
phosphatidylethanolamine (Table 33). Therefore, the activity of the 
acyltransferases measured is primarily that of lysolecithin acyltransferase, with 
only a small contribution from the enzyme acylating phosphatidylethanolamine. 
3.2.5.3 Measurement of Acyl-CoA Synthetase and Lysophospholipid 
Acyltransferase Activity in Rat Hepatic Microsomes 
The activities of the acyl-CoA synthetase and lysophospholipid acyltransferase 
were measured as a function of time at two different substrate concentrations 
(4.7 µM and 10.8 µM linoleic acid (corrected concentration)) by the method 
using differential organic extractions (Section 2.2.3.Ba, Method 
























The effect of time on the disappearance of fatty acid (substrate) (A) 
and on the formation of acyl-CoA (• , B) and the products of acylation 
of phospholipids (X, B) measured during the metabolism of linoleic 
acid (4. 7 µM) in hepatic microsomes. 
Substrate concentration, µM p-14c~ linoleic acid + endogenous linoleic 
acid; product concentration, µM [1- 4q linoleoyl-CoA + -y-linolenoyl-CoA 
(• ) and 2-W 14q linoleoyl- + 2-p-14q -y-linolenoyl phospholiphid 
formed (X). BSA concentration was 11.5 µg/ µg linoleic acid. Corrected 
substrate concentration was 4. 7 µM. Separation of the fatty acid, 
phospholipid and acyl-CoA was carried out by differential organic 
extractions (Section 2.2.3.Ba, Method B). Data represents quintupulate 

























The effect of time on the disappearance of fatty acid (substrate) (A) 
and on the formation of acyl-CoA <• , B) and the products of the 
acylation of phospholipids (X, B) measured during the metabolism of 
linoleic acid (10.8 µM) in hepatic microsomes. 
Substrate concentration, µM r,-14q linoleic acid + endogenous linoleic 
acid; product concentration, µM r,-14q linoleoyl-CoA + 
r-linolenoyl-CoA (• ), and 2-r,-1 4C] linoleoyl- + 2-[1-14q r-linolenoy1-
phospholipid formed (X). BSA concentration was 11.5 µg/ µg linoleic acid 
added. Corrected substrate concentration was 10.8 µM. Separation of the 
fatty acid, phospholipid and acyl-CoA was carried out by differential 
organic extractions (Section 2.2.3.Sa, Method B). Data represents 
quintupulate determinations on one preparation of hepatic microsomes. 
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endogenous substrate levels. The activity of the acyl-CoA synthetase, 
measured by acyl-CoA formation (•), was not linear with time at either substrate 
concentration, except, possibly, for an undetermined period within the first 
minute. At the lower substrate concentration (4. 7 µM linoleic acid) there was no 
further increase in acyl-CoA formation after the first minute, although there was 
still unesterified fatty acid present (•) (Figure 30). The activity of the acyl-CoA 
synthetase as a function of time was greater at the higher substrate 
concentration (10.8 µM linoleic acid) than at the lower substrate concentration 
(4.7 µM linoleic acid), but not in the proportion to the two-fold increase in total 
substrate concentration (Figure 30 and 31 )). 
The activity of the lysophospholipid acyltransferase did not increase linearly with 
time over the time period utilised; the activity was comparable at both 
concentrations of linoleic acid (4.7 µM and 10.8 µM, Figures 30 and 31, 
respectively). A time period of 3 min was chosen for subsequent experiments 
because shorter time would have resulted in increased inaccuracy in the 
determination of lysophospholipid acyltransferase activity, which was low, with 
no guarantee of being on the linear portion of either the acyl-CoA synthetase or 
lysophospholipid acyltransferase activity versus time curve. 
3.2.5.4 Kinetic Data for the Acyl-CoA Synthetase, A6-Desaturase and 
Lysophospholipid Acyltransferases in Rat Hepatic 
Microsomes 
The experimentally determined reaction rate versus substrate concentration 
curves for the acyl-CoA synthetase, A6-desaturase and lysophospholipid 























Plot of rate of formation of acyl-CoA versus linoleic acid concentration 
by rat hepatic microsomal acyl-CoA synthetase at the high (A) and 
low (B) BSA concentrations. 
Rate, µM [1-14q linoleoyl-CoA + [1-14q "(-linolenoyl-CoA formed/min; 
linoleic acid concentration, µM linoleic acid. Product formation was 
measured at 3 min and was normalised to 1 min by dividing by 3. BSA 
concentration was 115 (A) and 11.5 (8) µg/ µg linoleic acid added. 
Separation of the fatty acid, phospholipid and acyl-CoA was carried out by 
differential organic extractions (Section 2.2.3.8a, Method 8). Curve was 
drawn by Enzfitter (Section 2.2.3.10). Data represents the average of that 
obtained in triplicate from two preparations of hepatic microsomes (A) and 























Plot of rate of formation of -y-linolenic acid versus linoleic acid 
concentration by rat hepatic microsomal 66-desaturase at the high (A) 
and low (B) BSA concentrations. 
Rate, µM [1" 14C] -y-linolenoyl-CoA + 2-[1" 14C] -y-linolenoyl-phospholipid 
formed/min; linoleic acid concentration, µM linoleic acid. BSA 
concentrations were 115 (A) and 11.5 (B) µg/ µg linoleic acid added. 
66-Desaturase activity was measured by Method 2. Curves were drawn by 
Enzfitter (Section 2.2.3.1 O). Data represents the average of that obtained in 
triplicate from two preparations of hepatic micrm,omes for the high BSA 


























Plot of rate of acylation of phospholipids versus linoleic acid 
concentration by rat hepatic microsomal lysophospholipid 
acyltransferases at the high (A) and low (B) BSA concentrations. 
Rate, µM 2-[1·14q linoleoyl-phospholipid + 2-[1·14C] -y-linolenoyl-
phospholipid formed/min; linoleic acid concentration, µM linoleic acid. 
Product formation was measured at 3 min and was normalised to 1 min by 
dividing by 3. BSA concentration was 115 (A) and 11.5 (B) µ.g/ µ.g linoleic 
acid added. Separation of the tatty acid, phospholipid and acyl-CoA was 
carried out by differential organic extractions (Section 2.2.3.Sa, Method B). 
Curve was drawn by Enzfitter (Section 2.2.3.10). Data represents the 
average of that obtained in triplicate from two preparations of hepatic 
microsomes (A) and three to five determinations from three preparations of 
hepatic microsomes (8). 
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plots for all three enzymes were linear (Figures 35,36 and 37). The apparent 
Km and V max values for these enzymes were calculated using the 
Michaelis-Menten equation on the data in Figures 32, 33, 34, 35, 36 and 37, and 
these values are given in Table 34. These estimations of the apparent Km and 
Vmax values for the acyl-CoA synthetase and lysophospholipid acyltransferase 
are only approximate because of the inappropriate substrate concentration 
range used in their determination; it does not span the apparent Km value. In 
the case of the acyl-CoA synthetase, the substrate concentration range (3.35 -
10.8 µM) is too low, and for the lysophospholipid acyltransferase, it was too 
high. For these two enzymes, the rate versus substrate concentration curves 
illustrated in Figures 32 and 34 were used in further analysis of the kinetics of 
the t6-desaturase, and therefore more accurate determination of the apparent 
Km and Vmax values was not pursued. 
3.2.5.5 The Effect of lsoflurane on Rat Hepatic Microsomal Acyl-CoA 
Synthetase and Lysophospholipid Acyltransferase 
lsoflurane had no effect on the acyl-CoA synthetase or lysophospholipid 
acyltransferase activities in rat hepatic microsomes. The activity of the acyl-CoA 
synthetase was 1.44 ± 0.04 µM acyl-CoA formed/min in the presence or 
absence of isoflurane (2 mM) using a substrate concentration of 5.8 µM 
(corrected) linoleic acid. Similarly, the lysophospholipid acyltransferase activity 
at the same substrate concentration (5.8 µM linoleic acid) was 0.38 ± 0.02 µM 
and 0.43 ± 0.01 µM phospholipid formed/min in the presence and absence of 
2 mM isoflurane. These results represent the average of at least three sets of 
experiments on a single preparation of hepatic microsomes. 
1,0 
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0 0,1• 0.28 
1 /[UNOLEIC ACID] 
Lineweaver-Burk plot of the formation of acyl-CoA by the acyl-CoA 
synthetase in rat hepatic microsomes at the high (A) and low (B) BSA 
concentrations. 
Rate, µM [1-14C] linoleoyt-CoA + [1-1 4C] -Y-linolenoyt-CoA formed/min; 
linoleic acid concentration, µM linoleic acid. Product formation was 
measured at 3 min and was normalised to 1 min by dividing by 3. BSA 
concentration was 115 (A) and 11.5 (8) µg/ µg linoleic acid added. 
Separation of the fatty acid, phospholipid and acyt-CoA was carried out by 
differential organic extractions (Section 2.2.3.Ba, Method 8). Lines were 
drawn by Enzfitter (Section 2.2.3.10). Data represents the average of that 
obtained in triplicate from two preparations of hepatic microsomes (A) and 



























Lineweaver-Burk plot of the tis-desaturation of linoleic acid in rat 
hepatic microsomes at the high (A) and low (B) BSA concentrations. 
Rate, µM p-14q 'Y-linolenoyt-CoA + 2-p-14q 'Y-linolenoyt-phospholipid 
formed/min; linoleic acid concentration, µM linoleic acid. BSA 
concentration was 115 (A) and 11 .5 (B) µg/ µg linoleic acid added. 
£16-Desaturase activity was measured by Method 2. Lines were drawn by 
Enzfitter (Section 2.2.3. 1 O). Data represents the average of that obtained in 
triplicate from two preparations of hepatic microsomes for the high BSA 

























0 0.14 0.28 
1/[UNOLEIC ACID] 
Lineweaver-Burk plot for the acylation of phospholipids by the 
lysophospholipid acyltransferases in rat hepatic microsomes at the 
high {A) and low (B) BSA concentrations. 
Rate, µM 2-[1" 14q linoleoyl-phospholipid + 2-[1-14C] ')'-linolenoyt-
phospholipid formed/min; linoleic acid concentration, µM linoleic acid. 
Product formation was measured at 3 min and was normalised to 1 min by 
dividing by 3. BSA concentration was 115 (A) and 11.5 (B) µg/ µg linoleic 
acid added. Separation of the fatty acid, phospholipid and acyt-CoA was 
carried out by differential organic extractions (Section 2.2.3.Ba, Method 8). 
Lines were drawn by Enzfitter (Section 2.2.3.10). Data represents the 
average of that obtained in triplicate from two preparations of hepatic 
microsomes (A) and three to five determinations from three preparations of 
hepatic microsomes (8). 
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TABLE 34 
APPROXIMATE APPARENT Km AND Vmax VALUES FOR THE 
ACYL-CoA SYNTHETASE, 66-DESATURASE AND 


















440 ± 530 
266 ± 1232 
7.9 ± 0.8 
9.6 ± 0.4 
1.04 ± 0.84 





100 ± 130 
56.5 ± 254 
0.15 ± 0.01 
0.09 ± 0.01 
0.59 ± 0.07 
0.58 ± 0.12 
* Measured in reaction mixtures containing hepatic microsomes (0.5 mg protein/ml) and linoleic acid 
(3.35 -10.8 µM). Incubations were for 10 min for the M-desaturase, which was assayed using 
Method 2, and 3 min for the acyl-CoA synthetase and lysophospholipid acyltransferase, which were 
assayed by differential organic extractions (Section 2.2.3.8a, Method B). Other incubation conditions 
are given in the Methods (Section 2.2.3.2a). Values were obtained using the data illustrated in Figures 
32, 33, 34, 35, 36 and 37 and Enzfitter (Section 2.2.3.10). 
t Linoleic acid was the substrate. 
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3.2.6. Simulation of the Reaction Scheme by Computer Modelling Using 
Experimentally Obtained Data 
The reaction scheme outlined in Figure 38 was simulated using information 
available from the literature (Table 35) and the experimentally obtained data for 
the acyl-CoA synthetase (Figure 30), A6-desaturase (Figures 19 and 20) and 
lysophospholipid acyltransferases (Figure 30) (Section 3.2.5.4). The model 
required the concentrations (µM) of lysolecithin, and the enzymes acyl-CoA 
synthetase, A6-desaturase and lysophospholipid acyltransferase. The 
concentrations of these molecules used in the modelling were chosen or 
calculated as described in the comments in Table 35. All values are normalised 
to microsomes at 0.5 mg protein/ml, the experimental conditions used in all of 
the experiments relevant to this modelling. The rate constant for hydrolysis of 
acyl-CoAs by acyl-CoA hydrolase is also included therein. This constant was 
equated with k 13 in the model. Product formation with time for the various 
reactions is the experimentally determined data referred to below. 
The experimentally determined curves for fatty acid disappearance (Figure 30), 
acyl-CoA formation (Figure 30), A6-desaturation of linoleic acid 
(Figures 19 and 20) and acylation of phospholipids (Figure 30) versus time 
were used as a criterion of the success of the computer modelling as follows: 
i) For the disappearance of fatty acid, the rate constants in the simulated 
reaction scheme were altered until the sum of linoleic acid and linoleic 
acid bound to acyl-CoA synthetase (linoleic acid plus [linoleic acid.E1] in 

















































































































































































































































































































































































































































































































































































































LITERATURE DATA USED IN COMPUTER MODELLING OF THE 









Concentration = 11 µM•§ 
Concentration = 0.65 µM• 
Concentration = 0.05 µM• 
Concentration = 1.0 µM•§ 
Rate Constant = 0.11 min-1 
Comments (references) 
This value was higher than the literature values of 
2.2 µM (400). 
Calculated using MW = 168,000 (212), and specific 
activities of 55 nmol/min/mg protein in rat hepatic 
microsomes (355) and 250 nmol/min/mg protein 
using the purified enzyme (394). 
Within the range calculated using MW = 65,000 (263) 
and specific activities of 0.108 and 0.428 
nmol/min/mg protein in rat hepatic microsomes t 
and 34.4 nmol/min/mg protein for the purified 
enzyme (263). 
This value was higher than the values calculated 
(ca. 0.5 µM) using MW = 225,000 (228) and specific 
activities of 51.9 nmol/min/mg protein in rat hepatic 
microsomes and 2303 nmol/min/mg protein 
after a 30-fold purification (228), and specific 
activities of 46.7 nmol/min/mg protein in rat hepatic 
microsomes and 10,000 nmol/min/mg protein after 
140-fold purification (226). 
Calculated from initial reaction rates (219); 
equal to k13 in reaction scheme (Figure 38). 
At the microsomal protein concentration used in reaction mixtures: 0.5 mg protein/ml. 
§ From model 30 on, the concentrations of lysolecithin and lysophospholipid acyltransferases were 2.2 µM and 0.5 µM, 
respectively. 
t The maximum and minimum specific activities obtained for the ~6-desaturase herein. 
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linoleic acid with time as closely as possible at 4. 7 µM linoleic acid concentration 
(Figure 30). 
ii) For the formation of acyl-CoA, the rate constants in the simulated 
reaction scheme were altered until the sum of all the acyl-CoA species, 
free or enzyme-bound (linoleoyl-CoA, -y-linolenoyl-CoA, 
[linoleoyl-CoA. E2], [linoleoyl-CoA. E3] plus [ -y-linolenoyl-CoA. E3] in 
Figure 38) modelled the experimentally determined production of 
acyl-CoA with time as closely as possible at 4. 7 µM linoleic acid 
concentration (Figure 30). 
iii) For the A6-desaturation of linoleic acid, the rate constants in the 
simulated reaction scheme were altered until the sum of -y-linolenoyl-CoA 
plus -y-linolenoyl-CoA bound to the lysophospholipid acyltransferases as 
the enzyme substrate complex, and that incorporated into phospholipids 
following acylation thereof by lysophospholipid acyltransferase 
(-y-linolenoyl-CoA, [ -y-linolenoyl-CoA. E3], plus 2--y-linolenoyl-phospholipid 
in Figure 38), modelled the experimentally determined rate of 
A6-desaturation of linoleic acid with time as closely as possible at 4. 7 µM 
linoleic acid concentration (Figures 19 and 20). 
iv) For the acylation of phospholipids, the rate constants in the simulated 
reaction scheme were altered until the sum of 2-linoleoyl-phospholipid 
and 2--y-linolenoyl-phospholipid (Figure 38) mimicked the experimentally 
determined acylation of phospholipids with time as closely as possible at 
4.7 µM linoleic acid concentration (Figure 30). 
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For the simulated data, the enzyme-bound products were added to the relevant 
unbound products; in early models, some of these intermediates were found to 
present in significant concentrations. For example, in model 23, after 1 min 
reaction time, ca. 30% of the acyl-CoA was bound to the lysophospholipid 
acyltransferase in a reversible complex (data not shown). 
Prior to modelling the reaction scheme using the above data to obtain 
calculated values for the kinetic constants k1 to k12, it was necessary to make 
certain assumptions to simplify the kinetic treatment. Firstly, we assumed that 
E1, E2 and E3 followed rapid equilibrium kinetics. Therefore, k3/k2 (for E1), 
ks/k5 (for E2) and k 1 o/k9 and k 12/k 11 (for E3) were equated to 0.1 (399). 
Secondly, we assumed that the release of radiolabelled fatty acids from the 
phospholipids was negligible. This assumption was based on our results 
showing phospholipase A2 activity to be insignificant under our experimental 
conditions (see Section 3.2.5.1 ). The effect of endogenous alternate fatty acid 
substrates or endogenous fatty acid competitive inhibitors of E 1 or the 
corresponding acyl-CoA as alternate substrates/competitive inhibitors of E2 
and E3, was ignored in the model. 
The initial values of Km for E1, E2, and E3 were set at 2 µM, 10 µM and 3 µM, 
respectively, and of kcat were set at 41 min-1, 2 min-1 and 26 min-1, 
respectively (calculated from data/references in Tables 34, 35, 40 and 42). 
After ca. 14 modelling runs, we were still unable to closely mimic the shapes of 
the curves for the disappearance of linoleic acid and for the formation of 
acyl-CoA and phospholipid with time (Figure 30); we felt that it was not possible 
to simulate the experimental data closely with the existing reaction scheme. 
208 
Therefore, rate constants for the decay of E1, E2 and E3 were introduced. 
These unimolecular rate constants were k14, k15 and k16, respectively. 
Pathways allowing for the decay of these enzymes were thus introduced into 
the reaction scheme and are shown in Figure 38 (See below). 
Typical output from SLAM II is shown in Table 36. The rate constants used in 
the computer output in Table 36 are given at the bottom of page 210 in the 
order of k1, k2, k3, k4, k5, ks, k7, kg, kg, k10, k11, k12, k13, k14, k15 and k16-
Also on this page are the initial values of the components of the reaction 
scheme (Figure 38 and Section 2.2.3.12). The differential equations in SLAM II 
language are given in Section 2.2.3.12. The disappearance of substrate and 
formation of eight products as a function of time are shown on page 215 (see 
Section 2.2.3.12.1 for definition of abbreviations) and the data is illustrated 
graphically in low resolution on page 216. 
In Table 37 are shown the values of the rate constants used in each run in the 
computer modelling*. Values in boldface indicate that they were changed 
relative to the previous run or relative to the reference run indicated at the top of 
the Table. At the bottom of Table 37, are given the values calculated from the 
indicated run for the equilibrium constants and kcats for acyl-CoA synthetase 
(E1), ti6-desaturase (E2) and lysophospholipid acyltransferase (E3). 
Overlay plots of the outputs from selected runs are shown in Figures 39 to 80. 
Separate plots are shown for fatty acid (linoleic acid) disappearance, acyl-CoA 
formation, ti6-desaturation of linoleic acid and phospholipid formation with time. 
* The initial 15 preliminary modelling runs, which were performed prior to the 37 
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Data from several runs are overlaid on a single plot. Included in each plot for 
reference is the relevant experimental data. 
In models 2 - 4 (Figures 39, 40, 41 and 42), fatty acid concentration decayed 
towards zero in an exponential, while the experimental data appeared to be 
biphasic (Figure 39). No model fitted the shape of the curve well. Increasing k2 
by a factor of 15 (compare model 4 to model 2), decreased the loss of linoleic 
acid. The production of acyl-CoA esters was at too fast an initial rate in models 
2 and 3, and too slow an initial rate in model 4 (Figure 40). All three models 
showed too striking a secondary decay of acyl-CoA levels after about 1 to 3 
minutes. All three models approximated the t.6-desaturase reaction (Figure 41). 
None of the three modelled the shape of the curve for phospholipid formation, 
although values of phospholipid formation were within 50 to 100% of the 
experimental data (Figure 42). 
Models 7, 8 and 9 were compared to model 2 and the experimental data in 
Figures 43, 44, 45 and 46. k2 was increased in models 7, 8 and 9 relative to 
model 2 by a factor of 3 to 6, but was ca. two- to five-fold below the value in 
model 6. k5 was also intermediate between models 2 and 6; ks and k11 were 
unchanged relative to model 2. Models 7, 8 and 9 modelled the experimental 
data for fatty acid disappearance closer than did model 2 (Figure 43), with 
model 9 better than 8, and 8 better than 7, respectively. This correlated with 
and reflected the increase in k2. With regard to acyl-CoA formation, model 9 
most closely mimicked the data, but in all three models, acyl-CoA levels 
increased too strikingly up to 2 minutes and decreased faster than the 
experimental data thereafter (Figure 44). Models 7, 8 and 9 were, however, an 










Overlay plots of the effect of time on the disappearance of linoleic acid 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 2 (• ), 3 (+), 4 (•), and the experimental data from 
Figure 30 (X). 





















0 2 4 
TIME (min) 
6 8 
Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 2 <• ), 3 (+), 4 (•), and the experimental data from 
Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, µM free linoleoyl-CoA plus 















Overlay plots of the effect of time on the 1~desaturation of linoleic 
acid (4.7 µM) using data from models 2 (• ), 3 (+), 4 (•), and the 
experimental data from Figures 19 (!) and 20 (X). 
UC + PU + UCLE3, µM free "(-linolenoyl-CoA plus that bound to the 










0 2 4 
TIME (min) 
6 8 
Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 2 (• ), 3 ( + ), 4 (•), and the experimental data from 
Figure 30 (X). 













Overlay plots of the effect of time on the disappearance of linoleic acid 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 2 (D ), 7 (a), 8 ( + ), 9 (•) and the experimental data from 
Figure 30 (X). 
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TIME (min) 
6 8 
Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 2 (0), 7 (•), 8 (+), 9 (•) and the experimental data from 
Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, 
-y-linolenoyt-CoA plus that bound to 
lysophospholipid acyttransferase. 
µM free linoleoyl-CoA plus 
the 116-desaturase and 
















Overlay plots of the effect of time on the t~esaturation of linoleic 
acid (4.7 µM) using data from models 2 (D ), 7 (•), 8 (+), 9 (•) and the 
experimental data from Figures 19 (!) and 20 (X). 
UC + PU + UCLE3, µM free -y-linolenoyl-CoA plus that bound to the 













Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 2 (0 ), 7 (•), 8 ( + ), 9 (•) and the experimental data from 
Figure 30 (X). 
PF + PU, µM linoleoyl-CoA acid plus '}'-linolenoyl-CoA acylated into 
phospholipids. 
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and 9 approximated the t.6-desaturase reaction, but were ca. 50% above the 
experimental data (Figure 45). Models 7, 8, 9 and 2 all approximated 
phospholipid formation over 1 minute but exceeded experimental phospholipid 
formation thereafter (Figure 46). 
Figures 4 7, 48, 49 and 50 compare the results of models 8, 12, 13 and 14 to the 
experimental data. Relative to models 8 or 10, models 12 and 13 diminished k3 
by up to two-fold. In models 12 to 14, k5 was decreased by approximately 25% 
relative to model 8, and model 14 additionally increased kg and k12 by 3.6-fold 
relative to models 8 and 10. As with previous runs, although the computer 
generated data bracketed the experimental data, the computer generated data 
followed a smooth exponential or linear curves, while the experimental data 
appeared biphasic for fatty acid disappearance and phospholipid formation, 
respectively (Figures 47 and 50). This led us to introduce additional constants 
for the decay of activity of E 1, E2 and E3 in subsequent runs in an attempt to 
model the biphasic curves. Models 8, 12 and 14 generated almost identical 
curves for fatty acid disappearance with time (Figure 4 7); this reflected identical 
k1, k2, k4, k5, k7, kg, k10, k11 and k13 values in these models. k3 differed only 
by 20% among the models and this slight variation in k3 appeared to be without 
striking effect on fatty acid disappearance. The differences in kg and k12 
between models 13 and 14 were so late in the reaction pathway as apparently 
to be without significant effect on the first step in linoleic acid metabolism, viz: 
its conversion to acyl-CoA. 
Models 8, 12 and 14 showed acyl-CoA formation exceeding the experimental 
data over an initial period of from 0.5 to 4 minutes (Figure 48). After ca. 1 to 2 














Overlay plots of the effect of time on the disappearance of linoleic acid 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 8 (•), 12 (+), 13 (*), 14 (0) and the experimental data 
from Figure 30 (X). 
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TIME (min) 
6 8 
Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 8 (•), 12 (+), 13 (*), 14 (D) and the experimental data 
from Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, µM free linoleoyt-CoA plus 


















Overlay plots of the effect of time on the ~6-desaturation of linoleic 
acid (4.7 µM) using data from models 8 (•), 12 (+), 13 (•), 14 (D) and 
the experimental data from Figures 19 (!) and 20 (X). 
UC + PU + UCLE3, µM free -Y-linolenoyl-CoA plus that bound to the 













Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 8 (•), 12 (+), 13 (*), 14 (D) and the experimental data 
from Figure 30 (X). 
PF + PU, µM linoleoyl-CoA acid plus -y-linolenoyl-CoA acylated into 
phospholipids. 
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the experimental data. Model 13 mimicked acyl-CoA formation well up to 
ca. 0.5 minutes, then plateaued at approximately the same acyl-CoA levels as 
the experimental data and showed a slight decline after ca. 2 minutes. For the 
~6-desaturase reaction, model 8 provided data above experimental levels, and 
model 14, data well below the experimental (Figure 49). For the latter model, 
~6-desaturase product tapered off to a plateau not seen in the experimental 
data. Models 12 and 13 mimicked the experimental data for the ~6-desaturase 
well. For phospholipid formation, model 14 far exceeded the experimental data; 
the remaining models were virtually superimposible on each other, and on the 
experimental data for ca. 2 minutes. Thereafter, the modelled levels of 
phospholipid formation exceeded the experimental data (Figure 50). 
Figures 51, 52, 53 and 54 compare the results of models 16, 19, 20, 21 and 22 
to experimental data. In this set of models, non-zero values for rate constants 
14 and/or 16 are used. These constants allow for decay of the activity of E1 
and E3. k 15 remained zero, since the shape of the curve for the ~6-desaturase 
enzyme, E2, was modelled by the computer generated data. Values for k14 
varied from 0.1 to 0.8, and for k16 from Oto 10. Fatty acid disappearance over 
the first minute was closely approximated by models 19, 20, 21 and 22 
(Figure 51). Model 16 gave slightly lower loss of fatty acid over the first minute. 
The increasing value of k14 in models 20, 19 and 16 respectively resulted in the 
plateauing of the slower phase of fatty acid disappearance between 2 and 5 
minutes at increasing levels of fatty acid remaining. The introduction of k 16 of 1 
in model 21 did not significantly affect the plot relative to model 19, while 
increasing this constant to 10 in model 22 resulted in a non-plateau in fatty acid 
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TIME (min) 
Overlay plots of the effect of time on the disappearance of linoleic acid 
measured during the metabolism of linoleic acid (4. 7 µM) using data 
from models 16 (• ), 19 ( + ), 20 (•), 21 (D ), 22 (A) and the experimental 
data from Figure 30 (X). 



















Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 16 (• ), 19 ( + ), 20 (•), 21 (D ), 22 (!) and the experimental 
data from Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, 
"f-linolenoyl-CoA plus that bound to 
lysophospholipid acyltransferase. 
µM free linoleoyl-CoA plus 
the M-desaturase and 
0.6 















Overlay plots of the effect of time on the A6-clesaturation of linoleic 
acid (4.7 µM) using data from models 16 (•), 19 (+), 20 (•), 21 (D), 
22 (!) and the experimental data from Figure 20 (X). 
UC + PU + UCLE3, µM free -y-linolenoyl-CoA plus that bound to the 












Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 16 (• ), 19 ( + ), 20 (•), 21 (D ), 22 (A) and the experimental 
data from Figure 30 (X). 
PF + PU, µM linoleoyl-CoA acid plus -y-linolenoyl-CoA acylated into 
phospholipids. 
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In models 16, 19, 20, 21 and 22, the first minute of acyl-CoA production was 
modelled reasonably well; thereafter, however, models 19, 20 and 21 predicted 
decay of acyl-CoA levels in excess of the very slight decline found 
experimentally (Figure 52). Model 22 showed a plateau of acyl-CoA levels after 
ca. 2 minutes, but at ca. 50% above experimental levels. The ~6-desaturase 
was well mimicked by all models (Figure 53). Models 16, 19, 20 and 21 were 
within 50 to 100% of the phospholipid formation with time up to five minutes, but 
did not model the shape of the time course well (Figure 54). Run 22 provided 
data up to six-fold below the experimental data at longer time points. 
Models 23 to 26 (Figures 55, 56, 57 and 58) were based on model 21. Models 
23 to 26 had a ca. 70% increase in k14 and no change to four-fold change in 
k15 relative to model 21. Models 25 and 26, compared to model 24, adjusted 
k1 downward and in model 26, in addition, k3 was increased by ca. 20%. This 
set of models provided the best approximation to the time course for fatty acid 
disappearance compared to previous models (see especially 
Figures 39 and 43) and for acyl-CoA formation (see Figures 40, 44 and 48). 
Models 23 and 24 approximated the fatty acid disappearance curve slightly 
better than model 21 (Figure 55). Models 25 and 26 plateaued above the 
experimental data. All models were reasonably close to modelling acyl-CoA 
formation, with model 23 being closer to the data than the other models 
(Figure 56). ~6-Desaturation was essentially equivalently modelled by the 
computer runs 21, 23, 24, 25 and 26 (Figure 57). This set of runs showed a 
tightening of output into a narrower range. Since the modelling of the 
~6-desaturase component has been close throughout previous runs (see 
Figures 41, 45, 49 and 53), the current runs at most show a slight improvement 
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6 8 
Overlay plots of the effect of time on the disappearance of linoleic acid 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 21 (• ), 23 ( + ), 24 (*), 25 (D ), 26 (!) and the experimental 
data from Figure 30 (X). 





















Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 21 (•), 23 (+), 24 (•), 25 (O ), 26 (!) and the experimental 
data from Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, µM free linoleoyl-CoA plus 















Overlay plots of the effect of time on the As-desaturation of linoleic 
acid (4.7 µM) using data from models 21 (•), 23 (+), 24 (•), 25 (O ), 
26 (!) and the experimental data from Figure 20 (X). 
UC + PU + UCL::3, µM free "(-linolenoyl-CoA plus that bound to the 








0 2 4 
TIME (min) 
6 8 
Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 21 (• ), 23 ( + ), 24 (•), 25 (D ), 26 ( •) and the 
experimental data from Figure 30 (X). 
PF + PU, µM linoleoyl-CoA acid plus 'Y-linolenoyl-CoA acylated into 
phospholipids. 
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with models 24, 25 and 26 predicting ca. two-fold lower formation than the 
experimental data (Figure 58). The former runs provide a closer fit to the 
experimental data than previous runs (see Figures 42, 46, 50 and 54). 
Finer tuning of the model was performed with models 27, 28 and 29 (see 
Figures 59, 60, 61 and 62). These models were based on model 23, and only 
k6 was altered, being decreased in the order model 23 > 29 > 28 > 27. All these 
models generated identical plots for fatty acid disappearance, acyl-CoA 
formation and phospholipid acylation (Figures 59, 60 and 62). Only the plot of 
the ti6-desaturase reaction was affected, with the data approximating the 
experimental data in the following order 23 < 29 < 28 < 27, with model 27 fitting 
the data up to 5 minutes extremely well (Figure 61 ). 
Prior to the modelling described in the thesis, we made a number of earlier runs 
on the SLAM II program. In these earlier runs, we were unable to model the 
data at all closely without altering the concentrations of two of the components 
needed for the computer modelling. The components are lysophospholipid and 
lysophospholipid acyltransferase. The concentrations of both of these were set 
higher than the literature values (Table 35). At this current point in our 
modelling, we wished to check whether we could lower the levels of these 
components and still model the data. The relevant data is shown in Figures 63, 
64, 65 and 66 where data from model 27, run at 11 µM and 2.2 µM 
lysophospholipid concentration is presented with the experimental data. The 
decrease in lysophospholipid concentration was accompanied by a significant, 
but managable decrease in phospholipid formation (Figure 66). Therefore, the 
concentrations of lysophospholipid and lysophospholipid acyltransferase 
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Overlay plots of the effect of time on the disappearance of linoleic acid 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 23, 27, 28, 29 (• ), and the experimental data from 
Figure 30 (X). 
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Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 23, 27, 28, 29 (• ), and the experimental data from 
Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, µM tree linoleoyt-CoA plus 
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6 8 
Overlay plots of the effect of time on the 66-desaturation of linoleic 
acid (4.7 µM) using data from models 23 (.,, 27 ( + ), 28 (•), 29 (D ), and 
the experimental data from Figures 19 (A) and 20 (X). 
UC + PU + UCLEJ. µM free "{-linolenoyl-CoA plus that bound to the 












Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 23, 27, 28, 29 (• ), and the experimental data from 
Figure 30 (X). 
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Overtay plots of the effect of time on the disappearance of llnoleic acid 
measured during the metabolism of llnoleic acid (4.7 µM) using data 
from model 27 run at concentrations of 11 µM (• ) and 2.2 µM (•) 
lysophospholipid, and the experimental data from Figure 30 (X). 






Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from model 27 run at concentrations of 11 µM <• ) and 2.2 µM (*) 
lysophospholipid, and the experimental data from Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, µM free linoleoyl-CoA plus 















Overlay plots of the effect of time on the As-desaturation of linoleic 
acid (4.7 µM) using data from model 27 run at concentrations of 
11 µM (• ) and 2.2 µM (•) lysophospholipid, and the experimental 
data from Figures 19 (A) and 20 (X). 
UC + PU + UCLE3, µM free -y-linolenoyt-CoA plus that bound to the 










0 2 6 
TIME (min) 
Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from model 27 run at concentrations of 11 µM <• ) and 2.2 µM (•) 
lysophospholipid, and the experimental data from Figure 30 (X). 
PF + PU, µM linoleoyl-CoA acid plus -y-linolenoyl-CoA acylated into 
phospholipids. 
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models (Table 35). The constants in the model were adjusted to increase the 
activity of the lysophospholipid acyltransferase (Figure 66). 
In models 30, 31, 32 and 33, concentrations of 2.2 µM lysophospholipid and 
0.5 µM lysophospholipid acyltransferase were used, and the values of kg and 
k 12 were adjusted to compensate for decreased lysophospholipid 
acyltransferase activity accompaning the changes in component concentration. 
The results are given together with the data from model 27 and the experimental 
data in Figures 67, 68, 69 and 70. The decrease in the concentration of 
lysophospholipid and lysophospholipid acyltransferase without change in rate 
constants (compare models 27 and 30) was accompanied by very small 
changes in fatty acid disappearance (Figure 67) and ti6-desaturase activity 
(Figure 69), but striking changes in acyl-CoA formation (Figure 68) and 
lysophospholipid acyltransferase activity (Figure 70). At the lower 
concentrations of lysophospholipid and lysophospholipid acyltransferase, the 
four-fold increase in kg and k12 in model 30 to model 33 (Table 37) appears to 
be sufficient for the simulated data to approximately model the experimental 
data (Figures 67, 68, 69, and 70). 
Now that the simulated data for model 33 approximately modelled the 
experimentally determined data for substrate disappearance and product 
formation as a function of time, it was necessary to see if the simulated data for 
product formation with time for the acyl-CoA synthetase, fi6-desaturase and 
lysophospholipid acyltransferase versus initial linoleic acid concentration 
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Overlay plots of the effect of time on the disappearance of linoleic acid 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 27 (a), 30 (+), 31 (•), 32 (D ), 33 (A) and the experimental 
data from Figure 30 (X). 
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Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 27 (• ), 30 ( + ), 31 (•), 32 (0 ), 33 (!) and the experimental 
data from Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, µM free linoleoyl-CoA plus 














Overlay plots of the effect of time on the !is-desaturation of linoleic 
acid (4.7 µM) using data from models 27 (•), 30 (+), 31 (•), 32 (0 ), 
33 (!) and the experimental data from Figure 20 (X). 
UC + PU + UCLE3, µM free 'Y-linolenoyl-CoA plus that bound to the 












Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 27 (• ), 30 ( + ), 31 (•), 32 (D ), 33 (!) and the experimental 
data from Figure 30 (X). 
PF + PU, µM linoleoyl-CoA acid plus "(-linolenoyl-CoA acylated into 
phospholipids. 
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Using the constants from model 33 in Table 37 and the SLAM II program, data 
for product formation with time at various linoleic acid concentrations for the 
acyl-CoA synthetase, t.6-desaturase and lysophospholipid acyltransferase was 
obtained. The time period was chosen as 3 minutes, since this was the time 
period over which the experimental data was collected. The enzyme activities 
were measured as follows: 
i) for the acyl-CoA synthetase, the formation of the sum of the two 
acyl-CoA products plus all enzyme-bound acyl-CoA (linoleoyl-CoA, 
-y-linolenoyl-CoA, [linoleoyl-CoA. E2], [linoleoyl-CoA. E3] plus 
[-y-linolenoyl-CoA.E3] in Figure 38) over 3 minutes, normalised to 1 
minute, from the computer output is plotted versus initial linoleic acid 
concentration with the experimentally determined data (Figure 32 B) in 
Figure 71. 
ii) for the t.6-desaturase, the formation of free -y-linolenic acid plus that fatty 
acid esterified to CoA or phospholipid plus all enzyme-bound 
-y-linolenoyl-CoA (-y-linolenoyl-CoA, [ -y-linolenoyl-CoA. E3], and 
2--y-linolenoyl-phospholipid in Figure 38) over 3 minutes, normalised to 1 
minute, from the computer output is plotted versus initial linoleic acid 
concentration together with the experimentally determined data 
(Figure 33 B) in Figure 72. 
iii) for the lysophospholipid acyltransferases, the formation of 
2-linoleoyl-phospholipid plus 2--y-linolenoyl-phospholipid (Figure 38) 
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[UNOLEIC ACID] 
Overlay plots of the effect of linoleic acid concentration on the 
formation of acyl-CoA measured during the metabolism of linoleic acid 
using data from model 33 (• ) and the experimental data from 
Figure 32 B (X). 
Product, µM [1-14q linoleoyl-CoA + p-14q "(-linolenoyl-CoA formed/min 
for the experimental data and linoleoyl-CoA + "(-Hnolenoyl-CoA + 
[linoleoyl-CoA.E2] + ["f-linolenoyl-CoA.E3] + [linoleoyl-CoA.E3] 
formed/min for the simulated data; linoleic acid concentration, µM linoleic 
acid. Product formation was measured at 3 min and was normalised to 1 
min by dividing by 3. 
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0 2 4 6 8 10 12 
[UNOLEIC ACID] 
Overlay plots of the effect of linoleic acid concentration on the 
66-desaturation of linoleic acid using data from model 33 (•) and the 
experimental data from Figure 33 B (X). 
Product. µM [1"14q -y-linolenoyl-CoA + [1"14q -y-linolenoyl-phospholipid 
formed/min for the experimental data and µM -y-linolenoyl-CoA + 
-y-linolenoyl-phospholipid + ['Y-linolenoyl-CoA.E3] formed/min for the 
simulated data; linoleic acid concentration, µM linoleic acid. Product 
formation was measured at 3 min and was normalised to 1 min by dividing 
by 3. 
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plotted versus initial linoleic acid concentration together with the experimentally 
determined data (Figure 34 B) in Figure 73. 
In the overlay plots of the experimental data and the simulated data using the 
constants from model 33 as outlined above, there was good correlation 
between the experimental data and the simulated data for the acyl-CoA 
synthetase and lysophospholipid acyltransferase (Figures 71 and 73). 
However, for the ll6-desaturase, the rate of product formation calculated from 
the simulated reaction scheme using model 33 was ca. two-fold higher than that 
obtained experimentally (Figure 72). Further modelling was aimed at improving 
the agreement between the experimentally determined data and the data from 
the simulated reaction scheme for the ll6-desaturation of linoleic acid as a 
function of linoleic acid concentration. 
Overlay plots of the experimental data and simulated data from models 34, 35 
and 36 of product formation as a function of time are illustrated in Figures 7 4, 
75, 76 and 77. No changes were made to the rate constants for the acyl-CoA 
synthetase (k1, k2 and k3), and very small differences in the disappearance of 
fatty acid and formation of acyl-CoA were observed between models 33, 34, 35 
and 36. These changes did not affect the agreement between the experimental 
data and the simulated data plotted for linoleic acid disappearance or acyl-CoA 
formation as a function of time (Figures 74 and 75). In models 34, 35 and 36, kg 
and k 12 for the lysophospholipid acyltransferase were decreased by ca. 10%, 
resulting in small changes in the overlay plots for phospholipid formation 
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[UNOLEIC ACID] 
Overlay plots of the effect of linoleic acid concentration on the 
acylation of phospholipids measured during the metabolism of linoleic 
acid using data from model 33 (• ) and the experimental data from 
Figure 34 B (X). 
Product, µM [1-14q linoleoyl-phospholipid + [1-14q -y-linolenoyl-
phospholipid formed/min for the experimental data and µM 
linoleoyl-phospholipid + -y-linolenoyl-phospholipid formed/min for the 
simulated data; linoleic acid concentration, µM linoleic acid. Product 
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TIME (min) 
Overlay plots of the effect of time on the disappearance of linoleic acid measured during the metabolism of linoleic acid (4.7 µM) using data from models 33 ( + ), 34, 35, 36 (• ) and the experimental data from 
Figure 30 (X). 























0 2 4 6 
TIME (min) 
Overlay plots of the effect of time on the formation of acyl-CoA 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 33 ( + ), 34, 35, 36 <•) and the experimental data from 
Figure 30 (X). 
FC + FCE2 + FCLE3 + UC + UCLE3, µM free linoleoyl-CoA plus 














2 4 6 
TIME (min) 
Overlay plots of the effect of time on the fi6-desaturation of linoleic 
acid (4.7 µM) using data from models 33 (+), 34 (.,, 35 (•), 36 (D) and 
the experimental data from Figures 19 (!) and 20 (X). 
UC + PU + UCLE3, µM free -y-linolenoyl-CoA plus that bound to the 












Overlay plots of the effect of time on the acylation of phospholipids 
measured during the metabolism of linoleic acid (4.7 µM) using data 
from models 33 ( + ), 34, 35, 36 (• ), and the experimental data from 
Figure 30 {X). 
PF + PU, µM linoleoyl-CoA acid plus -y-linolenoyl-CoA acylated into 
phospholipids. 
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For the A6-desaturase, in model 34, the values of k5 and ks were increased 
three-fold, and decreased 20%, respectively. These changes resulted in a ca. 
two-fold decrease in the rate of product formation with time (Figure 76) and the 
simulated data no longer mimicked the experimental data closely, except that 
the shape of the curve appeared to be unaffected. Since the activity of the 
A6-desaturase varied up to 50% in different preparations of hepatic microsomes 
(see, for example, Table 28) and the data in Figures 19 and 20 were reported for 
a single preparation of hepatic microsomes, we attempted to maintain the linear 
shape, rather than the absolute activity value. Therefore, the changes in values 
of k4, k5 and ks for the A6-desaturase from models 34, 35 and 36 were aimed at 
improving the correlation between the data for the plot of product formation with 
linoleic acid concentration (Figure 33 B), while maintaining the linear nature of 
the plot of product formation with time (Figures 19 and 20). 
In the overlay plots of the experimental and simulated data for rate of product 
formation versus linoleic acid concentration for models 34, 35 and 36 (Figures 
78, 79 and 80), there was excellent agreement between the simulated data and 
the experimental data for all three models for the acyl-CoA synthetase and 
lysophospholipid acyltransferase (Figures 78 and 80). For the A6-desaturase, 
all three models were an improvement on model 33, with model 35 giving the 
closest agreement to the experimental data (Figure 79). 
Therefore, the constants from model 35 provided the best correlation between 
the experimentally determined product formation with time for the 
disappearance of linoleic acid, acyl-CoA formation, A6-desaturase and acylation 
of lysophospholipid and the product formation simulated using the SLAM II 
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[UNOLEIC ACID} 
Overlay plots of the effect of linoleic acid concentration on the 
formation of acyl-CoA measured during the metabolism of linoleic acid 
using data from models 33 ( + ), 34, 35, 36 (•) and the experimental 
data from Figure 32 B (X). 
Product, µM [1-14C] linoleoyl-CoA + [1-14q -y-linolenoyl-CoA formed/min 
for the experimental data and linoleoyl-CoA + 'Y-linolenoyl-CoA + 
[linoleoyt-CoA.E2] + [-y-linolenoyl-CoA.E3] + [linoleoyl-CoA.E3] 
formed/min for the simulated data; linoleic acid concentration, µM linoleic 
acid. Product formation was measured at 3 min and was normalised to 1 
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[UNOLEIC ACID] 
Overlay plots of the effect of linoleic acid concentration on the 
A6-desaturation of linoleic acid using data from models 33 ( + ), 34 (II), 
35 (•), 36 (D) and the experimental data from Figure 33 B (X). 
Product, [1-14q µM -y-linolenoyl-CoA + [1-14q -y-linolenoyl-phospholipid 
formed/min for the experimental data and µM -y-linolenoyl-CoA + 
-y-linolenoyl-phospholipid + ['Y-linolenoyl-CoA.E3] formed/min for the 
simulated data; linoleic acid concentration, µM linoleic acid. Product 
















0 2 4 6 8 10 12 
[UNOLEIC ACID] 
Overlay plots of the effect of linoleic acid concentration on the 
acylation of phospholipids measured during the metabolism of linoleic 
acid using data from models 33 ( + ), 34, 35, 36 (• ), and the 
experimental data from Figure 34 B (X). 
Product, µ.M [1-14C] linoleoyt-phospholipid + W14C] -y-linolenoyt-
phospholipid formed/min for the experimental data and µM 
linoleoyt-phospholipid + -y-linolenoyt-phospholipid formed/min for the 
simulated data; linoleic acid concentration, µ.M linoleic acid. Product 
formation was measured at 3 min and was normalised to 1 min by dividing 
by 3. 
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with time together with the simulated data for disappearance of fatty acid, 
acyl-CoA formation, ti6-desaturation of linoleic acid and acylation of 
lysophospholipid at 4. 7 µM linoleic acid are illustrated in Figures 81, 82, 83 and 
84, respectively. Similarly, the experimentally determined rate of product 
formation versus linoleic acid concentration is illustrated in 
Figures 85, 86 and 87, together with the rate determined from simulation of 
the reaction scheme using the constants from model 35 for the acyl-CoA 
synthetase, ti6-desaturase and lysophospholipid acyltransferase, respectively. 
The rate constants from model 35, and the apparent kcat, Km and Vmax values 
calculated therefrom are given in Table 38. 
Once the overall reaction scheme had been simulated at several substrate 
concentrations, the output from model 35 was used to assess the kinetics of 
E2, the ti6-desaturase, removing the contributions from lysophospholipid 
acyltransferase and acyl-CoA synthetase to the experimentally obtained data 
(Figure 38). This process was performed as follows: the tabulated output of 
product verus time (see, for example, Table 36, page 215), was examined for 
model 35 at each initial substrate concentration. A region in time where the 
concentration of acyl-CoA (free plus enzyme-bound forms) was relatively 
constant was found and chosen as illustrated in Figure 88 A (Table 39). The 
values of FC plus FCE2 with time chosen as essentially constant for each initial 
linoleic acid concentration are given in Table 39. This concentration of 
linoleoyl-CoA was used in Lineweaver-Burk and Eadie-Hofstee plots for the 
ti6-desaturase. The product formation (all forms of -y-linolenoyl-CoA, i.e. UC, 
UCLE3 and PU) over this time period at 0.2 minute intervals is given in 
Table 39. Product formation was plotted versus time and each plot checked for 






0 2 4 6 
TIME (min) 
The effect of time on the disappearance of fatty acid (substrate) 
measured during the metabolism of linoleic acid (4.7 µM) in hepatic 
microsomes using experimentally obtained data from Figure 30 (X) 
and data obtained from model 35 of the simulated reaction scheme(•). 
Substrate, µM [1-14CJ linoleic acid formed for the experimental data and 
[linoleic acid + linoleic acid.E1] formed for the simulated data. For the 
experimental data, BSA concentration was 11.5 µ.g/µ.g linoleic acid added. 
Separation of the fatty acid, phospholipid and acyl-CoA from hepatic 
microsomes was carried out by differential organic extractions (Section 
2.2.3.Ba, Method B). Data represents quintipulate determinations on one 





0 2 4 6 
TIME (min) 
The effect of time on the formation of acyl-CoA measured during the 
metabolism of linoleic acid (4.7 ,uM) in hepatic microsomes using 
experimentally obtained data from Figure 30 (X) and data obtained 
from model 35 of the simulated reaction scheme(•). 
Product, ,UM [1-14q linoleoyl-CoA + [1-14q r-linolenoyl-CoA formed for 
the experimental data and linoleoyl-CoA + r-linolenoyl-CoA + 
[linoleoyl-CoA.E2J + [r-linolenoyl-CoA.E3] + [linoleoyl-CoA.E3] formed for 
the simulated data. For the experimental data, BSA concentration was 
11.5 ,Ug/,Ug linoleic acid added. Separation of the fatty acid, phospholipid 
and acyl-CoA from hepatic microsomes was carried out by differential 
organic extractions (Section 2.2.3.Sa, Method B). Data represents 






The effect time on the tis-desaturation of linoleic acid (4. 7 µM) In 
hepatic microsomes using experimentally obtained data from 
Figures 19 (•) and 20 (X) and data obtained from model 35 of the 
simulated reaction scheme(•). 
Product, µM [1·1 4C] -y-linolenoyl-CoA + [1·14C] -y-linolenoyl-
phospholipid formed tor the experimental data and µM -y-linolenoyt-CoA + 
")'-linolenoyl-phospholipid + ["Y-linolenoyt-CoA.E3] formed tor the simulated 
data; linoleic acid concentration was 4.7 µM. fi6-Desaturase activity in 
hepatic microsomes was measured using Methods 1 (•) and 2 (X). For the 
experimental data, BSA concentration was 11.5 µg/ µg linoleic acid added 
in Method 1 (•), and 115 µg/µg linoleic acid added in Method 2 (X). In 
both cases, data represents triplicate determinations on one preparation of 
hepatic microsomes. The shape of the curve is typical of that obtained 
with two other microsomal preparations, but product formation varied up 







The effect of time on the acylation of phospholipids during the metabolism of linoleic acid (4.7 µM) in hepatic microsomes using experimentally determined data from Figure 30 (X) and data obtained from model 35 of the simulated reaction scheme (a). 
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[LJNOLEIC ACID] 
Plot of formation of acyl-CoA by acyl-CoA synthetase versus linoleic 
acid concentration using experimentally obtained data from 
Figure 32 B (X) and data obtained from model 35 of the simulated 
reaction scheme(•). 
Rate, µM [1"14q linoleoyt-CoA + [1"14q "(-linolenoyt-CoA formed/min for 
the experimental data and linoleoyt-CoA + "(-linolenoyt-CoA + 
[linoleoyt-CoAE2] + ["(-linolenoyt-CoAE3] + [linoleoyt-CoA.E3] 
formed/min for the simulated data; linoleic acid concentration, µM linoleic 
acid. Product formation was measured at 3 min and was normalised to 1 
min by dividing by 3. For the experimental data, BSA concentration was 
11.5 µg/ µg linoleic acid added. Separation of the fatty acid, phospholipid 
and acyt-CoA from hepatic microsomes was carried out by differential 
organic extractions (Section 2.2.3.Sa, Method B). Data represents the 
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[LJNOLEIC ACID] 
Plot of rate of formation of 1-linolenic acid by A6-desaturase versus 
linoleic acid concentration using experimentally obtained data from 
Figure 33 B (X) and data obtained from model 35 of the simulated 
reaction scheme(•). 
Rate, µ.M [1-14q "(-linolenoyl-CoA + [1-14q -y-linclenoyl-phospholipid 
formed/min for the experimental data and µ.M -y-linolenoyl-CoA + 
"(-linolenoyf-phospholipid + ["f-linolenoyf-CoA.E3] formed/min for the 
simulated data; linoleic acid concentration, µ.M linoleic acid. Product 
formation was measured at 3 min and was normalised to 1 min by dividing 
by 3. For the experimental data, BSA concentration was 11.5 µ.g/ µ.g 
linoleic acid added. A6-Desaturase activity in hepatic microsomes was 
measured using Method 2. Data represents the average of that obtained in 
triplicate from three preparations of hepatic microsomes. 
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Plot of rate of acylation of phospholipids by the lysophospholipid 
acytransferases versus linoleic acid concentration using 
experimentally obtained data from Figure 34 B (X} and data obtained 
from model 35 of the simulated reaction scheme (a). 
Rate, µM [1-14q 2-linoleoyl- + [1-14q 2--y-linolenoyl-phospholipid 
formed/min for the experimental and simulated data; linoleic acid 
concentration, µM linoleic acid. Product formation was measured at 3 min 
and was normalised to 1 min by dividing by 3. For the experimental data, 
BSA concentration was 11.5 µg/µg linoleic acid added. Separation of the 
fatty acid, phospholipid and acyl-CoA from hepatic microsomes was 
carried out by differential organic extractions (Section 2.2.3.Sa, Method B). 
Data represents the average three to five determinations obtained from 









* in µM-1, min -1 
t in min ·1 
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TABLE 38 
RATE CONSTANTS FROM COMPUTER MODELLING OF MODEL 35 









k7 = k 10 
ks = k11 







1.5 X 103 t 
2.5X101 t 
5.5 X 101 * 





1.1 X 10·1 t 





(k2+k3)/k1 = 10.17 
(k5 + k5)/k4 = 1.57 
(ks+ kg)/k7 = 




k3 = 25 
k5 = 1.28 
kg = k12 = 
2.0 


























Formation of all the species of linoleoyl-CoA (A) and 
'Y-linolenoyl-CoA (B) from linoleic acid (4. 7 µM) with time using data 
from model 35 of the simulated reaction scheme. 
FC + FCE2, free linoleoyl-CoA + linoleoyl-CoA bound to the acyl-CoA 
synthetase; UC + UCLE3 + PU, free -y-linolenoyl-CoA + 'Y-linolenoyl-CoA 




THE EFFECT OF TIME ON THE CONCENTRATIONS OF INTERMEDIATES GENERATED FROM 
COMPUTER MODELLING OF MODEL 35 AT DIFFERENT INITIAL CONCENTRATIONS OF 
LINOLEIC ACID 
Intermediates * Time Total Concentration of Intermediates 
(min) (J.LM) 
Initial linoleic acid 3.35 3.8 4.7 5.8 7.3 8.3 10.8 
concentration (µM) 
FC + FCE2t 1.4 1.27 1.52 
1.6 1.29 1.56 2.08 
1.8 1.30 1.57 2.12 2.82 
2.0 1.30 1.57 2.13 2.85 3.82 4.47 
2.2 1.28 1.55 2.12 2.85 3.85 4.51 
2.4 1.26 1.53 2.10 2.85 3.85 4.54 6.21 
2.6 2.84 3.84 4.53 6.24 
2.8 2.80 4.50 6.25 
3.0 6.23 
UC + UCLE3 + PU 1.4 0.062 0.066 
* 
t 
1.6 0.074 0.078 0.088 
1.8 0.086 0.091 0.098 0.105 
2.0 0.098 0.103 0.112 0.119 0.125 0.128 
2.2 0.110 0.116 0.125 0.133 0.139 0.142 
2.4 0.122 0.129 0.139 0.147 0.154 0.157 0.162 
2.6 0.161 0.168 0.172 0.177 
2.8 0.182 0.186 0.192 
3.0 0.207 
FC + FCE2, linoleoyl-CoA plus linoleoyl-CoA bound to the M-desaturase; UC + UCLE3 + PU, 
"(-linolenoyl-CoA plus "(-linolenoyl-CoA bound to the lysophospholipid acyltransferase plus that 
acylated into phospholipids (see Figure 38). 
Underlined concentrations were used as the initial substrate concentration for linoleoyl-CoA for 
reciprocal plots of the t.6-desaturase activity shown in Figure 89. 
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-y-linolenoyl-CoA, i.e. UC, UCLE3 and PU) at the beginning of this time period 
was subtracted from product levels at the end of this time period and 
normalised to 1 minute. The output, viz: total -y-linolenoyl-CoA formed per 
minute, was used as the initial rate data for Lineweaver-Burk and Eadie-Hofstee 
plots for the t.6-desaturase. 
Lineweaver-Burk and Eadie-Hofstee plots constructed using the linoleoyl-CoA 
concentration and the rate of product formation calculated from the simulated 
data from model 35 as outlined above, are shown in Figure 89. The 
Lineweaver-Burk and Eadie-Hofstee plots for the conversion of linoleoyl-CoA to 
-y-linolenoyl-CoA by the t.6-desaturase were linear (Figure 89). 
The apparent Km and kcat (or Vmax) values for this reaction were calculated in 
two different ways as follows: 
i) first, they were calculated directly from the rate constants from model 35 
viz: (k5 + k6)/k4 equal to Km; and k6 equal to kcat, as shown in 
Table 38. 
ii) second, the data in Figure 89 was curve fit using the Michaelis Menten 
equation; the Km value calculated from this plot was 1.52 ± 0.04 µM and 
the Vmax value was 0.063 ± 0.001 µM/min. 
The inhibition of the t.6-desaturase by isoflurane using computer modelling of 
the reaction scheme was examined. In model 35A, the value of k4 was 

















Lineweaver-Burk (A) and Eadie-Hofstee (8) plots for the 
tfkjesaturation of linoleoyl-CoA using data from model 35 the 
simulated reaction scheme. 
Rate, µM )'-linolenoyl-CoA + )'-linolenoyl-CoA bound to the 
lysophospholipid acyltransferases and acylated into phospholipids 
formed/min; linoleoyl-CoA concentration, µM linoleoyl-CoA. Lines were 
drawn by Enzfitter (Section 2.2.3.1 O). 
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scheme using data from model 35A and the experimental data for the rate of 
product formation as a function of linoleic acid concentration for the 
ti6-desaturase in the presence of isoflurane*, are illustrated in Figure 90. In 
order to adjust the output of the computer model to fit the experimental data for 
the inhibition of the ti6-desaturase by isoflurane, only one rate constant had to 
be changed: k4 was reduced to 4.6 x 101 µM-1 min-1. By adjusting k4, the Km 
value for the ti6-desaturase in the presence of isoflurane calculated from the 
constants (k5 + k5)/k4 was increased to 1.88 µM from 1.57 µM, the value seen 
in the absense of isoflurane (Table 38). The kcat value was unaffected, and 
remained 1.28 min-1. For the modelled data of the inhibition of the 
ti6-desaturase by isoflurane, reciprocal plots of the output rates versus 
linoleoyl-CoA concentration were determined in an analogous manner to that 
shown in Table 39. The double reciprocal for the presence of isoflurane was 
linear, and intersected on the Y-axis with the line for minus isoflurane 
(Figure 91 ). The Km value for E2 in the presence of isoflurane calculated from 
fitting the Michaelis-Menten equation to the data in Figure 91 was 
1.89 ± 0.01 µM, which differed from the value calculated in the absence of 
isoflurane (1.52 ± 0.04). The Vmax value for the ti6-desaturase was the same 
whether calculated from the data in the presence or absence of isoflurane, viz: 
0.064 ± 0.001 µM/min and 0.063 ± 0.001 µM/min for the presence and 
absence of isoflurane, respectively. 
* Experimental data for ti6-desaturase activity measured in the presence and 
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[UNOLEIC ACID] 
Plot of rate of formation of 'Y-linolenic acid by fi6-desaturase versus 
linoleic acid concentration in the presence of isoflurane (2mM) using 
experimentally obtained data (X) and data obtained from model 35A of 
the simulated reaction scheme (a). 
Rate, µM [1-14C] -y-linolenoyl-CoA + [1-14C] -y-linolenoyl-phospholipid 
formed/min for the experimental data and µM -y-linolenoyl-CoA + 
-y-linolenoyl-phospholipid + ['Y-linolenoyl-CoA.E3] formed/min for the 
simulated data; linoleic acid concentration, µM linoleic acid. Product 
formation was measured at 3 min and was normalised to 1 min by dividing 
by 3. For the experimental data, BSA concentration was 11.5 µg/ µg 
llnoleic acid added. 66-Desaturase activity in hepatic microsomes was 
measured using Method 2. Data represents the average of that obtained in 
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1 /[UNOLEOYL-CoA] 
Lineweaver-Burk plot for the As-desaturation of linoleoyl-CoA in the 
absence (X) and presence (0) of isoflurane using data from models 35 
and 35A of the simulated reaction scheme. 
Rate, µM 'Y-linolenoyl-CoA + r-linolenoyl-CoA bound to the 
lysophospholipid acyltransferases and acylatec:1 into phospholipids 
formed/min; linoleoyl-CoA concentration, µM linoleoyl-CoA. Lines were 
drawn by Enzfitter (Section 2.2.3.1 O). 
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4. DISCUSSION 
Since many of the deleterious effects of volatile anaesthetics can be attributed 
to their metabolism, much attention has focussed on understanding the details 
of anaesthetic metabolism, including the binding of the drug and their 
metabolites to cellular macromolecules and the influence of administered drugs 
on anaesthetic metabolism. In this study we have attempted to contribute to the 
understanding of the metabolism of the anaesthetic agent isoflurane, by 
investigating the following: 
i) the metabolism of isoflurane by rat hepatic cytochrome P-450 isozymes 
which are members of the gene families I, II and Ill, and by cytochrome 
P-450 in human hepatic microsomes. 
ii) the identification of the organofluoride metabolites of isoflurane in rat and 
human hepatic microsomes resulting in further elucidation of the 
pathways of isoflurane metabolism. 
iii) the interaction of isoflurane (and other anaesthetic agents) with the fatty 
acid desaturases. 
iv) the inhibition of the t.6-desaturase by isoflurane. 
Firstly, the metabolism of isoflurane by rat and human hepatic cytochrome 
P-450 is discussed. 
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4.1 THE INTERACTION OF ISOFLURANE WITH RAT AND HUMAN 
HEPATIC CYTOCHROME P-450 
The results presented in this thesis confirm that the major non-volatile 
metabolite of isoflurane is fluoride ion ( 4, 184, 193,194). The Km and V max 
values for isoflurane defluorination in microsomes from 
phenobarbital-pretreated rats herein can now be compared with those for 
enflurane and methoxyflurane defluorination reported by lvanetich et al (182). 
From a comparison of the Vmax values (per nmol cytochrome P-450) for the 
rates of defluorination of these anaesthetic agents, it appears that the rate of 
defluorination in vitro increased in the same order as the relative extent of their 
metabolism in vivo (182,191), as follows: isoflurane (Vmax = 0.017 nmol 
fluoride ion/nmol cytochrome P-450/min) < enflurane (Vmax = 0.055 nmol 
fluoride ion/nmol cytochrome P-450/min) < methoxyflurane 
(Vmax = 0.42 nmol fluoride ion/nmol cytochrome P-450/min). In contrast, 
the Km values decreased in the same order, viz: isoflurane (Km = 0.86 mM) 
> enflurane (Km = 0.355 mM) > methoxyflurane (Km = 0.099 mM) (182). 
The decrease in the Km values and increase in Vmax in the series isoflurane, 
enflurane and methoxyflurane is consistent with their reactivities towards 
0-dealkylation and dechlorination proposed by Loew et al (183), and with the 
in vitro rates of defluorination (182). 
Although fluoride ion production from isoflurane in rat hepatic microsomes was 
dependent on the presence of NADPH, NADH supported the defluorination of 
isoflurane to a greater extent (73%) than that observed for most cytochrome 
P-450 dependent reactions (5 - 10%) (Table 14) (34,62). The high extent to 
which NADH supported the defluorination of isoflurane suggests that 
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cytochrome b5 may play a role in electron transfer to cytochrome P-450 during 
the reaction. Alternatively, NADH may in part support the defluorination of 
isoflurane by another enzyme system. This possibility was not investigated, but 
could occur since isoflurane interacted with the t.6-desaturase (which will be 
discussed later), and possibly other enzyme systems. 
Although inhibition of NADPH and/or NADH supported hepatic microsomal 
metabolic reactions by CO is often used to identify a 
cytochrome-P-450-catalysed reaction, the extent of CO-inhibition of isoflurane 
defluorination was very small (Table 13). There are a number of other 
cytochrome P-450-catalysed reactions which are poorly inhibited by CO, such 
as those catalysed by the biosynthetic cytochrome P-450 isozymes (111). The 
extent of inhibition by CO is known to vary with the substrate and the isozyme 
(377). The significant, if small, inhibition of isoflurane defluorination by CO and 
metyrapone, nevertheless, suggests that cytochrome P-450 catalyses this 
reaction, at least in part. The greater extent of inhibition of isoflurane 
defluorination observed with metyrapone than with CO may result from 
inhibition of the reaction at both the substrate- and ligand-binding sites by 
metyrapone; metyrapone has been shown to bind to both sites and is reported 
to be more effective in inhibiting cytochrome P-450-dependent reactions than 
co (111,113). 
Further evidence that cytochrome P-450 catalysed the defluorination of 
isoflurane is provided by the rates of fluoride ion production following induction 
of the different cytochrome P-450 isozymes (Table 12). By comparing the rates 
of defluorination of isoflurane in hepatic microsomes from rats which had 
received pretreatments resulting in preferential induction of different cytochrome 
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P-450 isozymes, it was possible to ascertain which of the isozyme(s) primarily 
catalysed this reaction in microsomal preparations. 
Since pretreatment of rats with ,B-naphthoflavone had no effect on the rate of 
defluorination of isoflurane, the .B-naphthoflavone-inducible cytochrome P-450 
isozymes (cytochrome P-450c and d) appeared to play no role in this reaction 
(Table 12). These results are consistent with the report by Mazze and Hitt that 
pretreatment of rats with 3-methylcholanthrene, also an inducer of cytochrome 
P-450c and cytochrome P-450d, did not increase the rate of isoflurane 
defluorination in rat hepatic microsomes (184). 
Pretreatment of rats with phenobarbital or pregnenolone-16a-carbonitrile 
enhanced the rate of isoflurane defluorination in rat hepatic microsomes 
(Table 12) suggesting that one or more of the isozymes induced by these 
agents may catalyse isoflurane metabolism. Phenobarbital induces cytochrome 
P-450 isozymes of the P45011B gene subfamily, including cytochrome P-450b 
and e, as well members of the P450IIIA gene subfamily, cytochrome 
P-450PCN 1 and cytochrome P-450PCN2 (119,126). Pregnenolone-16a-
carbonitrile pretreatment of animals elevates the levels of only cytochrome 
P-450PCN1 (119,126), and that to a greater extent than phenobarbital. 
From the results presented in Table 12, it can be seen that the defluorination of 
isoflurane in hepatic microsomes from phenobarbital- and 
pregnenolone-16a-carbonitrile-pretreated rats proceeded at rates respectively 
3.7-fold and 7.9-fold (pmol fluoride ion/mg microsomal protein) higher than 
that in uninduced hepatic microsomes. Since pregnenolone-16a-carbonitrile 
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induction enhanced the rate of isoflurane defluorination to a. greater extent than 
phenobarbital induction of cytochrome P-450, it appears that the cytochrome 
P-450 isozyme preferentially induced by pregnenolone-16a-carbonitrile, and 
significantly induced by phenobarbital, viz: cytochrome P-450PCN1, catalysed 
the defluorination of isoflurane. Our results did not eliminate a possible role for 
cytochrome P-450b and cytochrome P-450e in isoflurane defluorination. 
Confirmation of the involvement of cytochrome P-450PCN 1, and not 
cytochrome P-450b or cytochrome P-450e in the metabolism of isoflurane, can 
only be obtained from a study of the defluorination of isoflurane using the 
purified isozymes in a reconstituted system together with the other components 
necessary for catalytic activity (Figure 2). 
A comparison of the Km and V max values for fluoride ion production from 
isoflurane in hepatic microsomes from phenobarbital- and 
pregnenolone-16a-carbonitrile-pretreated rats provided further evidence that 
cytochrome P-450PCN 1 catalysed the defluorination of isoflurane. Since the 
Km values were the same in hepatic microsomes from both phenobarbital- and 
pregnenolone-16a-carbonitrile-pretreated rats (0.86 ± 0.05 mM), a single 
isozyme of cytochrome P-450 may catalyse the defluorination of isoflurane. The 
V max value was approximately two-fold higher in hepatic microsomes from 
pregnenolone-16a-carbonitrile-pretreated rats (Section 3.1.2) indicating that the 
isozyme which catalysed the defluorination of isoflurane was induced to a 
greater extent by pregnenolone-16a-carbonitrile than phenobarbital, i.e. 
cytochrome P-450PCN 1. 
Until fairly recently, most studies of the defluorination of anaesthetic agents 
have focussed on the phenobarbital-inducible isozymes (cytochrome P-450b 
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and/or cytochrome P-450e) or the polycyclic aromatic hydrocarbon-inducible 
isozymes (cytochrome P-450c and/or cytochrome P-450d) (182,184). The 
results reported herein confirmed earlier reports that phenobarbital 
pretreatment of rats enhances the rate of isoflurane defluorination in vitro 
whereas the polycyclic aromatic hydrocarbon inducing agents, e.g . 
.B-napthoflavone and 3-methylcholanthrene, do not (184). These results also 
suggested that cytochrome P-450PCN 1 participates in anaesthetic metabolism 
but the role played by cytochrome P-450PCN 1 in the metabolism of other 
anaesthetic agents is still unknown. The recent report that isoflurane inhibits the 
oxidative, but not the reductive metabolism of halothane suggests that oxidative 
metabolism of halothane and defluorination of isoflurane may be catalysed by 
the same cytochrome P-450 isozyme, namely cytochrome P-450PCN1 and/or 
cytochrome P-450 3a (178,179,185,186). Cytochrome P-450 3a is the 
ethanol-inducible isozyme shown to metabolise isoflurane (186). In contrast, 
isoflurane does not inhibit the reductive metabolism of halothane (378,379). 
The reductive metabolism of halothane has been shown to be catalysed by the 
major phenobarbital-inducible cytochrome P-450 isozyme from rabbit liver, 
cytochrome P-450LM2 (175,176), confirming that this isozyme does not appear 
to catalyse the defluorination of isoflurane. 
The metabolism of isoflurane was also measured indirectly by the CO-inhibitable 
NADPH consumption (Table 10). The rate of NADPH oxidation was far higher 
than the rate of fluoride ion production from isoflurane; in hepatic microsomes 
from phenobarbital-, .B-naphthoflavone-pretreated and untreated rats, the rate of 
NADPH oxidation was approximately 100-fold higher than the rate of fluoride ion 
production, whereas in hepatic microsomes from pregnenolone-
16a-carbonitrile-pretreated rats, the rate of NADPH oxidation was approximately 
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10-fold higher than the rate of fluoride ion production (Tables 10 and 12). Since 
two fluoride ions are produced for every isoflurane molecule metabolised, the 
difference between NADPH oxidation and fluoride ion production was a factor of 
two higher than that measured, i.e. 20- to 200-fold. 
The observed stoichiometry for defluorination of isoflurane in 
phenobarbital-induced hepatic microsomes was as follows: 5. 7 nmol NADPH 
oxidised:2.12 nmol hydrogen peroxide generated:0.06 nmol fluoride produced 
(Tables 10, 12 and 16). In the absence of isoflurane, 5.19 nmol hydrogen 
peroxide is produced (Table 16); on the addition of isoflurane, the hydrogen 
peroxide produced is reduced by 3.07 nmol, but only 0.06 nmol fluoride is 
produced. Therefore, considering the combined stoichiometry of cytochrome 
P-450 monooxygenase and oxidase activities (Introduction, equations 1 and 2, 
pages 14 and 19, respectively), there was a difference between the NADPH 
oxidation and hydrogen peroxide generation (3.58 nmol more NADPH 
oxidised) which was not quantitatively balanced by fluoride ion production 
(0.06 nmol). Since the discrepancy between NADPH oxidation, hydrogen 
peroxide generation and fluoride ion production could not be explained, the 
experimental conditions of hydrogen peroxide measurement were examined. 
Optimum conditions for accurate measurement of hydrogen peroxide 
measurement by the spectrophotometric method were determined (Table 15) 
and finally the rate of hydrogen peroxide generation was measured using two 
different assays. The results from the two assays were identical (Table 16). 
The exact fate of the extra reducing equivalents utilised in the defluorination of 
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isoflurane is still not clear. However, possible fates may be as follows: 
i) a four-electron transfer may be required by cytochrome P-450 during the 
defluorination of isoflurane, similar to that which occurs during the 
oxidation of ethanol (82); the occurrence of a four-electron transfer is 
reported to depend on the substrate (380). However, this would account 
for only 0.06 nmol of the extra 3.58 nmol NADPH utilised. 
ii) a four-electron transfer may occur in the presence of substrate, resulting 
in the production of water instead of active oxygen species or fluoride ion 
(Figure 4)(83). 
Since water production was not measured, this remains a possible fate for the 
extra reducing equivalents. In pregnenolone-16a-carbonitrile-induced hepatic 
microsomes, the difference between NADPH oxidation and fluoride ion 
production was far less than that observed in phenobarbital- or 
,8-naphthoflavone-induced hepatic microsomes. It is therefore possible that the 
phenobarbital- and ,8-naphthoflavone-inducible isozymes are involved in a 
four-electron transfer to water, but not the pregnenolone-16a-
carbonitrile-inducible isozyme. 
It is apparent from the results presented herein that isoflurane does not 
enhance the production of hydrogen peroxide relative to experiments in the 
absence of the drug (Table 16), thereby uncoupling the cytochrome P-450 
electron transfer pathway. The stoichiometry of the cytochrome 
P-450-catalysed defluorination of isoflurane was not investigated further. 
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Since fresh human liver was available from transplant donors, it was possible to 
study isoflurane metabolism in human hepatic microsomes: isoflurane was 
shown to be defluorinated at a rate comparable to that of untreated male Long 
Evans rats (Tables 12 and 17). Such a measurement of the rate of isoflurane 
defluorination by human hepatic microsomes does not allow for any 
comparison with the rate of defluorination of other anaesthetic agents, or with 
the in vivo rate of defluorination of isoflurane in other individuals following 
isoflurane anaesthesia. Therefore, further studies on the metabolism of 
isoflurane by human and phenobarbital-induced rat hepatic microsomes 
focussed on the identification of the organofluorine metabolites of isoflurane 
metabolism in vitro, and subsequent extension of the pathways of isoflurane 
metabolism (Figure 5). 
4.1.1 Identification of Organofluorine Metabolites of lsoflurane 
Possible metabolites of isoflurane are trifluoroacetic acid or 
trifluoroacetaldehyde, depending on the pathway of isoflurane metabolism; 
0-dealkylation results in trifluoroacetaldehyde (Pathway I, Figure 5) and 
0-insertion followed by dechlorination or 0-dealkylation results in trifluoroacetic 
acid (Pathway II, Figure 5). The fluoride ion production was accurately 
measured as inorganic fluoride. Accurate measurement of trifluoroacetic acid 
production from isoflurane in rat hepatic microsomes was attempted using gas 
chromatography, which proved too insensitive to detect the small amounts of 
trifluoroacetic acid produced (results not shown). An alternative method 
reported by Soltis and Gandolfi (365) for the detection of small quantities of 
fluorinated metabolites of volatile anaesthetic agents was attempted but was 
found not to be able to quantitate the total metabolites of fluorinated anaesthetic 
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agents. Essential conditions for utilisation of the method of Soltis and Gandolfi 
(365) for the quantitation of metabolites of isoflurane were found to be: 
i) that the fluorinated anaesthetic agent was volatile 
ii) that the fluorinated metabolites of the anaesthetic agent were non-volatile 
(see Table 18). 
Although isoflurane is a volatile anaesthetic agent and was almost completely 
removed by lyophilisation, a small, but significant amount remained in hepatic 
microsomes (Table 19). The amount remaining was small in comparison to the 
initial isoflurane concentration, but significant compared to metabolite 
production (Table 19). lsoflurane has 5 fluoride ions per molecule in contrast 
to only 3 in the expected organofluorine metabolites. The amount of isoflurane 
which remained in the microsomes after lyophilisation was corrected for by 
subtracting out fluoride measurements in zero-time samples which contained 
isoflurane, an NADPH-generating system and EDTA (Table 19). 
Since the fluorinated metabolites had to be in a non-volatile form for 
measurement by the method of Soltis and Gandolfi (365), this method was 
modified in our laboratory (Section 2.2.2.6) (396) to ensure that either 
trifluoroacetic acid or trifluoroacetaldehyde were non-volatile as outlined in 
Sections 3.1.5 and 3.1.6. 
The standard curves for fluoride ion (sodium fluoride) measured as described in 
Section 2.2.2.6 were slightly different from that where the fluoride was derived 
from either trifluoroacetic acid, trifluoroacetaldehyde or sodium 
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fluoride (Figures 16 and 17). Therefore, accurate quantitation of total 
non-volatile organic fluoride (trifluoroacetic acid or trifluoroacetaldehyde plus 
fluoride ion) in a single sample was not possible. Results were sufficiently 
accurate, however, to further elucidate the pathways of metabolism of isoflurane 
in rat and human hepatic microsomes. 
Metabolism of isoflurane via either Pathway I or Pathway II (Figure 5) should 
result in the production of 1 molecule of trifluoroacetaldehyde or trifluoroacetic 
acid for every 2 fluoride ions produced. Therefore, a comparison of total 
fluoride (trifluoroacetic acid or trifluoroacetaldehyde plus fluoride ion) to fluoride 
ion production alone should give a ratio of 5/2, i.e. 2.5. Where fluoride ion 
alone is measured, i.e. under conditions designed to ensure that the 
trifluoroacetic acid or trifluoroacetaldehyde produced was volatile during total 
fluoride analysis (Figure 11 ), this ratio should be 1. Therefore, this ratio, 
together with the method of total fluoride analysis (Figure 11 ), can be used as 
an qualitative indicator of the pathway of isoflurane metabolism in rat and 
human hepatic microsomes. 
In phenobarbital-induced rat hepatic microsomes, the ratio of production of total 
fluoride to fluoride ion was 11.4 where trifluoroacetaldehyde was measured as a 
phenylhydrazone, and 6.2 where it was measured as a Schiff base bound to 
microsomes (Table 19). These two ratios far exceeded the calculated ratio of 
2.5 for total fluoride to fluoride ion. In contrast, the ratio of total fluoride to 
fluoride ion where trifluoroacetic acid was measured in phenobarbital-induced 
rat hepatic microsomes, was < 1. From the comparison of these ratios for total 
fluoride to fluoride ion, it is apparent that in phenobarbital-induced rat hepatic 
microsomes, isoflurane was primarily metabolised via Pathway I, i.e. to fluoride 
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ion and trifluoroacetaldehyde (Figure 5). Since trifluoroacetaldehyde was 
detected in a non-volatile form either as a phenylhydrazone or under conditions 
where it was normally volatile (Table 18), it appeared that some of the 
trifluoroacetaldehyde produced binds as a Schiff base to cellular 
macromolecules, thus converting it to a non-volatile form. The lower yield of 
trifluoroacetaldehyde when measured without added phenylhydrazone 
suggested, however, that not all the trifluoroacetaldehyde produced was bound 
to cellular macromolecules, and that some was lost during lyophilisation 
(Table 19). Thus, trifluoroacetaldehyde appears to be a product of isoflurane 
metabolism in rat hepatic microsomes measured by a modification of the 
method of Soltis and Gandolfi. 
The measurement of trifluoroacetaldehyde as a metabolite of isoflurane in 
phenobarbital-induced rat hepatic microsomes confirmed the results in which 
trifluoroacetaldehyde produced from isoflurane defluorination was identified by 
an indirect method (Section 3.1.6). In this method, trifluoroacetaldehyde was 
oxidised to trifluoroacetic acid, separated by TLC and the trifluoroacetic acid 
identified by comparison of Rt values with those of standards. These results 
showed that trifluoroacetaldehyde is a metabolite of isoflurane in rat hepatic 
microsomes and provide the first identification of trifluoroacetaldehyde as a 
metabolite of an anaesthetic agent. The binding of trifluoroacetaldehyde to 
microsomal macromolecules may result in the formation of a protein adduct, 
which serves as an antigen resulting in cross-sensitisation and hepatotoxicity. 
Such immunoreactive protein adducts have been identified in rat liver following 
isoflurane anaesthesia (387). 
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In human hepatic microsomes, only trifluoroacetic acid was measured following 
defluorination of isoflurane since insufficient material was available for 
measurement of trifluoroacetaldehyde. Using the modified method of Soltis and 
Gandolfi (Section 2.2.2.6) to determine trifluoroacetic acid, ratios for total 
fluoride to fluoride ion of 6.2 and 2.2 were obtained in the case of livers 2 and 3, 
respectively (Table 19). A comparison of the ratio of total fluoride to fluoride ion 
obtained when trifluoroacetic acid was measured in human hepatic microsomes 
(6.2 and 2.2) with that obtained in rat hepatic microsomes ( < 1) (Table 19), 
suggested that in human hepatic microsomes, isoflurane was metabolised 
primarily via Pathway II (Figure 5), i.e. to fluoride ion and trifluoroacetic acid. 
Since measurement of trifluoroacetaldehyde as a metabolite of isoflurane in 
human hepatic microsomes was not possible, the metabolism of isoflurane via 
Pathway I to trifluoroacetaldehyde in human hepatic microsomes cannot be 
excluded. From the results presented herein, however, trifluoroacetic acid 
appears to be the major metabolite of isoflurane (besides fluoride ion) in human 
hepatic microsomes, although trifluoroacetaldehyde may be produced in small, 
possibly insignificant, amounts. 
The results of this investigation may explain the differences in the ratios of 
urinary metabolites of isoflurane in the rat and human reported by Hitt et 
al (195). In rats exposed to isoflurane, the low urinary ratio of non-volatile 
fluoride (non-ionic fluoride) to fluoride ion may be explained by the insignificant 
production of non-volatile organofluorine metabolites, i.e. trifluoroacetic acid. 
Because trifluoroacetic acid is found in small amounts in rats exposed to 
isoflurane, it would appear that a low, but significant capability for the oxidation 
of trifluoroacetaldehyde exists in liver cytosol (which was not demonstrated 
herein, Section 3.1. 7), or elsewhere in the rat. In contrast, in humans, ionic 
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fluoride (fluoride ion) and non-ionic fluoride in the form of trifluoroacetic acid 
were recovered in the urine. The source of this trifluoroacetic acid could 
presumably have been 
i) from direct metabolism of isoflurane via Pathway II to trifluoroacetic acid, 
or, less likely 
ii) via Pathway I to trifluoroacetaldehyde which could be directly oxidised in 
the liver cytosol to trifluoroacetic acid. 
The ability of human hepatic microsomes to metabolise isoflurane to 
trifluoroacetaldehyde has not been proved to be a general phenomenon. 
Human liver cytosol from a single individual oxidised trifluoroacetaldehyde to 
trifluoroacetic acid but not the livers of the other two individuals (Section 3.1. 7). 
Identification of the metabolites of isoflurane by Hitt et -at (195) and herein, 
indicate that in human liver, Pathway II is the favoured pathway for isoflurane 
metabolism (Figure 5). Fluoride ion and trifluoroacetic acid have been 
identified as metabolites of cytochrome P-450-dependent metabolism in vitro 
and as urinary metabolites following in vivo biotransformation of 
isoflurane (195). Consequently, isoflurane appears to undergo metabolism 
primarily in a single step catalysed by hepatic cytochrome P-450, and the 
metabolites of this step are readily excreted in the urine. In contrast, in rat liver, 
Pathway I is favoured for isoflurane metabolism (Figure 5), since fluoride ion 
and trifluoroacetaldehyde have been identified as metabolites of cytochrome 
P-450 metabolism in vitro. Fluoride ion has been identified as the major urinary 
metabolite following in vivo biotransformation of isoflurane (195), and a small 
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amount of trifluoroacetic acid, which could result from a low, but significant 
oxidation of trifluoroacetaldehyde in the rat. It is apparent, however, that the 
majority of the trifluoroacetaldehyde undergoes an alternate fate, viz: the 
binding of trifluoroacetaldehyde to cellular macromolecules as a Schiff base 
(which was demonstrated in this thesis) or perhaps reduction to trifluoroethanol 
followed by conjugation. 
The major conclusions of the study of the metabolism of isoflurane by 
cytochrome P-450 in hepatic microsomes can, therefore, be summarised as 
follows: 
i) Another isozyme of cytochrome P-450, besides cytochrome P-450 3a 
(178,179,185,186), appears to catalyse the defluorination of isoflurane in 
the rat; this isozyme is probably cytochrome P-450PCN1. 
ii) lsoflurane appears to be metabolised primarily by different pathways in 
the rat and human liver; consequently the rat appears to be an 
unsuitable model for studying the effects of biotransformation of this 
anaesthetic agent and another more suitable model should be sought. 
iii) The the newly identified metabolite of isoflurane in the rat 
(trifluoracetaldehyde) may contribute to the toxic potential of the 
anaesthetic in this species, especially as it has been shown to bind to 
cellular macromolecules in the liver. This effect could account for the 
hepatic centrilobular necrosis observed after exposure of rats to 
isoflurane which has been reported by Van Dyke (381). In contrast, the 
metabolites of isoflurane in the human were shown not to bind to cellular 
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macromolecules. It seems unlikely that metabolism of isoflurane to low 
levels of trifluoroacetic acid in humans would contribute to the toxic 
potential of this anaesthetic. 
After identification of the metabolites of isoflurane in rat and human hepatic 
microsomes, we went on to investigate the interaction of isoflurane with the rat 
hepatic cyanide-sensitive factors, including the fatty acid desaturases. 
4.2 THE INTERACTION OF ISOFLURANE AND OTHER ANAESTHETIC 
AGENTS WITH THE CYANIDE-SENSITIVE FACTORS 
A study of the interaction of isoflurane with the cyanide-sensitive factors was 
prompted by reports by lvanetich and co-workers which concluded that 
halothane, methoxyflurane and enflurane interact with hepatic microsomal 
ti9-desaturase (313,314). Although these anaesthetic agents did not inhibit the 
ti9-desaturation of stearoyl-CoA, they stimulated the cyanide-sensitive 
re-oxidation of cytochrome b5, suggesting that these drugs interacted with the 
cyanide-sensitive factors, which include the fatty acid desaturases (314). Since 
cytochrome b5 is an electron carrier for a number of metabolic pathways in 
hepatic microsomes, the enzyme system(s) responsible for the stimulation of 
re-oxidation of cytochrome b5 by a particular compound can only be identified 
indirectly. The biochemical pathways in which cytochrome b5 participates in 
hepatic microsomes are fatty acid chain elongation (335,337), cholesterol 
biosynthesis (316,342), plasminogen biosynthesis (316,342), desaturation of 
fatty acids (198) and some cytochrome P-450 drug oxidation (95-99). The 
autooxidation of cytochrome b5 can also be stimulated (313). 
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The ability of a compound to stimulate the reoxidation of cytochrome b5 in 
hepatic microsomes suggests that it interacts with one or more of the above 
enzymes. If the stimulation of electron transfer is inhibited by low 
concentrations of cyanide, the compound probably interacts with either the fatty 
acid desaturases or enzymes of cholesterol biosynthesis (A 7-sterol 
5-desaturase and 4-methyl sterol oxidase (382) )(235,316). Cytochrome P-450 
is inhibited by cyanide, but at higher concentrations (236). 
The ability of isoflurane to stimulate the re-oxidation of cytochrome b5 and the 
inhibition of this effect by cyanide (0.5 mM) (Table 24) suggests that isoflurane 
interacts with one or more of the cyanide-sensitive factor(s), viz: the fatty acid 
desaturases and/or enzymes of cholesterol biosynthesis. Our subsequent 
experiments focussed on assessing whether isoflurane interacted with the fatty 
acid desaturases. 
The interaction of isoflurane with the A9-desaturase was assessed indirectly by 
the reoxidation of microsomal cytochrome b5 as an index of fatty acid 
desaturase activity, and directly, by the effect on A9-desaturation of 
stearoyl-CoA. 
The A9-desaturase is induced by a high-carbohydrate diet, but the A5- and 
A6-desaturases are not (Table 8)(284-288). Dietary treatment was thus used to 
distinguish the A9-desaturase from the A5- and A6-desaturases. In hepatic 
microsomes from rats fed a high-carbohydrate diet, stearoyl-CoA (the substrate 
for the A9-desaturase) stimulated re-oxidation of cytochrome b5 5-fold 
confirming induction of the A9-desaturase (Table 25). In hepatic microsomes 
from rats fed a normal diet which does not strikingly induce the A9-desaturase, 
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stearoyl-CoA stimulated the rate of re-oxidation of cytochrome b5 only 1.8-fold 
(Table 25). 
Linoleoyl-CoA (the substrate for the ti6-desaturase) stimulated the re-oxidation 
of cytochrome b5 similarly in microsomes from rats fed normal, or 
high-carbohydrate diets (1.2- and 1.6-fold stimulation, respectively)(Table 25). 
From the above comparison of the effects of stearoyl-CoA and linoleoyl-CoA on 
the cytochrome b5 reoxidation in hepatic microsomes from differently 
pretreated rats, it appeared that we succeeded in reproducing induction of 
ti9-desaturase by high-carbohydrate diets (284-286,288) and that the 
ti6-desaturase was not induced by a high-carbohydrate diet. 
From literature data (314) we can compare the extent of interaction of 
halothane, methoxyflurane and enflurane with the fatty acid desaturases in 
hepatic microsomes from rats fed high-carbohydrate or normal diets. 
Halothane, methoxyflurane and enflurane stimulated cytochrome b5 reoxidation 
1.5-, 1.6- and 2.0-fold, respectively, in hepatic microsomes from rats fed a 
high-carbohydrate diet, and 1.6-, 1.2- and 1.5-fold, respectively from rats fed a 
normal diet; the stimulation of cytochrome b5 reoxidation by stearoyl-CoA was 
3.8- versus 1.3-fold for high-carbohydrate and normal diets (314). Since there is 
not much difference between the extents to which these anaesthetic agent 
stimulate the re-oxidation of cytochrome b5 in microsomes from rats fed the 
different diets (compared to stearoyl-CoA), it appears that these anaesthetic 
agents may not interact primarily with the ti9-desaturase, but may stimulate 
electron flow through cytochrome b5 to some extent by interacting with other 
cyanide-sensitive factors (314). 
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By the same argument, since isoflurane stimulated the re-oxidation of 
cytochrome b5 similarly in hepatic microsomes from rats fed high-carbohydrate 
and normal diets (1.7-fold and 1.4-fold, respectively) (Table 25) it appears that 
isoflurane does not interact preferentially with the A9-desaturase. This is 
consistent with the lack of effect of isoflurane on the A9-desaturation of 
stearoyl-CoA: isoflurane did not inhibit the A9-desaturase using NADH as 
electron donor and only slightly diminished activity with NADPH as electron 
donor (Table 26). The latter effect may reflect a small amount of inhibition by 
isoflurane, or may reflect the high rate of utilisation and perhaps the consequent 
depletion of NADPH by cytochrome P-450 in the presence of isoflurane (see 
Table 10). In any event, the extent, if any, of the effect of isoflurane on the 
A9-desaturase was of too low magnitude to pursue. 
It would therefore appear that isoflurane may stimulate cytochrome b5 
reoxidation by interacting with the A6-desaturase, the A5-desaturase or other 
cyanide sensitive factors, which are not induced by high-carbohydrate diet. The 
effects of isoflurane on the A5- and A6-desaturases were studied directly by 
measuring the A6-desaturation of linoleic and a-linolenic acids and the 
AS-desaturation of eicosa-8, 11, 14-trienoic acid. 
lsoflurane inhibited the A6-desaturation of linoleic acid at physiologically 
achievable concentrations of the anaesthetic (Figure 26). In contrast, isoflurane 
did not inhibit the A6-desaturation of another physiologically important fatty acid 
substrate, a-linolenic acid (Section 3.2.3.3). The lack of effect of isoflurane on 
the latter reaction suggested that a) isoflurane is not a competitive inhibitor of 
the A6-desaturase, viz: it does not bind directly to the fatty acyl-CoA binding site, 
and b) isoflurane inhibited the A6-desaturase with linoleic acid as substrate by 
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interacting directly with the fatty acid desaturase · rather than by disrupting 
electron transfer to this enzyme. The latter effect has been reported for the 
anti-inflammatory drug, ebselen (388). 
lsoflurane appeared also to interact with the A5-desaturase; isoflurane inhibited 
the A5-desaturase slightly and in a significant manner (Table 27). The inhibition 
of the A5-desaturase by isoflurane was achieved at ca. 10-fold higher 
concentration than for inhibition of the A6-desaturase. Inhibition of the 
A5-desaturase would not be expected to be significant in vivo since blood 
isoflurane levels do not exceed ca. 1 mM (4), while half maximal inhibition of the 
A5-desaturase is predicted to occur only above 8 mM isoflurane (Table 27). 
Since isoflurane inhibited the AS-desaturation of linoleic acid most strikingly, we 
anticipated that other fluorinated anaesthetics might also inhibit the 
A6-desaturase. However, neither halothane, methoxyflurane nor enflurane 
inhibited A6-desaturase activity toward linoleic acid (Table 30), even though the 
latter two anaesthetic ethers are close structural analogues of isoflurane. We 
conclude that either these three anaesthetic agents did not bind to the 
A6-desaturase, or interacted with the 116-desaturase at a site which does not 
affect enzyme activity. 
The activity of the A6-desaturase appeared to depend on the BSA concentration 
in reaction mixtures. Increasing the BSA concentration ten-fold increased the 
apparent activity of the enzyme, evidenced by the reaction rates for the 
A6-desaturase at two different BSA concentrations (Figure 33). Similarly, the 
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apparent Vmax value for the A6-desaturase was increased by additional BSA 
(0.09 ± 0.01 and 0.15 ± .01 µM -y-linolenic acid formed/min at the low and high 
BSA concentrations, respectively), whereas the apparent Km value remained 
essentially the same (ca. 8 µM) (Table 34). The stimulation of the A6-desaturase 
activity by BSA reported here is consistent with similar reports in the literature, 
where BSA was reported to increase the activity of the A6-desaturase by 50% in 
unwashed microsomes (276). The stimulation in activity observed in the 
presence of BSA both here and in the literature suggests that BSA may possibly 
have protected the enzyme from surface denaturation (276,383). Alternatively, 
the apparent effect of increasing BSA concentration on A6-desaturase activity 
may be an artifact resulting from the observed daily variations in activity (see 
e.g. Table 28)(247,249). 
Although the inhibition of the A6-desaturase by isoflurane was not reversed by 
bubbling with air (Table 29), no estimation of the isoflurane concentration 
subsequent to bubbling was made. Lyophilisation of hepatic microsomes 
resulted in 0.15 µM isoflurane remaining with microsomal membranes 
(calculated from data in Section 3.1.5). Assuming that bubbling with air for 5 
minutes was not as effective in removing isoflurane from hepatic microsomes as 
was lyophilisation, it is possible that the concentration of isoflurane was not 
lowered sufficiently by bubbling to prevent A6-desaturase inhibition or that the 
binding of isoflurane to the A6-desaturase is tight. 
lsoflurane has been demonstrated to be defluorinated by cytochrome P-450 
(Section 4.1). We addressed the question as to whether it was possible that this 
drug was also defluorinated during the course of its interaction with the 
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ti6-desaturase, and found some evidence that could be construed as 
supporting this possibility: 
i) NADH is the preferential electron donor for the ti6-desaturase, although it 
can donate electrons to cytochrome P-450 (34,62), and, in some cases, 
is the preferential electron donor (32). The extent (73%) to which NADH 
supports the defluorination of isoflurane relative to NADPH (Table 14) 
suggested that isoflurane may also be defluorinated by a microsomal 
enzyme which utilises NADH as preferential electron donor, such as the 
fatty acid desaturases. 
ii) isoflurane defluorination in hepatic microsomes was not greatly inhibited 
by CO (viz: 24% inhibition, Table 13), suggesting that either a) the 
cytochrome P-450 isozyme in question is not susceptible to CO 
inhibition, for which there is precedent (111), or b) another pathway 
which can utilise NADPH as electron donor and is not very sensitive to 
CO, such as the fatty acid desaturases, also metabolises isoflurane. 
iii) metyrapone inhibited the NADH-supported defluorination of isoflurane by 
cytochrome P-450 to a greater extent than that supported by NADPH 
(Tables 13 and 14). Metyrapone also inhibits the desaturation of linoleic 
acid to a far greater extent than CO (Table 28). Therefore, the relative 
extents of metyrapone and CO inhibition of the defluorination of 
isoflurane is consistent with metabolism by both cytochrome P-450 and 
the ti6-desaturase. 
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The low levels of fluoride ion production from isoflurane in hepatic microsomes 
from uninduced rats (Table 12) precluded determination whether fluoride 
production from isoflurane was cyanide inhibitable, and thus attributable to fatty 
acid desaturase activity (unpublished results). In any event, whatever enzymes 
defluorinate isoflurane in vivo and in vitro, the reaction proceeds with 
reluctance, slowly and to a small extent relative to analogues such as 
methoxyflurane or enflurane (182,191). 
Since isoflurane inhibited the ti6-desaturation of linoleic acid, it is surprising that 
it did not inhibit ti6-desaturation of the close structural analogue, a-linolenic acid. 
lsoflurane may inhibit the ti6-desaturation of linoleic acid selectively by 
interacting with a ti6-desaturase isozyme that preferentially metabolises linoleic 
acid. However, there is no evidence for ti6-desaturase isozymes of similar or 
differing substrate specificities. Alternatively, isoflurane may bind to a site 
outside of the acyl-CoA binding site and indirectly affect enzyme activity toward 
one substrate but not another. 
The following conclusions were drawn from the study of the interaction of 
isoflurane with the cyanide-sensitive factors: 
i) lsoflurane interacted with one or more of the cyanide-sensitive factors. 
ii) lsoflurane did not appear to interact with the ti9-desaturase. 
iii) lsoflurane weakly and slightly inhibited the ti5-desaturation of 
eicosa-8, 11, 14-trienoic acid. 
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iv) lsoflurane, at physiological achievable concentrations, inhibited the 
t.6-desaturation of linoleic acid but not a-linolenic acid. 
v) For reasons that are not clear, close structural analogues of isoflurane, 
such as enflurane and methoxyflurane, were not similarly efficaceous. 
It is possible that isoflurane affected other cyanide-sensitive factors, but this was 
beyond the scope of our investigations. We then went on to characterise 
kinetically the inhibition of the t.6-desaturase by isoflurane. 
4.2.1 Investigations into Factors Which Could Influence t.6-Desaturase 
Activity in Hepatic Microsomes 
In the course of attempting to characterise isoflurane inhibition of the hepatic 
microsomal t.6-desaturase, we began to realise that the experimental kinetics of 
the t.6-desaturase, even in the absence of isoflurane, were complex. There are, 
in fact, a number of reasons why the kinetics of the fatty acid desaturases are 
more complex than generally appears to be appreciated. The complexity of the 
experimental kinetics of the A6-desaturase (and other fatty acid desaturases) in 
hepatic microsomes reflects the following factors: 
i) Other enzymes compete with the t.6-desaturase for the acyl-CoA 
substrate; this includes enzymes such as the lysophospholipid 
acyltransferases. 
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ii) The acyl-CoA substrate can partition between the aqueous and lipid 
phases, rendering exact calculations of substrate levels available to the 
enzyme problematic. 
iii) Endogenous fatty acids are present in significant amounts in the 
microsomal membrane (Table 23)(397) and can act as alternate 
substrates or inhibitors. Many fatty acids are substrates for the acyl-CoA 
synthetase (213). Thus, endogenous fatty acid substrates for the 
acyl-CoA synthetase would be converted to acyl-CoA derivatives that 
could act as alternate substrates or inhibitors of the ti6-desaturase. In 
this way, endogenous fatty acids can affect apparent ti6-desaturase 
activity. For example, for the desaturation of linoleic acid, possible 
competing substrates found in the microsomal membrane in significant 
amounts would include oleate (found but not quantitated) and 
a-linolenate (see Section 3.2.2.2, Figure 24 and Table 23). Furthermore, 
endogenous unlabelled microsomal linoleate would dilute out the added 
radiolabelled substrate thus directly affecting true substrate levels, the 
specific activity of both the substrate and product and apparent rate of 
product formation. The effect of endogenous substrate was found to be 
highly significant for linoleic acid ti6-desaturation and, to a lesser extent, 
a-linolenic acid desaturation and would be a factor for any enzyme 
system using as substrates the fatty acids shown in Table 23 and 
Figure 24. These endogenous fatty acids would affect apparent kinetics 
whether or not radioisotopic assay methods were used (376). 
iv) Most fatty acid desaturase assay systems use added fatty acid plus an 
acyl-CoA generating system to generate the acyl-CoA substrate for the 
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fatty acid desaturase (see, for example, 266-270). It has not been fully 
established that this esterification reaction is pre-rate determining under 
all experimental conditions. 
Some or all of the above factors may have influenced measurement of 
desaturase activity and the effect of isoflurane on this process under our 
experimental conditions. We attempted to remove, isolate or correct for these 
processes and clarify the underlying kinetics of the fl6-desaturase before trying 
to superimpose the inhibition by isoflurane thereon. In particular, we attempted 
to establish and correct for the effects of endogenous substrate on 
fl6-desaturase activity in hepatic microsomes, and to dissociate the kinetics of 
the t.6-desaturase from the acyl-CoA synthetase pre-reaction and lipid synthesis 
post-reactions. 
The kinetic parameters that we measured for apparent fl6-desaturase activity in 
hepatic microsomes (Table 34) were consistent with those reported in the 
literature; linear Lineweaver-Burk plots were obtained and the apparent Km for 
linoleic acid value fell within the range reported in the literature (ca. 10 µM 
compared to the values in Table 40). However, the apparent Km values 
reported for the fl6-desaturase for linoleic acid in the literature (Table 40) fell 
over an extremely wide range. 
The breadth of the Km range could be explained by several factors: firstly, 
several plots contained an insufficient number of data points for accurate 
calculation of an apparent Km. For example, the reciprocal plots shown in four 
publications contained only three points each (see e.g. 266,269,270,395). 
Second, in some reports, the range of substrate concentrations was too small 
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TABLE 40 
LITERATURE DATA FOR THE t6-DESATURASE 
t6-Desaturase Source Km Substrate* Range of Ref. 
(concentration in (µM) Substrate 
mg protein/ml) Concentration 
(fold) 
Hepatic microsomes from 2.5 Linoleic acid 8 269 
rats fed a fat free diet (1.3) (0.25 - 2 µM) 
Hepatic microsomes from 160 Linoleic acid 2.5 266 
rats fed a fat deficient (40 - 100 µM) 
diet (2.0) 
Hepatic microsomes from 200 Linoleoyl-CoA 2 266 
rats fed a fat deficient (50 - 100 µM) 
diet (2.0) 
Hepatic microsomes from :::: 0.5 Linoleic acid 5 267 
rats fed a normal (0.4 - 2 µM) (Figure 1) 
diet (0.053) 
Hepatic microsomes from :::: 27 Linoleic acid 7.5 268 
rats fed a fat deficient (12.3 - 93 µM) (Figure 1) 
diet (3.3) 
Hepatic microsomes from 13 Linoleic acid :::: 20 270 
rats fed a fat deficient :::: 1-20 µM 
diet (1.3) 
Hepatic microsomes from 39 Linoleic acid ::::5 395 
rats fed a fat deficient :::: 0.8-4.0 µM 
diet (1.3) 
Hepatic microsomes from 9.6 Linoleic acid 24 Table 34 
rats fed a normal (0.45-10.8 µM) 
diet (0.5) 
Purified from rat hepatic 45 Linoleoyl-CoA unknown 255 
microsomes 
* Concentrations are of added substrate. 
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to obtain an accurate apparent Km value; the substrate concentrations do not, 
in fact, span the apparent Km value in four of the studies of ~6-desaturase 
activity shown in Table 40. With two other studies, the substrate concentration 
range did not extend to more than 10% below the apparent Km (Table 40). 
In none of the above studies was the effect of endogenous linoleic acid 
concentrations recognised, measured or corrected for. 
In measuring apparent ~6-desaturase activity, we did, however, take into 
account the level of endogenous linoleic acid in hepatic microsomes. We report 
in this thesis that endogenous linoleic acid concentrations are approximately 
3 µM in the rat hepatic microsomal preparations used (Table 23). The level of 
endogenous linoleic acid is highly significant compared to the lower end of the 
range of added linoleic acid concentrations used in determination of kinetic 
constants for the ~6-desaturase in this thesis and the range of linoleic acid 
concentrations used in the literature (ca. 0.25 µM to 40 µM, Table 40). For a 
clear demonstration of how reciprocal plots can be affected by endogenous 
substrate levels, see Figure 25 for treatment of the data in this thesis, as well as 
I.H. Segel, pages 93 and 94 (376). The apparent Km is particularly sensitive to 
levels of endogenous substrate. The omission of consideration of the effects of 
endogenous substrate levels by investigators using linoleic acid as substrate 
provided a basis for doubting the validity of most of the reported kinetic 
parameters for the ~6-desaturase obtained with microsomal preparations. 
Although we avoided the aforementioned problems of unsuitable substrate 
concentration range and lack of correction for endogenous substrate in our 
studies, there were factors that, because of their complexity, were ignored both 
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here and in the literature (266-270,395). For example, the possible effects of 
endogenous alternate substrates and endogenous inhibitors on the 
ti6-desaturase were ignored (266-270,395). a-Linolenic acid, which is an 
alternate physiological substrate for the ti6-desaturase and is metabolised at a 
greater rate than linoleic acid (197,198,237), is present in hepatic microsomal 
preparations. The concentration of this compound in hepatic microsomes is low 
(ca. 0.3 µM, Table 23) relative to the concentration of linoleic acid, but the extent 
of its effects on the kinetics of the ti6-desaturase is not known. 
In addition, the well documented ability of fatty acids and acyl-CoA derivatives to 
form micelles is known to affect kinetics (218). The critical micelle concentration 
of linoleoyl-CoA is reported to be 5.5 µMin aqueous solution (218); it is likely to 
be higher in the presence of both hepatic microsomes and BSA due to binding 
to these components (278,279). In our kinetic studies, all but the highest 
concentration of linoleic acid added (7.9 µM linoleic acid added, 10.8 µM total 
linoleic acid (added plus endogenous)) appeared to produce maximal 
concentrations of linoleoyl-CoA that were below the critical micelle 
concentration of linoleoyl-CoA. However, the total concentration of all acyl-CoA 
species is unknown (due to the presence of endogenous fatty acids), as is the 
question of whether micelle formation affected the kinetics of the ti6-desaturase 
under the conditions of our experiments. This effect has been ignored in the 
kinetic studies reported here. It has to our knowledge been ignored in all 
literature studies of the ti6-desaturation of linoleic acid. 
In our studies and most of those in the literature (see, for example, 266-270), 
apparent ti6-desaturase activity measured with hepatic microsomes reflects a 
combination of the activity of the ti6-desaturase plus acyl-CoA synthetase and 
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lysophospholipid acyltransferase activities. The activity of all three enzymes is 
measured because (i) acyl-CoA synthetase is a pre-reaction that produces the 
substrate for the ti6-desaturase, and (ii) microsomal reaction mixtures are 
saponified prior to quantitation of fatty acid substrate and product resulting in 
measurement of unesterified (or free fatty acids) together with fatty acids 
esterified into lipids or into acyl-CoA. The effects of these enzymes on 
ti6-desaturase activity will be discussed in more detail. 
In addition to the acyl-CoA synthetase and lysophospholipid acyltransferase, 
other enzymes which may influence apparent ti6-desaturase activity are the fatty 
acid elongase and the phospholipases (Figure 7). Some of these enzymes 
could influence ti6-desaturase activity by competing for acyl-CoA substrate, 
e.g., fatty acid elongase. Others, e.g., phospholipases, could release fatty acid 
from membrane lipids, thus diluting the radiolabelled fatty acid substrate. The 
activity of these enzymes was investigated or considered under our 
experimental conditions. 
Firstly, fatty acid elongase was inactive under the conditions used: the 
radioactivity from the ti6-desaturase reaction was recovered quantitatively as 
[1-14c] linoleic acid plus [1-14C] -y-linolenic acid (see Section 3.2.1.2). This 
was not unexpected since acetyl-CoA, the cofactor required for chain 
elongation was not added to reaction mixtures (335). 
Secondly, the phospholipases, in particular phospholipase A2 (Figure 7), could 
have influenced apparent fatty acid desaturase activity measurements by 
decreasing the specific activity of the radiolabelled substrate and/or providing 
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endogenous alternate substrates. If active, phospholipase would release 
unlabelled linoleic acid from membrane phospholipids. 
The activity of phospholipase A2 was measured in hepatic microsomes under 
the experimental conditions used to measure A6-desaturase activity; this 
enzyme was shown to be essentially inactive (Section 3.2.5.1 ). Phospholipase 
A2 activity was measured rather than phospholipase A1 activity because linoleic 
acid is esterified primarily in the second position of phospholipids which is the 
site attacked by phospholipase A2 (222). Phospholipase C, which, together 
with diglyceride lipase, catalyses the release of fatty acids from phospholipids, 
was not considered since it is cytosolic rather than microsomal in origin and 
specifically attacks phosphotidylinositol releasing arachidonic acid (230-233). 
The phospholipases appear not to influence hepatic microsomal A6-desaturase 
activity under our experimental conditions. 
The two enzymes already mentioned which are closely linked to the methods by 
which A6-desaturase activity was measured in hepatic microsomes, may affect 
A6-desaturase activity as follows: firstly, the acyl-CoA synthetase generates the 
substrate for the A6-desaturase (linoleoyl-CoA) from the commonly added, far 
less expensive precursor, linoleic acid. Secondly, the lysophospholipid 
acyltransferase competes with the A6-desaturase for the linoleoyl-CoA 
substrate. The generation of linoleoyl-CoA from linoleic acid which is catalysed 
by the acyl-CoA synthetase has been reported to be rapid and pre-rate 
determining (266,384). This reaction has been reported to essentially go to 
completion, and therefore not to influence the activity of the A6-desaturase in 
microsomes (266,384). In contrast, the lysophospholipid acyltransferases are 
reported to affect the activity of the A6-desaturase in hepatic microsomes 
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(269-270,395). Another enzyme in hepatic microsomes which also uses 
acyl-CoA substrate, is the acyl-CoA hydrolase. This enzyme was not 
investigated because it is reported to be relatively inactive compared to the 
lysophopholipid acyltransferases (218). 
The effects of the acyl-CoA synthetase and lysophospholipid acyltransferase on 
the kinetic parameters of the ti6-desaturase were assessed using computer 
modelling. 
4.2.2 Computer Modelling 
The data for the ti6-desaturase, acyl-CoA synthetase and lysophospholipid 
acyltransferase in hepatic microsomes were subjected to computer modelling in 
order to dissect the kinetic parameters for these enzymes, and remove the 
kinetic contributions from the other enzymes. Our focus was on obtaining more 
accurate kinetic parameters for the ti6-desaturase. All experimental data used 
in this operation were corrected for endogenous substrate levels. 









i.e. a series of coupled reactions catalysed by three different enzymes. The 
reason why the ti6-desaturase reaction is measured as a coupled reaction is 
because the substrate, added as linoleic acid, and the product (1-linolenic acid) 
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are quantitated after saponification of the microsomes, a process which splits 
the ester bonds in acyl-CoA and lipids, releasing all fatty acids. 
The reaction scheme incorporating these enzymic reactions, shown in 
Figure 38, was modelled using the SLAM II program (see Section 2.2.3.11 to 
Section 2.2.3.12.4). The effects of variations of the individual rate constants in 
the different models (Table 37) were considered in the Results (Section 3.2.6) 
and will not be further discussed here. However, some generalities about the 
modelling are relevant to discuss. 
The rate constants reported for model 35 (the final model) in Table 37 comprise 
one set of rate constants that model the experimental data with sufficient 
accuracy compared to experimental error. Using the existing computer 
program, we had no mechanism for searching for all possible combinations of 
rate constants and other parameters that would do so. We would like to 
emphasise that we have presented one possible solutio·n, but others may be 
equally reasonable. The large errors associated with some of the data points 
make us wary of overmodelling the data and overinterpreting the results of the 
modelling. 
The initial values of the rate constants in the model were such that all of the 
reactions were assumed to follow rapid equilibrium kinetics (399). This is still 
true for the final values of the constants for E 1 and E2, where k2 > > k3 and 
k5 >>ks (Table 38). For E3, however, kg is only 2.25-fold greater than kg. This 
difference is not sufficiently large to maintain rapid equilibrium kinetics. 
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The Km and kcat values from the literature for E 1, E2 and E3 utilised to 
generate constants for the initial model (previous to the models shown in 
Table 37) and the Km and kcat values for E1, E2 and E3 calculated from the 
rate constants in the final run (Model 35) are compared in Table 41. The 
calculated Km for E 1 is 5-fold greater than the literature value used, but between 
the two reported values of 2 µMand 30 µM (386,392). The generated Km for E2 
is within the broad range reported in the literature (Table 40). The remaining 
modelled Km and kcat values approximate the experimental data except for the 
kcat for E3; the literature kcat was generated under saturating conditions of the 
acyl acceptor, while our experiments were conducted with only endogenous 
microsomal lipid levels of acyl acceptor present (see Table 42 and references 
therein). Therefore, the modelled results are in no case providing unreasonable 
values compared to experimental and literature data (Tables 40, 41 and 42). 
Coupling of the ti6-desaturase with the acyl-CoA synthetase is reported to have 
no effect on the activity of the ti6-desaturase (266,384). This proposal is not 
consistent with the experimental results or the output of the computer modelling 
of the desaturase reaction reported in this thesis. Firstly, the experimentally 
determined utilisation of linoleic acid with time does not show instantaneous 
disappearance of linoleate (see Figures 30 and 31 ). Especially at an initial 
linoleic acid concentration of 10.8 µM, utilisation of linoleate is slow, with only 
ca. 40% of the substrate being utilised within 3 minutes. The computer 
modelling confirms for 4. 7 µM linoleic acid initial concentration, that over one 
minute, the linoleate concentration declines by ca. 75% (Figure 81) and 
production of acyl-CoA increases significantly in 0.2 minute increments up to 




A COMPARISON OF THE THE LITERATURE Km ANO kcat VALUES USED INITIALLY 
















Initial value taken * 





1 - 4 min-1 
26 min-1 
* Taken from Tables 40, 42, and references cited therein. 
t Calculated from rate constants in model 35 (Table 37). 
















































































































































































































































































































































































































































































































































The relative values of Km and V max calculated from the modelling also support 
the conclusion that under certain conditions the acyl-CoA synthetase reaction 
could significantly affect the apparent kinetics of the ll6-desaturase. The Km for 
the acyl-CoA synthetase is ca. 6-fold higher than that for the desaturase, while 
the calculated V max value for the acyl-CoA synthetase is approximately 250-fold 
greater than that for the ll6-desaturase (Table 38). From these comparisons, it 
would appear that at least at substrate concentrations in the low µM range, 
which is in the experimentally achievable range, the lower Km for the 
ll6-desaturase would to some extent compensate for its relatively low Vmax and 
the acyl-CoA synthetase activity would significantly affect measurement of 
ll6-desaturase activity using linoleic acid as the source of the substrate. 
The modelling of the reaction scheme showed that the lysophospholipid 
acyltransferase affected the kinetics of the ll6-desaturase, which is in accord 
with literature reports (268-270,395). Firstly, the lysophospholipid 
acyltransferase competes with the ll6-desaturase for the same acyl-CoA 
substrate. From the computer modelling, the Km value for the lysophospholipid 
acyltransferase is, within experimental error, equivalent to the Km for the 
ll6-desaturase for linoleoyl-CoA substrate. Both Km values were ca. 1 µM 
(Table 38); the calculated Vmax values for the lysophospholipid acyltransferase 
exceed that for the ll6-desaturase by between ca. six- and fifteen-fold (modelling 
results, Table 38, and experimentally determined value, Table 34). Therefore, it 
would appear likely that the lysophospholipid acyltransferase would significantly 
affect the apparent activity of the ll6-desaturase measured in hepatic 
microsomes using a typical assay system. 
• 
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The apparent Km value for the lysophospholipid acyltransferases (ca. 2 µM) 
determined experimentally in hepatic microsomes (Section 3.2.5.4, Figure 34 
and Table 34) was compared with that determined from the modelling (ca. 1 µM, 
Table 38). Both values agreed closely with those reported in the literature 
(ca. 1.5 µM to 3 µM from Table 42 and references therein). In determining the 
Km values for this enzyme in the literature and in our modelling studies, 
linoleoyl-CoA was used as substrate while linoleic acid was used for our 
experimentally determined Km value. Nevertheless, possibly because of 
competing factors, the Vmax for the experimental data and computer modelling 
are surprisingly close for this enzyme (compare Tables 34 and 38) . 
Although the apparent Km values for the t.6-desaturase obtained from hepatic 
microsomes in the literature are subject to some doubt on theoretical bases, 
they do bracket the computer generated Km for the t.6-desaturase (see 
Section 3.2.6). The single report of an apparent Km value for the isolated 
enzyme (255) of 45 µM is ca. 40-fold greater than the Km value of 1.5 µM 
calculated using data from the simulated reaction scheme (Table 38). This 
difference could reflect the differences in enzyme preparation: the isolated 
t.6-desaturase was solubilised in detergent (255) while our data is for the 
membrane-bound enzyme. Detergent solubilisation and the structure of the 
detergent are well known to affect kinetic parameters. 
When the kinetics of the t.6-desaturase were dissected free of contributions 
from the acyl-CoA synthetase and lysophosphilipid acyltransferases, the initial 
rate data plotted versus the concentration of the authentic substrate, 
linoleoyl-CoA, provided reciprocal plots that were excellent approximations to 
Michaelis Menten kinetics, with calculated Km of 1.5 µM and Vmax of 
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0.063 µM/min (Section 3.2.6). The Km differed considerably from the apparent 
Km value calculated directly from the identical experimental data utilised in the 
computer modelling. The experimentally determined Km values was 9.6 µM 
(Table 34). The experimentally determined Vmax of 0.09 µM/min was similar to 
the modelling result (Tables 34 and 38). It should be noted that the discrepancy 
in the Km value does not reflect endogenous substrate (which was corrected for 
in both cases), but probably reflects interference from E1, and E3 in accurate 
determination of Km for E2 in hepatic microsomes. 
The main conclusions arising from this study of the computer modelling of 
competing reactions on measurement of the kinetics of the A6-desaturase in 
hepatic microsomes were as follows: 
i) Neither chain elongation nor the phospholipases appeared to influence 
the A6-desaturase activity in hepatic microsomes. 
ii) The acyl-CoA synthetase is coupled with the A6-desaturase and is 
responsible for production of its acyl-CoA substrate when fatty acid is 
added as precursor; the kinetics of the acyl-CoA synthetase are such 
that it is anticipated that, at least at some concentrations of substrate, the 
acyl-CoA synthetase reaction is not rapid and pre-equilibrium for 
desaturation. The acyl-CoA synthetase, therefore, appears to influence 
the kinetics of the A6-desaturase in hepatic microsomes, when fatty acid 
is added as the source of substrate. 
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iii) The lysophospholipid acyltransferases also affected the activity of 
ti6-desaturase. These enzymes compete with the ti6-desaturase for the 
linoleoyl-CoA substrate. Secondly, the lysophospholipid acyltransferases 
would remove the product of desaturation of linoleate, viz: 
linolenoyl-CoA, thus preventing potential product inhibition of the 
ti6-desaturase; the extent of this latter effect and whether it would be 
kinetically significant is not known. 
iv) Using the kinetic data for the ti6-desaturase generated from the 
simulated reaction scheme, the ti6-desaturase was shown to follow 
simple Michaelis-Menten kinetics resulting in linear reciprocal and double 
reciprocal plots (Figure 89). 
The kinetics of the inhibition of the ti6-desaturase by isoflurane were also 
assessed by computer modelling. lsoflurane had no effect on either acyl-CoA 
synthetase or lysophospholipid acyltransferase (Section 3.2.5.5). Therefore, 
only the kinetic constants for E2, the ti6-desaturase, were adjusted until the 
model output approximated the experimental rate versus substrate 
concentration curve in the presence of isoflurane. Double reciprocal plots of 
the kinetics of the inhibition of the ti6-desaturase by isoflurane showed that it 
apparently acts like a competitive inhibitor, i.e., it alters the Km value of the 
enzyme without affecting the Vmax value (Figure 91 ). Because isoflurane 
competitively inhibits the ti6-desaturation of linoleic acid, it appears to bind in 
such a manner as to affect the linoleoyl-CoA binding site of the enzyme. Since 
isoflurane does not inhibit the ti6-desaturation of a-linolenic acid, it would 
appear that the inhibitor does not compete by fully blocking the site for 
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acyl-CoA binding, if we assume that the same isozyme desaturates both 
o-linolenoyl-CoA and linoleoyl-CoA. 
It is obvious that many of the complications in the kinetics of the ll6-desaturase 
are a function of the enzyme source used, namely hepatic microsomes. 
Problems such as endogenous substrate, competing enzymes, etc. could be 
avoided entirely by using a purified reconstituted ll6-desaturase enzyme system 
including the ll6-desaturase and electron transfer protein(s) plus lipid with 
linoleoyl-CoA as substrate. 
The purification and reconstitution of the ll9-desaturase and ll6-desaturase 
systems has been reported (255). In the initial stages of our studies we 
planned to investigate the effects of anaesthetic agents on the ll9-desaturase 
and successfully purified the electron transfer proteins, but were repeatedly 
unable to purify the ll9-desaturase (unpublished results). More than one 
laboratory report using the isolated reconstitued ll9-desaturase system 
(251,254,258,259), whereas there is only a single report using the 
ll6-desaturase system (255). After our lack of success in purifying the 
ll9-desaturase, we did not attempt isolation of the ll6-desaturase as the 
procedure was lengthy, yielding very little enzyme. To our knowledge, no 
reports in the literature cite the use of the isolated ll6-desaturase by the 
reported method. 
Of necessity, we resorted to the kinetic modelling to characterise the kinetics of 
the ll6-desaturase, and until the ll6-desaturase isolation and reconstitution is 
successfully used, we feel that ours was a reasonable and fruitful! approach. 
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4.2.3 Physiological Significance of the Interaction of lsoflurane with the 
ti6-Desaturase, and Possible Future Areas of Research 
The inhibition of the ti6-desaturase by isoflurane could influence prostglandin 
biosynthesis as well as ti6-desaturation. The role of the ti6-desaturase in 
prostaglandin biosynthesis (in particular, the 1-series) is presently uncertain; it 
has been speculated that ti6-desaturase is the controlling step in PGE 1 
synthesis (350). This may be possible, if not likely, since direct the fatty acid 
precursor of the 1-series of prostaglandins, dihommogammalinolenic acid, is 
not quantitatively an important fatty acid constituent of membrane 
phospholipids and the total cellular phospholipid pool, excepting in seminal 
vesicles where PGE1 is produced in abnormally high amounts (201). Thus, it 
might be anticipated that it would be biosynthesised via ti6-desaturation of 
linoleate as needed. Little appears to be known about the rate-limiting step in 
the biosynthesis of the 1-series of prostaglandins. Therefore the inhibition of 
the ti6-desaturase by isoflurane may or may not directly affect this pathway 
(Figure 10), and may or may not have any physiological significance. The 
extent of the inhibition is slight in vitro; nevertheless, the apparent Ki is in the 
low mM range, which is physiologically achievable. Further studies of PGE1 
synthesis are required before we would feel comfortable speculating on this 
issue. 
It might be of interest to assess the effects of the inhibition of the ti6-desaturase 
on PGE1 in a whole cell system. The cell system often used to study the 
synthesis of the 2-series of prostaglandins is polymorphonuclear leukocytes 
because the latter is reported to have a high activity of cyclo-oxygenase, the 
enzyme catalysing the synthesis of prostaglandins from fatty acids. A 
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preliminary investigation into a cell system suitable to use for the study of the 
inhibition of the t:.6-desaturase by isoflurane and effects on PGE1 synthesis, 
showed that polymorphonuclear leukocytes lacked t:.6-desaturase activity 
(unpublished results) (389). Therefore, in order to study the relationship 
between the t:.6-desaturase and PGE1 synthesis, a cell system containing both 
t:.6-desaturase and cyclo-oxygenase activity will have to be found. Recently, a 
mouse fibrosarcoma line has been used to study the mass production of PGE1 
and PGE2 and the role of the t:.5-desaturase in the PGE2/PGE1 ratio (393). 
Should this cell line have an active t:.6-desaturase, isoflurane may help in the 
study of the relationship between t:.6-desaturase activity and PGE1 synthesis. It 
is, however, anticipated that the chances of success in such an endeavour 
would be enhanced with a more potent inhibitor than isoflurane. Nevertheless, 
since this is one of the few non-physiological, xenobiotic compounds known to 
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